CA2296632A1 - Smooth muscle controller - Google Patents
Smooth muscle controller Download PDFInfo
- Publication number
- CA2296632A1 CA2296632A1 CA002296632A CA2296632A CA2296632A1 CA 2296632 A1 CA2296632 A1 CA 2296632A1 CA 002296632 A CA002296632 A CA 002296632A CA 2296632 A CA2296632 A CA 2296632A CA 2296632 A1 CA2296632 A1 CA 2296632A1
- Authority
- CA
- Canada
- Prior art keywords
- applying
- electric field
- field
- electrodes
- excitatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36007—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of urogenital or gastrointestinal organs, e.g. for incontinence control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36071—Pain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/205—Applying electric currents by contact electrodes continuous direct currents for promoting a biological process
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36114—Cardiac control, e.g. by vagal stimulation
- A61N1/36117—Cardiac control, e.g. by vagal stimulation for treating hypertension
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36514—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
- A61N1/36564—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure controlled by blood pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
Abstract
A method of promoting the healing of a lesion in a smooth muscle (200), comprises selecting a smooth muscle portion having a lesion, and applying a non-excitatory electric field (210) to the portion, which reduces the mechanical activity of the portion.
Description
SMOOTH MUSCLE CONTROLLER
FIELD OF THE INVENTION
The present invention is related to the field of controlling mechanical and/or electrical activity of smooth muscle by applying electrical fields to the muscle.
s BACKGROUND OF THE INVENTION
In many body tissues, activity of individual cells, especially contraction, is initiated by changes in trans-membrane potentials. These types of tissue are also called excitable tissue, since when they are excited by an electrical signal, they react by activation.
Some examples of excitable tissue include: cardiac muscle, skeletal muscle, smooth muscle and neural tissue. In ~ o many cases, the activity of large numbers of such excitable tissue cells is synchronized by propagating electrical activation signals. An activation signal is an electrical signal which, when it reaches an excitable cell, causes it to depolarize and perform its activity. In addition, the depolarization creates a new propagating activation signal which then continues to propagate towards the next un-activated cell. In most excitable tissue, the cell is refractory ~ 5 after a depolarization, such that the activation signal cannot immediately travel backwards.
The gastrointestinal (GI) tract is an example of a major physiological system in which many activities are coordinated by propagating electrical activation signals.
The GI tract comprise a stomach, a small intestine and a large intestine. In a typical digestive process, food is chewed in the mouth and enters the stomach for digestion. The food is periodically passed to 2o the antrum for grinding down and then passed back to the stomach. After a period of time, the pyloric sphincter opens and the food is passed to the small intestine. In the small intestine the food is churned and passed forward by a rhythmic motion of the intestines, until it reaches the large intestine. A one way sphincter allows movement only from the small intestine to the large intestine. Once in the large intestine, the food is further churned and compacted by is motions of the large intestines. These motions also advance the digested food, now feces, to a pair of outlet sphincters, which mark the end of the GI tract.
The GI tract is mostly composed of smooth muscle, which, when depolarized, contracts. All of the above described movements of the GI tract are synchronized by propagating activation signals. As can be appreciated, in many cases, these electrical signals 3o are not properly activated and/or responded to, resulting in disease. In one example, an ulcer causes inflammation of GI tissue. The inflamed tissue may generate spurious activation signals, which can cause the stomach to contract in a chaotic manner. The inflamed tissue may also affect the activation profile of the stomach by not conducting activation signals or by having a different conduction velocity than healthy tissue.
Pacing the GI tract is well known in the art, for example as shown in US
patents 5,292,344 and 5,540,730, the disclosures of which are incorporated herein by reference. The '730 patent describes both increasing and decreasing the excitability of the GI tract by stimulating different portions of the vagus nerve. The '344 Patent describes a pacemaker which directly stimulates portions of the GI tract. Electrical stimulation of the GI
tract is also known to be used for stimulating the GI tract of patients suffering from post operative damping syndrome, as evidenced by SU 1039506, the disclosure of which is incorporated herein by ~o reference.
The uterus also comprises smooth muscle, which contracts in response to electrical activation signals. "Uterine Electromyography: A Critical Review" by D.
Devedeux, et al., Am. J. Obstet Gvnecol 1993; 169:1636-53, the disclosure of which is incorporated herein by reference, describes the different types of uterine muscle and electrical signals generated by i 5 such muscles. An important finding which is described therein is that electrical activity in the uterus appears to be uncorrelated prior to labor, but when labor is established, the contractions and the electrical activity associated to them become highly synchronized.
In current medical practice, labor can be delayed by administering certain drugs.
However, the operation of these drugs is somewhat uncertain. In addition, labor can be 2o induced using other drugs, such as Oxytocin. Unfortunately, the dosage of Oxytocin which is required cannot be known in advance and overdoses of the drug can result in over-contraction which can mechanically damage the fetus and/or the mother.
SU 709078, the disclosure of which is incorporated herein by reference, describes stimulating the uterus after labor using an externally applied electrical current, to increase the 25 contractions and aid in the expulsion of the afterbirth and reduce bleeding by rapidly shrinking the uterus.
The use of locally applied electrical fields for reducing pain is well known in the art.
"Electrical Field Stimulation - Meditated Relaxation of a Rabbit Middle Cerebral Artery", D.A. Van Ripper and J. A. Bevan, Circulatory Research 1992; 70:1104-1112, the disclosure of ao which is incorporated herein by reference, describes causing the relaxation of an artery by applying an electric field. US Patent 4,537,195, the disclosure of which is incorporated herein by reference, describes treatment of pain using TENS (Transcutaneous Electrical Nerve stimulation), for treatment of headaches. It is hypothesized in this patent that the electrical stimulation prevents the constriction of arteries by stimulation of the muscle in the walls of the arteries, thereby preventing the dilation of capillaries, which dilation is a cause of headaches.
SU 1147408, the disclosure of which is incorporated herein by reference, describes a method of changing the distribution of blood flow in and about the liver, by applying electrical fields to arteries, varying the frequency of the field in synchrony with the cardiac rhythm.
US Patent 5,447,526, the disclosure of which is incorporated herein by reference, describes a transcutaneous electrical smooth muscle controller for inhibiting or decreasing the contraction of smooth muscle, especially uterine muscle. The controller, which is applied to the outside of the abdomen may also sense muscle contractions and effect inhibitory or ~ o stimulatory pulses unto the uterus as a whole, depending on the medical application, in response to sensed contractions.
SUMMARY OF THE INVENTION
It is an object of some aspects of the present invention to provide a method of directly and locally controlling the contraction and/or force of contraction of smooth muscles. Such ~ s control is especially employed, in particular preferred embodiments of the invention, in the gastrointestinal (GI) tract, the uterus, the bladder, endocrine glands, the gall bladder and blood vessels.
The inventors have found that the force of contraction of a smooth muscle can be both increased and decreased by a judicial application of a non-excitatory electric field. A non-Zo excitatory electric field is an electric field which does not induce a propagating action potential in the smooth muscle. Such a non-excitatory electric field does, however, modify the reaction of the smooth muscle to an excitatory field. The inventors have also found that it is possible to desensitize smooth muscle to an activation signal, thereby the desensitized smooth muscle does not respond to an activation signal and also does not propagate the activation signal.
25 Shortly after the field is removed, its effects are undone. It should be appreciated that many smooth muscles are characterized by multiple layers of fibers, the fibers in each layer having a preferred orientation. In a preferred embodiment of the invention, individual layers are selectively controlled by applying the electric field to be substantially parallel to the fiber orientation (in which case the field is highly effective). When a lesser degree of interaction ao between the muscle layer and the field is desired, the field is preferably applied perpendicular to the muscle fibers.
It is an object of some embodiments of the present invention to provide a method of more precisely controlling the GI tract than is possible using drugs and/or single or multi-site pacing. In a preferred embodiment of the present invention, the force of contraction of a portion of the GI tract is increased, such as to compensated for weakened contraction and/or to advance an otherwise stuck bolus. Alternatively or additionally, the force of contraction may be reduced, such as to treat a patient with overly sensitive intestines.
Alternatively or additionally, a section of the intestines may be desensitized or blocked from electrical activation signals in order to promote the healing of a lesion in the section.
Reducing or blocking contraction is also useful in treating acute diarrhea and to stop leakage from a stoma, when such leakage is undesired. Additionally or alternatively, the activation profile of the GI
tract, which normally includes a forward moving wave and a returning wave, is changed, for ~ o example, by blocking the returning wave (the reflux), so as to increase the motility of the intestines. Blocking the returning wave may be performed by desensitizing one or more segments of the intestines after the forward wave has passed, so that the returning wave will be stopped at the desensitized segment. Alternatively, the entire length of the intestines is desensitized for the duration of the returning wave. After the returning wave is stopped, the desensitizing field is preferably stopped so as to allow the forward wave to properly propagate.
The forward and returning waves can be detected either by their mechanical activity or, more preferably, by their electrical activity.
In a particular preferred embodiment of the present invention, the tension of the lower end of the colon is reduced so as to improve local blood supply and aid in the healing of zo hemorrhoids and anal fissures. It has recently been suggested that much of the pain associated with hemorrhoids is caused by ischemia of the tissue, which in turn, is caused by abnormally increased tension of the lower colon. Such tension has been hereunto been treated using topically applied drugs, such as nitroglycerin.
An endoscope, in accordance with another preferred embodiment of the present 2s invention, locally controls the activity of the intestines so as to cause the smooth muscle to advance and/or retreat the endoscope. Alternatively or additionally, local electrical desensitization is used as a replacement and/or in addition to relaxation of the bowels using drugs.
Although some of the embodiments of the present invention have been described with 3o respect to an endoscope or a colonoscope, these embodiments of the invention should be understood to apply to invasive probes in general and to endoscopes, colonoscopes, hysteroscopes and rectoscopes, in particular.
FIELD OF THE INVENTION
The present invention is related to the field of controlling mechanical and/or electrical activity of smooth muscle by applying electrical fields to the muscle.
s BACKGROUND OF THE INVENTION
In many body tissues, activity of individual cells, especially contraction, is initiated by changes in trans-membrane potentials. These types of tissue are also called excitable tissue, since when they are excited by an electrical signal, they react by activation.
Some examples of excitable tissue include: cardiac muscle, skeletal muscle, smooth muscle and neural tissue. In ~ o many cases, the activity of large numbers of such excitable tissue cells is synchronized by propagating electrical activation signals. An activation signal is an electrical signal which, when it reaches an excitable cell, causes it to depolarize and perform its activity. In addition, the depolarization creates a new propagating activation signal which then continues to propagate towards the next un-activated cell. In most excitable tissue, the cell is refractory ~ 5 after a depolarization, such that the activation signal cannot immediately travel backwards.
The gastrointestinal (GI) tract is an example of a major physiological system in which many activities are coordinated by propagating electrical activation signals.
The GI tract comprise a stomach, a small intestine and a large intestine. In a typical digestive process, food is chewed in the mouth and enters the stomach for digestion. The food is periodically passed to 2o the antrum for grinding down and then passed back to the stomach. After a period of time, the pyloric sphincter opens and the food is passed to the small intestine. In the small intestine the food is churned and passed forward by a rhythmic motion of the intestines, until it reaches the large intestine. A one way sphincter allows movement only from the small intestine to the large intestine. Once in the large intestine, the food is further churned and compacted by is motions of the large intestines. These motions also advance the digested food, now feces, to a pair of outlet sphincters, which mark the end of the GI tract.
The GI tract is mostly composed of smooth muscle, which, when depolarized, contracts. All of the above described movements of the GI tract are synchronized by propagating activation signals. As can be appreciated, in many cases, these electrical signals 3o are not properly activated and/or responded to, resulting in disease. In one example, an ulcer causes inflammation of GI tissue. The inflamed tissue may generate spurious activation signals, which can cause the stomach to contract in a chaotic manner. The inflamed tissue may also affect the activation profile of the stomach by not conducting activation signals or by having a different conduction velocity than healthy tissue.
Pacing the GI tract is well known in the art, for example as shown in US
patents 5,292,344 and 5,540,730, the disclosures of which are incorporated herein by reference. The '730 patent describes both increasing and decreasing the excitability of the GI tract by stimulating different portions of the vagus nerve. The '344 Patent describes a pacemaker which directly stimulates portions of the GI tract. Electrical stimulation of the GI
tract is also known to be used for stimulating the GI tract of patients suffering from post operative damping syndrome, as evidenced by SU 1039506, the disclosure of which is incorporated herein by ~o reference.
The uterus also comprises smooth muscle, which contracts in response to electrical activation signals. "Uterine Electromyography: A Critical Review" by D.
Devedeux, et al., Am. J. Obstet Gvnecol 1993; 169:1636-53, the disclosure of which is incorporated herein by reference, describes the different types of uterine muscle and electrical signals generated by i 5 such muscles. An important finding which is described therein is that electrical activity in the uterus appears to be uncorrelated prior to labor, but when labor is established, the contractions and the electrical activity associated to them become highly synchronized.
In current medical practice, labor can be delayed by administering certain drugs.
However, the operation of these drugs is somewhat uncertain. In addition, labor can be 2o induced using other drugs, such as Oxytocin. Unfortunately, the dosage of Oxytocin which is required cannot be known in advance and overdoses of the drug can result in over-contraction which can mechanically damage the fetus and/or the mother.
SU 709078, the disclosure of which is incorporated herein by reference, describes stimulating the uterus after labor using an externally applied electrical current, to increase the 25 contractions and aid in the expulsion of the afterbirth and reduce bleeding by rapidly shrinking the uterus.
The use of locally applied electrical fields for reducing pain is well known in the art.
"Electrical Field Stimulation - Meditated Relaxation of a Rabbit Middle Cerebral Artery", D.A. Van Ripper and J. A. Bevan, Circulatory Research 1992; 70:1104-1112, the disclosure of ao which is incorporated herein by reference, describes causing the relaxation of an artery by applying an electric field. US Patent 4,537,195, the disclosure of which is incorporated herein by reference, describes treatment of pain using TENS (Transcutaneous Electrical Nerve stimulation), for treatment of headaches. It is hypothesized in this patent that the electrical stimulation prevents the constriction of arteries by stimulation of the muscle in the walls of the arteries, thereby preventing the dilation of capillaries, which dilation is a cause of headaches.
SU 1147408, the disclosure of which is incorporated herein by reference, describes a method of changing the distribution of blood flow in and about the liver, by applying electrical fields to arteries, varying the frequency of the field in synchrony with the cardiac rhythm.
US Patent 5,447,526, the disclosure of which is incorporated herein by reference, describes a transcutaneous electrical smooth muscle controller for inhibiting or decreasing the contraction of smooth muscle, especially uterine muscle. The controller, which is applied to the outside of the abdomen may also sense muscle contractions and effect inhibitory or ~ o stimulatory pulses unto the uterus as a whole, depending on the medical application, in response to sensed contractions.
SUMMARY OF THE INVENTION
It is an object of some aspects of the present invention to provide a method of directly and locally controlling the contraction and/or force of contraction of smooth muscles. Such ~ s control is especially employed, in particular preferred embodiments of the invention, in the gastrointestinal (GI) tract, the uterus, the bladder, endocrine glands, the gall bladder and blood vessels.
The inventors have found that the force of contraction of a smooth muscle can be both increased and decreased by a judicial application of a non-excitatory electric field. A non-Zo excitatory electric field is an electric field which does not induce a propagating action potential in the smooth muscle. Such a non-excitatory electric field does, however, modify the reaction of the smooth muscle to an excitatory field. The inventors have also found that it is possible to desensitize smooth muscle to an activation signal, thereby the desensitized smooth muscle does not respond to an activation signal and also does not propagate the activation signal.
25 Shortly after the field is removed, its effects are undone. It should be appreciated that many smooth muscles are characterized by multiple layers of fibers, the fibers in each layer having a preferred orientation. In a preferred embodiment of the invention, individual layers are selectively controlled by applying the electric field to be substantially parallel to the fiber orientation (in which case the field is highly effective). When a lesser degree of interaction ao between the muscle layer and the field is desired, the field is preferably applied perpendicular to the muscle fibers.
It is an object of some embodiments of the present invention to provide a method of more precisely controlling the GI tract than is possible using drugs and/or single or multi-site pacing. In a preferred embodiment of the present invention, the force of contraction of a portion of the GI tract is increased, such as to compensated for weakened contraction and/or to advance an otherwise stuck bolus. Alternatively or additionally, the force of contraction may be reduced, such as to treat a patient with overly sensitive intestines.
Alternatively or additionally, a section of the intestines may be desensitized or blocked from electrical activation signals in order to promote the healing of a lesion in the section.
Reducing or blocking contraction is also useful in treating acute diarrhea and to stop leakage from a stoma, when such leakage is undesired. Additionally or alternatively, the activation profile of the GI
tract, which normally includes a forward moving wave and a returning wave, is changed, for ~ o example, by blocking the returning wave (the reflux), so as to increase the motility of the intestines. Blocking the returning wave may be performed by desensitizing one or more segments of the intestines after the forward wave has passed, so that the returning wave will be stopped at the desensitized segment. Alternatively, the entire length of the intestines is desensitized for the duration of the returning wave. After the returning wave is stopped, the desensitizing field is preferably stopped so as to allow the forward wave to properly propagate.
The forward and returning waves can be detected either by their mechanical activity or, more preferably, by their electrical activity.
In a particular preferred embodiment of the present invention, the tension of the lower end of the colon is reduced so as to improve local blood supply and aid in the healing of zo hemorrhoids and anal fissures. It has recently been suggested that much of the pain associated with hemorrhoids is caused by ischemia of the tissue, which in turn, is caused by abnormally increased tension of the lower colon. Such tension has been hereunto been treated using topically applied drugs, such as nitroglycerin.
An endoscope, in accordance with another preferred embodiment of the present 2s invention, locally controls the activity of the intestines so as to cause the smooth muscle to advance and/or retreat the endoscope. Alternatively or additionally, local electrical desensitization is used as a replacement and/or in addition to relaxation of the bowels using drugs.
Although some of the embodiments of the present invention have been described with 3o respect to an endoscope or a colonoscope, these embodiments of the invention should be understood to apply to invasive probes in general and to endoscopes, colonoscopes, hysteroscopes and rectoscopes, in particular.
It is an object of another preferred embodiment of the present invention to provide a method of more precisely controlling labor, including, delaying and/or advancing the onset of labor, increasing or decreasing the length of labor and/or stopping labor from proceeding after it has started or when it is still in the pre-labor stages. Stopping labor is especially important for treating cases of pre-term onset of labor. Such control is exerted, in accordance with a preferred embodiment of the invention, by reducing the contractility of the uterine muscles, increasing their contractility or by desensitizing them so that synchronized contractions cannot occur. It is hypothesized that labor is a self feeding process, where increased forces of contraction generate even stronger forces of contraction in the next contraction cycle. By ~ o damping the contraction force, such a feedback loop can be broken. In addition, when the uterus is desensitized, contractions cannot occur and labor is at least temporarily stopped, without significant danger to the fetus, as might be expected from drugs.
Labor interrupted in this way can be rapidly restarted, without the problems associated which drug-terminated labor. In a preferred embodiment of the invention, spurious electrical activation signals arising ~ s from anomalous portions of the uterus, such as fibroid containing portions, which activation signals may cause premature labor, are reduced by local desensitizing and/or blocking of the uterine tissue.
It accordance with another preferred embodiment of the invention, menstruationally meditated contractions of the uterus (cramps) are treated by detecting such cramps and 2o applying a desensitizing electrical field to the uterus to damp such cramps. Alternatively, such a desensitizing electric field may be applied during the time when such cramps may be expected to occur.
An object of another preferred embodiment of the present invention is to control the contractility of the bladder. In one preferred embodiment of the invention, the bladder is 25 desensitized such that it does not spontaneously contract when such contraction is undesirable.
Preferably, an apparatus for controlling the bladder in accordance with a preferred embodiment of the invention, includes a feedback mechanism, which stops its activity when the bladder becomes over full. In an additional or alternative embodiment of the invention, the force of contraction of the bladder is increased during urination. In a preferred embodiment of the so invention, the force of contraction of the bladder is increased in patients having bladder hypertrophy, so that the bladder will gradually shrink. Such treatment is preferably combined with drug treatment and/or an implantation of a stmt, which treatments may be used to reduce blockage of the urethra.
Labor interrupted in this way can be rapidly restarted, without the problems associated which drug-terminated labor. In a preferred embodiment of the invention, spurious electrical activation signals arising ~ s from anomalous portions of the uterus, such as fibroid containing portions, which activation signals may cause premature labor, are reduced by local desensitizing and/or blocking of the uterine tissue.
It accordance with another preferred embodiment of the invention, menstruationally meditated contractions of the uterus (cramps) are treated by detecting such cramps and 2o applying a desensitizing electrical field to the uterus to damp such cramps. Alternatively, such a desensitizing electric field may be applied during the time when such cramps may be expected to occur.
An object of another preferred embodiment of the present invention is to control the contractility of the bladder. In one preferred embodiment of the invention, the bladder is 25 desensitized such that it does not spontaneously contract when such contraction is undesirable.
Preferably, an apparatus for controlling the bladder in accordance with a preferred embodiment of the invention, includes a feedback mechanism, which stops its activity when the bladder becomes over full. In an additional or alternative embodiment of the invention, the force of contraction of the bladder is increased during urination. In a preferred embodiment of the so invention, the force of contraction of the bladder is increased in patients having bladder hypertrophy, so that the bladder will gradually shrink. Such treatment is preferably combined with drug treatment and/or an implantation of a stmt, which treatments may be used to reduce blockage of the urethra.
In accordance with another preferred embodiment of the invention, the output rate of endocrine or neuro-endocrine glands is controlled, preferably reduced, by applying a desensitizing electric field. In a preferred embodiment of the invention, a desensitizing electric field is applied to the beta islet cells of the pancreas, so as to reduce insulin generation in s patients suffering from hyper-insulinemia levels. Preferably, such control is applied without measuring the electrical activity of the beta islet cells. Alternatively or additionally, such control is applied while monitoring the blood glucose level. The desensitizing field is preferably a locally applied DC field, whose polarity is switched at a very low frequency, such as once an hour, so as to avoid polarization of the electrodes and/or damage to the tissue.
Another aspect of the present invention relates to treating vascular spasm, angina pectoris and/or abnormal blood pressure, by electrically controlling large blood vessels in the body. In accordance with a preferred embodiment of the invention, large veins, such as the abdominal veins are relaxed by applying a local inhibitory electric field to them. Alternatively or additionally, large arteries, such as the aorta, are relaxed by applying a local inhibitory ~ s electric field to them. Alternatively or additionally, excitatory fields are applied to the arteries and/or veins so as to constrict them. As can be appreciated, changing the volume of the arteries and veins can directly affect a patient's blood pressure and/or cardiovascular performance. In addition, relaxing the veins reduces the preload to the heart, which can stop an episode of ischemia, e.g., angina pectoris. Further, relaxing the aorta is useful in cases of vascular spasm, zo which, in many cases, is the cause of angina pectoris.
The relaxing electrical field is preferably applied to the blood vessels in spasm, which, in some cases, may be coronary blood vessels. Electrically induced relaxation of blood vessels may be used instead of or in addition to pharmaceuticals. Further, forced relaxation of arteries and veins is useful for treating an acute ischemic event. Typically, the ischemic event causes 25 increased heart rate which further strains ischemic cardiac tissue. By reducing the preload and/or the afterload of the heart, the cardiac demand is reduced, which reduces the oxygen demand of the ischemic tissues and/or allows better perfusion of the ischemic tissues.
Additionally or alternatively, the diastole may be extended to aid the perfusion of the cardiac muscle. Extending the diastole may be achieved, for example, by desensitizing at least a 3o portion of the heart. using techniques, such as described in PCT
IL97/00012, "Electrical Muscle Controller", filed on January 8, 1997, the disclosure of which is incorporated herein by reference.
Another aspect of the present invention relates to treating vascular spasm, angina pectoris and/or abnormal blood pressure, by electrically controlling large blood vessels in the body. In accordance with a preferred embodiment of the invention, large veins, such as the abdominal veins are relaxed by applying a local inhibitory electric field to them. Alternatively or additionally, large arteries, such as the aorta, are relaxed by applying a local inhibitory ~ s electric field to them. Alternatively or additionally, excitatory fields are applied to the arteries and/or veins so as to constrict them. As can be appreciated, changing the volume of the arteries and veins can directly affect a patient's blood pressure and/or cardiovascular performance. In addition, relaxing the veins reduces the preload to the heart, which can stop an episode of ischemia, e.g., angina pectoris. Further, relaxing the aorta is useful in cases of vascular spasm, zo which, in many cases, is the cause of angina pectoris.
The relaxing electrical field is preferably applied to the blood vessels in spasm, which, in some cases, may be coronary blood vessels. Electrically induced relaxation of blood vessels may be used instead of or in addition to pharmaceuticals. Further, forced relaxation of arteries and veins is useful for treating an acute ischemic event. Typically, the ischemic event causes 25 increased heart rate which further strains ischemic cardiac tissue. By reducing the preload and/or the afterload of the heart, the cardiac demand is reduced, which reduces the oxygen demand of the ischemic tissues and/or allows better perfusion of the ischemic tissues.
Additionally or alternatively, the diastole may be extended to aid the perfusion of the cardiac muscle. Extending the diastole may be achieved, for example, by desensitizing at least a 3o portion of the heart. using techniques, such as described in PCT
IL97/00012, "Electrical Muscle Controller", filed on January 8, 1997, the disclosure of which is incorporated herein by reference.
. There is therefore provided for, in accordance with a preferred embodiment of the invention, a method of promoting the healing of a lesion in a smooth muscle, comprising:
selecting a smooth muscle portion having a lesion; and applying a non-excitatory electric field to the portion, which field reduces the s mechanical activity at the portion.
Preferably, applying an electric field comprises desensitizing the smooth muscle portion. Alternatively or additionally, applying an electric field comprises blocking the electrical activity of smooth muscle surrounding the lesion.
Preferably, the lesion is an ischemic portion of the muscle. Alternatively or ~o additionally, the lesion is a sutured portion of the muscle.
Preferably, reducing the mechanical activity comprises inhibiting mechanical activity at the location.
In a preferred embodiment of the invention, the smooth muscle portion is part of a gastrointestinal (GI) tract.
There is also provided in accordance with a preferred with a preferred embodiment of the invention, a method of treating diarrhea, comprising:
selecting a portion of irritated intestine; and applying an electric field to the portion, which field reduces the mechanical activity at the portion.
Zo There is also provided in accordance with a preferred embodiment of the invention, a method of treating obesity, comprising:
selecting at least a portion of a stomach; and applying an electric field to the portion, which field delays or prevents the emptying of the stomach.
25 There is also provided in accordance with a preferred embodiment of the invention, a method of treating nausea, comprising, selecting at least a portion of a stomach; and applying an electric field to the portion, which field reduces the mechanical activity of the stomach.
ao There is also provided in accordance with a preferred embodiment of the invention, a method of controlling emptying of a stoma, comprising:
applying an electric field to an exit portion of the stoma, which field reduces the motility of the end portion; and removing said field when emptying of the stoma is desired.
Preferably, the method further comprises applying a second electric field to the exit portion, which second field increases the motility of the stoma, when emptying of the stoma is desired. The second field may be an excitatory field. Additionally or alternatively, the second s field is one which increases the force of contraction.
There is also provided in accordance with a preferred embodiment of the invention, a method of treating a hemorrhoid, comprising:
providing a patient having a colon; and applying an electric field to a portion of the colon, which field relaxes at least a portion i o of the colon, near an exit therefrom.
Preferably, the hemorrhoid is not situated at said portion of the colon.
Alternatively or additionally, the method comprises:
measuring a tension in the portion of the colon, wherein applying an electric field comprises applying an electric field when the ~ s measured tension is above a predetermined amount.
In a preferred embodiment of the invention, in a method a described above, applying an electric field comprises applying the electric field at a delay after a local activation time.
There is also provided in accordance with a preferred embodiment of the invention, a method of increasing the motility of a GI tract, comprising:
Zo selecting a portion of the GI tract; and applying a non-excitatory electric field to the portion, which field increases the force of contraction at the portion.
Preferably the method includes applying a second electric field to a second portion of the GI tract, downstream from said portion, which second electric field decreases the force of 25 contraction at the second portion.
There is also provided in accordance with a preferred embodiment of the invention, a method of increasing the motility of a GI tract, comprising:
determining a timing of a returning wave in the GI tract; and applying an electric field to at least a portion of the GI tract, which electric field so reduces the response of the GI tract to the returning wave.
Preferably, determining a timing comprises detecting a forward wave and wherein applying an electric field comprises applying an electric field only at times where it does not substantially interfere with the forward wave.
selecting a smooth muscle portion having a lesion; and applying a non-excitatory electric field to the portion, which field reduces the s mechanical activity at the portion.
Preferably, applying an electric field comprises desensitizing the smooth muscle portion. Alternatively or additionally, applying an electric field comprises blocking the electrical activity of smooth muscle surrounding the lesion.
Preferably, the lesion is an ischemic portion of the muscle. Alternatively or ~o additionally, the lesion is a sutured portion of the muscle.
Preferably, reducing the mechanical activity comprises inhibiting mechanical activity at the location.
In a preferred embodiment of the invention, the smooth muscle portion is part of a gastrointestinal (GI) tract.
There is also provided in accordance with a preferred with a preferred embodiment of the invention, a method of treating diarrhea, comprising:
selecting a portion of irritated intestine; and applying an electric field to the portion, which field reduces the mechanical activity at the portion.
Zo There is also provided in accordance with a preferred embodiment of the invention, a method of treating obesity, comprising:
selecting at least a portion of a stomach; and applying an electric field to the portion, which field delays or prevents the emptying of the stomach.
25 There is also provided in accordance with a preferred embodiment of the invention, a method of treating nausea, comprising, selecting at least a portion of a stomach; and applying an electric field to the portion, which field reduces the mechanical activity of the stomach.
ao There is also provided in accordance with a preferred embodiment of the invention, a method of controlling emptying of a stoma, comprising:
applying an electric field to an exit portion of the stoma, which field reduces the motility of the end portion; and removing said field when emptying of the stoma is desired.
Preferably, the method further comprises applying a second electric field to the exit portion, which second field increases the motility of the stoma, when emptying of the stoma is desired. The second field may be an excitatory field. Additionally or alternatively, the second s field is one which increases the force of contraction.
There is also provided in accordance with a preferred embodiment of the invention, a method of treating a hemorrhoid, comprising:
providing a patient having a colon; and applying an electric field to a portion of the colon, which field relaxes at least a portion i o of the colon, near an exit therefrom.
Preferably, the hemorrhoid is not situated at said portion of the colon.
Alternatively or additionally, the method comprises:
measuring a tension in the portion of the colon, wherein applying an electric field comprises applying an electric field when the ~ s measured tension is above a predetermined amount.
In a preferred embodiment of the invention, in a method a described above, applying an electric field comprises applying the electric field at a delay after a local activation time.
There is also provided in accordance with a preferred embodiment of the invention, a method of increasing the motility of a GI tract, comprising:
Zo selecting a portion of the GI tract; and applying a non-excitatory electric field to the portion, which field increases the force of contraction at the portion.
Preferably the method includes applying a second electric field to a second portion of the GI tract, downstream from said portion, which second electric field decreases the force of 25 contraction at the second portion.
There is also provided in accordance with a preferred embodiment of the invention, a method of increasing the motility of a GI tract, comprising:
determining a timing of a returning wave in the GI tract; and applying an electric field to at least a portion of the GI tract, which electric field so reduces the response of the GI tract to the returning wave.
Preferably, determining a timing comprises detecting a forward wave and wherein applying an electric field comprises applying an electric field only at times where it does not substantially interfere with the forward wave.
. Alternatively or additionally, determining a timing comprises detecting a returning wave and wherein applying an electric field comprises applying an electric field only at times where it substantially interfere with the returning wave.
Alternatively or additionally, applying an electric field comprises applying an electric field which inhibits the propagation of an activation signal, which activation signal synchronizes the returning wave.
Alternatively or additionally, applying an electric field comprises applying an electric field which reduces the force of contraction in at least a portion of the GI
tract.
There is also provided in accordance with a preferred embodiment of the invention, a i o method of selectively exciting only a layer of muscle in a smooth muscle having a plurality of muscle layers, each with a different fiber orientation, comprising:
applying an inhibitory electrical field, parallel to the a fiber orientation of a first layer of muscle, to the muscle; and applying an excitatory electric field to the muscle, which electrical field excites a ~ s second layer of the muscle.
There is also provided in accordance with a preferred embodiment of the invention, a method of selectively increasing the force of contraction of only a layer of muscle in a smooth muscle having a plurality of muscle layers, each with a different fiber orientation, comprising:
applying an inhibitory electrical field, parallel to the a f ber orientation of a first layer 20 of muscle, to the muscle; and applying a second electric field to the muscle, which second electric field is oriented parallel to the fiber orientation of a second layer of muscle and which second field increases the force of contraction in the second layer of muscle.
There is also provided in accordance with a preferred embodiment of the invention, a 25 method of mufti-point pacing for a smooth muscle, comprising:
applying excitatory electric fields at a plurality of locations on said muscle; and applying at least one inhibitory electric field at a second plurality of locations, situated among said plurality of locations, wherein said inhibitory electric field prevents the propagation of an activation signal between said first plurality of paced locations.
3o There is also provided in accordance with a preferred embodiment of the invention, apparatus for controlling at least the local activity of a portion of an in vivo smooth muscle, comprising:
Alternatively or additionally, applying an electric field comprises applying an electric field which inhibits the propagation of an activation signal, which activation signal synchronizes the returning wave.
Alternatively or additionally, applying an electric field comprises applying an electric field which reduces the force of contraction in at least a portion of the GI
tract.
There is also provided in accordance with a preferred embodiment of the invention, a i o method of selectively exciting only a layer of muscle in a smooth muscle having a plurality of muscle layers, each with a different fiber orientation, comprising:
applying an inhibitory electrical field, parallel to the a fiber orientation of a first layer of muscle, to the muscle; and applying an excitatory electric field to the muscle, which electrical field excites a ~ s second layer of the muscle.
There is also provided in accordance with a preferred embodiment of the invention, a method of selectively increasing the force of contraction of only a layer of muscle in a smooth muscle having a plurality of muscle layers, each with a different fiber orientation, comprising:
applying an inhibitory electrical field, parallel to the a f ber orientation of a first layer 20 of muscle, to the muscle; and applying a second electric field to the muscle, which second electric field is oriented parallel to the fiber orientation of a second layer of muscle and which second field increases the force of contraction in the second layer of muscle.
There is also provided in accordance with a preferred embodiment of the invention, a 25 method of mufti-point pacing for a smooth muscle, comprising:
applying excitatory electric fields at a plurality of locations on said muscle; and applying at least one inhibitory electric field at a second plurality of locations, situated among said plurality of locations, wherein said inhibitory electric field prevents the propagation of an activation signal between said first plurality of paced locations.
3o There is also provided in accordance with a preferred embodiment of the invention, apparatus for controlling at least the local activity of a portion of an in vivo smooth muscle, comprising:
. a plurality of electrodes, adapted to be in contact with a portion of smooth muscle to be controlled; and a controller which electrifies said electrodes with an electrical field which does not generate a propagating action potential in the smooth muscle, which electrical field modifies a the reaction of the smooth muscle to an activation signal.
Preferably, the apparatus includes an electrical activity sensor which detects electrical activity at the portion and wherein said controller electrifies said electrodes responsive to signals from said sensor. Preferably, the controller electrifies each of said electrodes is responsive to its local electrical activity. Additionally or alternatively, the electrical activity i o sensor senses electrical activity through ones of said plurality of electrodes.
Alternatively or additionally, the apparatus includes an impedance sensor, which senses at least one impedance between selected ones of said plurality of electrodes.
Alternatively or additionally, the apparatus includes a force transducer which detects mechanical activity at the portion and wherein said controller electrifies said electrodes responsive to signals from said sensor. Preferably, said controller applies an inhibitory electric field to the muscle, when said mechanical activity is above a certain threshold. Alternatively or additionally, the electrification at each of said electrodes is responsive to its local mechanical activity.
Alternatively or additionally, the non-excitatory field inhibits mechanical activity at the zo portion. Alternatively or additionally, the non-excitatory field reduces the force of contraction at the portion. Alternatively or additionally, the non-excitatory field increases the force of contraction at the portion. In a preferred embodiment of the invention, the controller electrifies at least one of said electrodes with an excitatory electric field.
In a preferred embodiment of the invention, the plurality of electrodes are arranged in a 2s two-dimensional matrix.
Alternatively or additionally, the controller selectively electrifies ones of said plurality of electrodes to selectively generate one of two perpendicular electric fields.
In a preferred embodiment of the invention, the controller is adapted to be implanted inside a stomach and attached to the stomach wall.
ao Alternatively or additionally, the apparatus is adapted to be implanted inside a uterus and attached to the uterus wall.
Alternatively or additionally, the apparatus is adapted to be implanted inside the body and outside a portion of the GI tract.
IO
Alternatively or additionally, the apparatus is adapted to be implanted inside the body and outside a uterus.
In a preferred embodiment of the invention, where the controller is adapted for a uterus, the controller determines a frequency of contractions in the uterus and wherein said controller electrifies said electrodes responsive to said determined frequency.
Preferably, the electrodes comprise elastic leads.
In a preferred embodiment of the invention, the electrodes are attached ~to a plurality of remote regions of said uterus.
In a preferred embodiment of the invention, the controller senses and inhibits ~ o mechanical activity in substantially the entire uterus. Alternatively or additionally, the controller increases the force of contraction in substantially the entire uterus.
In a preferred embodiment of the invention, the controller is in a capsule adapted to be inserted into a rectum or into a vagina.
Alternatively or additionally, the electrodes are adapted to be implanted inside the body while said controller is adapted to be situated outside the body. Preferably, the electrodes are adapted to be disconnected from said smooth muscle from outside the body.
There is also provided in accordance with a preferred embodiment of the invention, an anastomosis button comprising:
a sleeve portion for joining two portions of a GI tract;
2o at least two electrodes adapted to be in electrical contact with the GI
tract, at either side of the button; and a controller which electrifies the electrodes to reduce the force of contraction in the GI
tract near the button.
Preferably, the controller transmits a pacing signal from the GI tract on one side of the 25 button to the GI tract on the other side of the button.
Alternatively or additionally, reducing the force comprises inhibiting electrical activity of the GI tract at the button.
There is also provided in accordance with a preferred embodiment of the invention, apparatus for inhibiting a returning wave in an intestine, comprises:
so at least one electrode for applying an inhibiting electric field to a portion of the intestine;
a sensor which senses the propagation of waves in the intestine; and a controller which electrifies said electrode responsive to a sensed propagating wave.
Preferably, the sensor detects the returning wave.
There is also provided in accordance with a preferred embodiment of the invention, apparatus for advancing a bolus comprising:
s at least one first electrode, for applying an electrical Held to a first portion of the GI
tract adjacent said bolus;
at least one second electrode, for applying an electric field to a second portion of the GI
tract downstream from said bolus; and a controller which electrifies the at least one first electrode with a non-excitatory field ~ o which increases the force of contraction at the first portion and which electrifies the at least one second electrode with a non-excitatory electric field which relaxes the muscle at the second portion.
Preferably, the apparatus comprises an impedance sensor for detecting the existence of a bolus at the first portion of the GI tract.
There is also provided in accordance with a preferred embodiment of the invention, a method of aiding the examination of a GI tract, comprising:
providing an elongated probe, having a tip, inside a portion of a GI tract;
and applying a non-excitatory electric field to the portion of the GI tract adjacent the tip of the probe, which electric field is operative to relax the portion of the GI
tract.
Zo Preferably, the method includes inflating the portion of the GI tract after applying said field.
Preferably. the portion of the GI tract is a portion adjacent a bile duct.
There is also provided in accordance with a preferred embodiment of the invention, a method of advancing an elongated probe having a tip and inserted in a portion of the GI tract, 25 comprising:
applying a first electric field at the tip, which field constricts the portion of GI tract to grasp the probe; and applying a second electric field to a second portion of the GI tract adjacent a portion of the probe distal from the tip, which electric field causes the elongation of the second portion of 3o the GI tract.
Preferably, the method includes applying a third electrical field to a third portion of the GI tract, adjacent portions of the probe distal from the tip, which electrical field relaxes the third portion of the GI tract so that it does not constrict around the probe.
_ Alternatively or additionally, the method includes applying an inhibitory electric field to block the propagation of activation signals between the first portion and other portions of the GI tract.
There is also provided in accordance with a preferred embodiment of the invention, a s method of advancing an elongated probe, comprising:
providing an elongated probe, having a tip, inside a portion of a GI tract;
and applying an excitatory electric field to the portion of the GI tract, which excitatory electric field causes the bowel to transport the probe in a desired direction.
Preferably, the excitatory field is selectively applied either at the tip or at a different ~ o location along the probe, distal from the tip, depending on the desired direction of transport.
Alternatively or additionally, the method includes applying an inhibitory electric field, to the portion, to block the propagation of activation signals between the portion and the rest of the GI tract.
In a prefen-ed embodiment of the invention, the probe is an endoscope.
Alternatively, i s the probe is a colonoscope.
There is also provided in accordance with a preferred embodiment of the invention, an elongated probe adapted for advancing in a GI tract, comprising:
an elongated body having a tip;
a plurality of electrodes disposed at least at the tip; and 2o a controller which selectively electrifies the electrodes to produce non-excitatory electric fields which affect the contraction of smooth muscle.
Preferably, the probe includes a second plurality of electrodes distributed along at least a portion of the body of the probe.
Alternatively or additionally, the controller electrifies said first plurality of electrodes 25 to cause said portion of GI tract to selectively advance or retreat said probe.
Alternatively or additionally, the controller electrifies ones of said first and said second pluralities of electrodes to inhibit the propagation of activation signals from the portion of the GI tract adjacent the tip of the probe to other portions of the GI tract.
There is also provided in accordance with a preferred embodiment of the invention, a ao method of controlling a uterus, comprising:
determining a portion of the uterus suspected of generating undesirable activation signals; and applying a local inhibitory electrical field, to the uterus muscle, around the suspected portion.
There is also provided in accordance with a preferred embodiment of the invention, a method of controlling a uterus, comprising:
determining a portion of the uterus suspected of generating undesirable activation signals; and applying a local desensitizing electrical field to the suspected portion.
There is also provided in accordance with a preferred embodiment of the invention, a method of controlling labor, comprising:
determining a local activation at a plurality of locations of a uterus; and applying a non-excitatory electric field, to each of the plurality of locations, at a time delay from said local activation time.
Preferably. the non-excitatory field increases the force of contraction at ones of said plurality of locations.
Alternatively or additionally, said non-excitatory field reduces the force of contraction at ones of said plurality of locations.
Alternatively or additionally, the non-excitatory field inhibits the conduction of propagating action potentials across the uterus.
In a preferred embodiment of the invention, the method includes implanting a plurality zo of electrodes at the plurality of locations. Preferably, the electrodes comprise encapsulated power sources. Alternatively or additionally, the implanting is performed during a cesarean section.
There is also provided in accordance with a preferred embodiment of the invention, a method of aiding birth, comprising applying a non-excitatory electrical field to a birth canal, zs which non-excitatory f eld relaxes the birth canal.
There is also provided in accordance with a preferred embodiment of the invention, a method of preventing premature birth, comprising applying a non-excitatory electrical field to a birth canal, which non-excitatory field increases the force of contraction in the birth canal.
There is also provided in accordance with a preferred embodiment of the invention, a 3o method of Treating cramps of the uterus, comprising:
detecting electrical or mechanical activity in at least one location of the uterus; and applying a non-excitatory electrical field at the at least one location.
There is also provided in accordance with a preferred embodiment of the invention, a method of treating cramps, comprising:
providing at least one electrode inside the uterus, which one electrode is in contact with at least a portion of the uterus, at at least one location thereof; and s applying a non-excitatory electrical field to the portion.
In a preferred embodiment of the invention, the non-excitatory field inhibits the propagation of activation signals at the at least one location. Alternatively or additionally, non-excitatory field reduces the force of contraction at the at least one location.
There is also provided in accordance with a preferred embodiment of the invention, ~ o apparatus for controlling a smooth muscle, comprising a plurality of individual capsules, each capsule including at least one electrode and a power source which electrifies the electrode, which electrode applies a local non-excitatory field. Preferably, each of said capsules includes a sensor which measures local activity of the smooth muscle.
Alternatively or additionally, the capsules are operative to synchronize the electrification of their electrodes without the meditation of an external controller.
There is also provided in accordance with a preferred embodiment of the invention, apparatus for treating cramps, comprising:
a flexible body having an outside portion and adapted to snugly engage the inside of a uterus;
zo a plurality of electrodes disposed on the outside of said body; and a controller which electrifies said electrodes to generate a non-excitatory electrical field.
Preferably, the flexible body is inflatable. Alternatively or additionally, the apparatus includes a second electrode adapted to be placed outside the uterus.
zs There is also provided in accordance with a preferred embodiment of the invention, a method of controlling a circulatory system, including a heart, comprising:
providing electrodes adjacent a vein; and electrifying the electrodes to constrict the vein, such that the preload on the heart is - increased.
3o There is also provided in accordance with a preferred embodiment of the invention, a method of controlling a circulatory system, including a heart, comprising:
providing electrodes adjacent a vein; and electrifying the electrodes to expand the vein, such that the preload on the heart is reduced.
There is also provided in accordance with a preferred embodiment of the invention, a method of controlling a circulatory system, including a heart, comprising:
providing electrodes adjacent an artery; and electrifying the electrodes to constrict the artery, such that the afterload on the heart is increased.
There is also provided in accordance with a preferred embodiment of the invention, a method of controlling a circulatory system, including a heart, comprising:
~o providing electrodes adjacent an artery; and electrifying the electrodes to expand the artery, such that the afterload on the heart is reduced.
There is also provided in accordance with a preferred embodiment of the invention, a method of controlling vascular spasm, in a circulatory system having a heart, comprising:
determining a vessel in spasm, which results in an abnormally constricted lumen; and applying a non-excitatory electric field to the vessel, which field causes the lumen to expand.
It should be appreciated that two or more of the above methods of controlling the circulatory system may also be practiced together.
zo In a preferred embodiment of the invention, the method includes applying a non-excitatory electric field to at least a portion of the heart.
There is also provided in accordance with a preferred embodiment of the invention, apparatus for controlling a circulatory system having a heart, comprising:
a plurality of electrodes disposed about at least one major blood vessel;
zs a blood pressure sensor which measures blood pressure; and a controller which electrifies the plurality of electrodes responsive to the measured blood pressure.
Preferably. the apparatus includes an external control which activates said controller.
Alternatively or additionally, the apparatus includes an ECG sensor which detects the ao cardiac rhythm. Alternatively or additionally, the controller relaxes said blood vessel to reduce the blood pressure. Alternatively or additionally, the controller contracts said blood vessel to increase the blood pressure.
There is also provided in accordance with a preferred embodiment of the invention, a method of controlling the output of a gland, comprising:
providing at least one electrode near the gland; and applying a non-excitatory electric field to the gland.
Preferably, the non-excitatory electric field inhibits the activity of hormone producing cells in the gland. Alternatively or additionally, the non-excitatory electric field is a substantially DC field. Preferably, the method includes periodically changing the polarity of the field. Preferably, one polarity is applied for a significantly larger portion of the time.
In a preferred embodiment of the invention, the gland is a pancreas.
Preferably, the ~ o method includes monitoring a level of glucose in the blood, wherein applying said electric field comprises applying said field responsive to said monitored level.
There is also provided in accordance with a preferred embodiment of the invention, apparatus for controlling the output of a gland, comprising:
a sensor for measuring a level of a chemical in a blood stream;
at least one electrode adjacent said gland; and a controller which electrifies said electrode with a non-excitatory electric field, responsive to the measured level.
Preferably, the chemical is glucose. Alternatively or additionally, the apparatus is completely implantable.
2o There is also provided in accordance with a preferred embodiment of the invention, a method of controlling the activation profile of a smooth muscle organ, comprising:
determining a desired activation profile for the organ; and applying at least one non-excitatory field to a portion of the organ to modify its activation profile.
is Preferably, the activation profile comprises a mechanical activation profile.
In a preferred embodiment of the invention, the method includes:
measuring a tension in the smooth muscle; and modifying the application of the non-excitatory field responsive to the measured tension.
ao Alternatively or additionally, the method includes:
measuring a pressure in the smooth muscle; and modifying the application of the non-excitatory field responsive to the measured pressure.
Alternatively or additionally, the method includes applying at least one excitatory electric field to the smooth muscle.
Alternatively or additionally, the method includes applying a non-excitatory field comprises applying an inhibitory electric field to the muscle.
s Alternatively or additionally, applying a non-excitatory field comprises applying an electric field which reduces the force of contraction in the muscle.
Alternatively or additionally, applying a non-excitatory field comprises applying an electric field which increases the force of contraction in the muscle.
Preferably, the organ is a stomach. Alternatively or additionally, the organ is a small ~ o intestine. Alternatively or additionally, the organ is a large intestine.
Alternatively or additionally, the organ is a uterus.
There is also provided in accordance with a preferred embodiment of the invention, apparatus for dictating a mechanical activation profile to a smooth muscle organ, comprising:
at least three electrodes, adapted to be distributed over the organ;
i s at least one sensor which senses local mechanical activity of the organ;
and a controller which electrifies selected ones of said electrodes, responsive to the sensed local mechanical activity, to dictate a particular activation profile to the organ.
Preferably, the organ is a uterus and wherein the activation profile is a pattern of contraction during labor.
2o Although many embodiments of the present invention are described herein mainly as methods, it should be appreciated that the scope of the invention includes apparatus adapted to perform these methods. In particular, the scope of the invention includes programmable electric field generators which are programmed to supply an electric field in accordance with a preferred embodiment of the invention. In a preferred embodiment of the invention, 25 programmable variables include, waveforms, amplitudes, frequencies, durations, delays, synchronization and response to locally measured parameters of muscle activity. It should be appreciated that the behavior of a muscle in one portion thereof can be modified by applying an electric field to a second portion thereof, for example, by inhibiting the propagation of an activation signal to the one portion or by changing the layout of forces acting on the one 3o portion.
BRIEF DESCRIPTION OF THE DRAWINGS
. The present invention will be more clearly understood from the following detailed description of the preferred embodiments of the invention, together with the accompanying figures, in which:
Fig. 1 is a schematic illustration of a gastrointestinal (GI) tract;
Fig. 2 is a schematic illustration of an unfolded GI tract, illustrating various preferred embodiments of the present invention;
Fig. 3 is a partial cut-through schematic illustration of a laid-open portion of the GI
tract, showing the orientation of smooth muscle fibers of the GI tract;
Fig. 4 illustrates a method of advancing a colonoscope using local control of the GI
~o tract;
Fig. 5 is a schematic illustration of a capsule for treatment of hemorrhoids in accordance with a preferred embodiment of the present invention;
Fig. 6 is a schematic diagram of a uterus, illustrating applying local inhibitory electric fields to small portions of the uterus, in accordance with a preferred embodiment of the present ~ s invention;
Fig. 7 illustrates an implantable multi-site stimulator/inhibitor, attached to a uterus, in accordance with a preferred embodiment of the invention;
Fig. 8 illustrates a balloon-type insert for a uterus, for controlling cramps;
Fig. 9 illustrates a controller which modifies the output of a gland, such as the 2o pancreas;
Fig. 10 illustrates a blood pressure and/or heart load controller, attached to major blood vessels, in accordance with a preferred embodiment of the invention;
Fig. 11 is a schematic illustration of an experimental setup used to determine effects of a non-excitatory field on smooth muscle cells;
25 Fig. 12 is a graph of experimental results showing an increase in the force of contraction of a smooth muscle, as a result of the application of a non-excitatory electric field, in accordance with a preferred embodiment of the invention;
Figs. 13-17 are graphs of experimental results each showing a significant decrease in the force of contraction of a smooth muscle, as a result of the application of a non-excitatory 3o electric field in accordance with a preferred embodiment of the invention;
Fig. 18 is a graph of experimental results showing an increase in the force of contraction of a smooth muscle of the urine bladder, as a result of the application of a non-excitatory electric field, in accordance with a preferred embodiment of the invention; and Fig. 19 is a graph of experimental results showing a decrease in the force of contraction of a smooth muscle of an unpaced uterus, as a result of the application of a non-excitatory electric field, in accordance with a preferred embodiment of the invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Fig. 1 is a schematic illustration of a gastrointestinal (GI) tract 22 of a patient 20. In accordance with a preferred embodiment of the i-nvention, local control of the force of contraction and/or the sensitivity of portions of the GI tract to excitation is achieved by applying local, non-excitatory electric fields directly to the portion to be controlled. Although such non-excitatory electric fields do not create a propagating action potential in the controlled ~ o portion, the fields does modify the response of the portion to an artificial or naturally occurring activation signal, when it arrives. In particular, the inventors have found that it is possible to increase or to decrease the force of contraction of a portion of GI tract. In addition, it is possible to desensitize a muscle segment so that it has a reduced reaction or so it does not react at all to normal amplitudes of activation signals. This desensitization, while reversible, may be ~ s made to last a certain period of time after the removal of the controlling electric field.
Two particular waveforms of non-excitatory electric fields have been found to be beneficial. A first type is a substantially constant field (whose polarity may be occasionally switched to reduce ionic polarization effects). This field may be applied without any synchronization to the controlled muscle. However, the inventors have found it useful to stop 2o the inhibiting field shortly before the activation signal is to arrive at the controlled muscle, so as to reduce the amplitude of activation signal required to excite the controlled muscle. A
second type of non-excitatory field is a pulse which is applied in synchrony with the arrival of an activation signal. The pulse is applied either before, during the arrival of the signal or at a delay after its arrival (a long enough delay after activation is equivalent to applying the pulse 25 before activation). The inventors believe that a non-excitatory electric field applied after the activation signal tends to increase the force of contraction of the controlled muscle, by increasing a plateau duration of the muscle contraction. It is hypothesized that a non-excitatory field applied at a greater delay after the arrival of the activation signal extends the refractory period (possibly by hyperpolarizing the muscle cells so that the activation signal does not 3o cause a depolarization). As a result, at least some of the muscle cells do not respond to the activation signal and the force of contraction of the muscle is reduced. Thus, the stronger the non-excitatory signal, the more cells will be hyperpolarized and the lower will be the force of contraction. In an extreme case, none of the muscle cells will respond to the activation signal and the propagation thereof will be inhibited. It is also possible that the non-excitatory field directly reduces affects the force of contraction achieved by a single muscle fiber.
It should be noted that various embodiments of the present invention, as described herein, can be used in conjunction with drug therapies, with a synergistic interaction andlor to s allow a reduced dose of drug to produce a desired effect and/or to allow increased dosages of drugs to be used, while limiting their adverse side effects using electrical control. In addition, such electrical control may be practiced together with electrical pacing of the GI tract, including mufti-site pacing. In accordance with a preferred embodiment of the present invention, substantially any activation profile of the GI tract may be achieved by selectively ~ o pacing portions of the GI tract and creating desensitized regions between the paced portions, so that an activation signal does not propagate from one paced portion to the next. In addition, such electrical control may also be practiced in combination with electrical stimulation of a vagus nerve.
The term "electric field" has been used to described the non-excitatory field used to control a muscle. The terms "field" and "current pulse" are used interchangeably herein, since, in the body, both are generated when a voltage potential is created between two electrodes. In a preferred embodiment of the invention, the field is applied by maintaining a constant current between at least two electrodes. Alternatively, a voltage potential may be controlled instead of controlling the current.
2o Muscle tissue generally adapts to frequent and/or intense activation by increasing its mass. In a preferred embodiment of the invention, the pacing location is chosen to increase the strength of the muscle at the location. Preferably, the area around the location is desensitized so that the activation signal does not propagate to the rest of the GI tract.
Alternatively or additionally, local muscle mass is increased by modifying the force of contraction at the 25 location. Generally, a maximum force of contraction is desired, since it will generally cause the greatest increase in muscle mass.
Fig. 2 is a schematic drawing of GI tract 22, unfolded for illustrative purposes, for illustrating various preferred embodiments of the present invention. GI tract 22 includes a stomach 24, a duodenum 26, a small intestine 27 and a large intestine 29.
3o In accordance with a first preferred embodiment of the invention, a portion of the GI
tract is desensitized and/or electrically isolated from activation signals.
Isolation from electrical signals may be achieved by desensitizing tissue which surrounds the portion.
Ulcers cause inflammation of the GI tract tissue, which inflamed tissue may generate spurious activation signals. Alternatively, the inflamed tissue may exhibit a very low threshold of excitability. Both these abnormalities may cause arrhythmias in stomach 24.
In a preferred embodiment of the invention, an ulcer 28 is prevented from generating abnormal electrical activity in stomach 24 by desensitizing the tissue surrounding the ulcer.
Depending on the exact configuration, ulcer 28 itself may be desensitized. Alternatively or additionally, a non-excitatory field will be applied to regions surrounding ulcer 28 to fence it in by non-action potential propagating tissue.
The term fencing, as used herein ,refers to electrically isolating one segment of muscle ~ o from other segments, by inhibiting electrical activity in the tissue surrounding the one segment. Thus, an activation signal can neither enter nor leave the one segment. Alternatively to completely enclosing a segment, fences can be used to channel an activation signal along a desired path by creating fences on either side of the desired path. It should be noted that in channeling, it my be sufficient to significantly reduce the conduction velocity in the tissue where the fence is applied, since this will also modify the propagation vector of the activation front.
In a preferred embodiment of the invention, the tissue desensitization is accomplished by a controller 32, comprising an electrode 30, in contact with the tissue surrounding ulcer 28.
Although in this embodiment, controller 32 is shown to be external to stomach 24 and either zo inside or outside the body, in an alternative preferred embodiment of the invention, controller 32 is implanted inside the stomach, preferably placed by the aid of an endoscope and/or an electrical activity mapping probe, and preferably fixed to the wall of stomach 24, such as by using clips.
In accordance with another preferred embodiment of the invention, the pacemaker 25 portion of stomach 24, which is usually in the upper portion of stomach 24, is electrically isolated from other portions of the stomach. In Fig. 2 this is accomplished by applying a fence 25 in a band around stomach 24. Alternatively or additionally, the rest of stomach 24 may be desensitized. Alternatively or additionally, the pacemaker region itself may be desensitized to reduce its excitation rate. Desensitizing stomach 24 is useful for treating nausea, pregnancy 3o related nausea, reflex vomiting and other stomach conditions characterized by undesirable activation of the stomach.
A particular example of a condition is in the treatment of obesity, treatable by stomach desensitization. where delaying emptying of stomach 24 leads to a "full"
feeling and reduces the consumption of food by the patient. Desensitization of the stomach is preferably applied together with pacing of the stomach to achieve the desired activation.
Alternatively or additionally, intestines 27 are also controlled in a like manner, especially by blocking electrical activation signals from stomach 24 from arriving at intestine 27, such as by applying a fence at s duodenum 26 and/or at the antrum. In such examples, controller 32 is preferably controllable from outside the body, such as by using magnetic reed switches or using RF
telemetry. Thus, controller 32 may activated and deactivated when the patient needs it.
Alternatively or additionally, controller 32 includes sensors which sense various states of GI
tract 22, including, the location of food in a portion thereof and local electrical activity. In such an i o embodiment, controller 32 can modify the activation profile of GI tract 22, responsive to the existence and position of food matter therein.
In accordance with another preferred embodiment of the invention, a portion of GI tract 22 is desensitized and/or fenced in to allow it to heal. Fig. 2 shows a sutured region 38, and a controller 40 which applies a pair of fences 42 and 44, so that region 38 will be electrically isolated and so that local muscle activity will not damage the suture. Region 38 might also comprise an area from which an ulcer has been recently removed. In a preferred embodiment of the invention, such a controller is incorporated in an anastomosis button, which is used to connect two segments of the intestine. Preferably, such an anastomosis button senses electrical activity at one side thereof and applied an excitatory signal at an opposite side thereof to assure Zo a natural contraction of the intestines. Alternatively to completely inhibiting electrical activity at region 38 it may be desirable to intermittently allow local electrical and/or mechanical activity. Alternatively or additionally, the local force of contraction may be substantially reduced so as to reduce local stretching of the sutures. In a preferred embodiment of the invention, electrodes are implanted at the treated region during a laproscopic procedure (or an 25 open-abdomen procedure). An inhibitory electrical field is applied until it is deemed unnecessary by medical opinion.
1n a preferred embodiment of the invention, the electrodes are connected to an external muscle controller. Once the field is not necessary, the electrodes may be retracted, for example, using pull-out electrodes, as known in the art, for example, by twisting the electrodes ao or by releasing a suture which attaches the electrode to the muscle.
In a preferred embodiment of the invention, emptying of a stoma is inhibited by desensitizing the last few inches of the stoma, until such time as emptying thereof is desired. A
controller for a stoma preferably includes electrodes implanted along the last few inches of the WO 99!03533 PCT/IL97/00243 stoma for applying inhibitory or excitatory pulses. A stoma controller preferably also includes an external control button which allows the patient to choose between inhibiting the stoma, to stop exiting of solid wastes and stopping the inhibiting and/or stimulating the stoma, to allow travel of solid wastes along the stoma.
In a preferred embodiment of the invention, an electrical controller is used in lieu of a pharmaceutical to relax the bowels. One example which such a used is desirable is in spastic constipation, where a vicious cycle of tension-pain-constipation can be broken by relaxing the tension in the large intestines. A relaxing electrical field may be applied tanscutaneously, by implanted electrodes or may be applied using an inserted probe.
i o In another preferred embodiment of the invention, pains caused by ischemia of the intestines are reduced by reducing the contractility of the muscle at the diseased area, thereby reducing oxygen consumption and/or allowing better perfusion. Preferably, such a controller includes a pressure sensor and the controller is adjusted to reduce the force of contraction after a preset local force of contraction is reached.
In another preferred embodiment of the invention, acute diarrhea is treated by relaxing small intestine 27 and/or large intestine 29, so that they do not expel liquids. Such treatment may be advantageously applied using a probe with electrodes mounted thereon.
The electrodes are preferably spring electrodes which extend (radially) from the probe to assure good contact with the intestinal wall. This treatment is also useful for patients have a chronic irritated zo bowel, such as patients using strong medication and AIDS patients. In patients with a chronic problem, electrodes are preferably implanted on the outside of portions of the GI tract.
Another aspect of the present invention relates to increasing the contractility of at least a portion of GI tract 22, typically, to compensate for a medical conditions where the contractility of at least a portion of GI tract 22 is reduced to below normal levels. Such 2s conditions are typical in older patients. Subnormal contraction forces are also found in patients in whom a portion of the bowel is denervated, in particular, in patients having Aclazia (acquired or chronic) and in other disorders such as diffuse systemic sclerosis, diabetic enteropathy and primary visceral myopathies. In such conditions, the non-excitatory electric field is preferably applied using wire electrodes which are either attached to the inside of GI
ao tract 22, implanted in the muscle of GI tract 22 itself and/or using electrodes which are implanted on the outside surface of GI tract 22. Preferably, such electrodes are implanted by advancing a surgical probe along the outside of GI tract 22 and attaching electrodes at locations along the outside of the tract. Alternatively, a plurality of encapsulated controllers may be implanted at a plurality of points along GI tract 22. Each encapsulated controller includes a power source, electrodes and a controller which can be activated by external command to apply a non-excitatory field. Alternatively, each such encapsulated controller comprises an induction coil which converts RF radiation, which is transmitted to the coil from s an external source, to a non-excitatory electric field.
Another aspect of the present invention relates to simultaneously applying several different types of control so as to achieve more precise control of the activation profile of GI
tract 22. In one preferred embodiment of the invention, the motility of small intestine 27 and/or large intestine 29 is increased by inhibiting a returning wave. In a normally activated i o intestine, there is a forward wave which advances food matter in the intestine and also a returning wave, which causes the food to retreat along the intestine and assists in churning the food. In this preferred embodiment of the invention, the forward wave is not inhibited and the returning wave is inhibited so as to allow greater motility. Preferably, the returning wave is inhibited at its origin, the end of the intestine, by applying a fence at the location. Fig. 2 shows a controller 46 which applied a fence 48 at the end of small intestine 27.
Preferably, controller 46 uses a sensor 52 and/or a sensor 50 to detect the forward wave and/or the returning wave, either by their electrical activity or by their mechanical action. In a preferred embodiment of the invention, fence 48 is synchronized to the forward wave and applied only enough time to block the returning wave. Controller 46 is preferably inserted using an endoscope, preferably, zo from inside the small intestine.
In accordance with another preferred embodiment of the invention, electrical control is used to advance a stuck bolus 56. To advance bolus 56, electrical control is applied to an area 60, forward of bolus 56, to relax it. An area 58, behind and around bolus 56 is preferably controlled to increase its contractility. A controller 54 may be permanently implanted at Zs location 58, if, due to damage to nerve and/or muscle, boluses are expected to be stuck at this location. In a preferred embodiment of the invention, a significant portion of GI tract 22 is wired. A plurality of sensors are placed along the portion to detect a bolus in the portion.
Thereafter, the above described method for advancing the bolus is applied at the detected location. The plurality of sensors may be impedance sensors, which preferably use the same ao electrodes as the field applying electrodes.
Fig. 3 is a partial cut-through schematic illustration of a laid-open portion 72 of GI
tract 22, showing the orientation of smooth muscle fibers of the GI tract. GI
tract 22 is typically composed of three muscle layers, a thin, electrically conducting layer (not shown), a inner layer 72 of fibers aligned generally along the length of GI tract 22 and an outer layer 74 of fibers aligned generally perpendicular to the fibers in layer 72. Layer 72 controls local changes in length of GI tract 22, while layer 74 controls local changes in diameter of GI tract 22.
s In a preferred embodiment of the invention, a non-excitatory electrical field is selectively applied either to layer 72 or to layer 74, to either increase or decrease the local force of contraction. This selectivity may be achieved by aligning the direction of the electric field either in parallel to fibers in layer 72 or in parallel to fibers in layer 74. It should be noted that this type of selectivity is not possible when using an excitatory electric field, since such a ~ o field excites both layers 72 and 74.
In a preferred embodiment of the invention, a net electrode 76, having a plurality of individual electrodes 78, is used to affect this selectivity. If the net is placed so that its main axes are parallel to the fiber directions, an electrical field, having a direction parallel to one of the layers may be generated by choosing selected ones of electrodes 78. Ones of electrodes 78 ~ s can also be selected to apply a field which is diagonal to fibers in both layers. Alternatively or additionally, electrodes 78 are alternatively electrified, so that electric fields in both directions are alternatively applied. In particular, an inhibitory field may be applied in one direction while a contractility increasing field may be applied in the perpendicular direction. As can be appreciated, electrodes 78 may also be used to supply a pacing signal. In a preferred zo embodiment of the invention, electrodes 78 are also used to sense local electrical activity so as to better time the non-excitatory field.
Another type of electrode which is preferred for use in controlling smooth muscle, is an elongated electrode which is useful for applying an inhibiting electrical field, to create a fence.
The propagation of an activation signal is most advantageously controlled (increased or z5 decreased) by applying an electric field which is parallel to the fibers in the innermost layer of muscle, since that muscle layer conducts the activation signal. The propagation of the activation signal may be increased by applying a contractility enhancing electric field to the inner layer. Another method of selectively applying an electric field to only one layer is to insert the electrodes into the muscle, between the layers, so that substantially only one layer is ao inside the field.
Various apparatus for and methodologies for applying a non-excitatory electric field to cardiac muscle are described in six PCT applications, filed by applicant New Technologies (SA-YSY) Ltd. et al., in the Israel receiving office: PCT application PCT/IL97/00012, "Electrical Muscle Controller", filed January 8, 1997, and five PCT
applications filed on 3uly 9, 1997: PCT/IL97/00231, "Apparatus and Methods for Controlling the Contractility of Muscles", PCT/IL97/00232, "Drug-Device Combination for Controlling the Contractility of Muscles", PCT/IL97/00233, "Fencing of Cardiac Muscle", PCT/IL97/00235 "Cardiac Output s Controller" and PCT/IL97/00236, "Cardiac Output Enhanced Pacemaker", the disclosures of which are incorporated herein by reference. In particular, these PCT
applications describe various waveforms which may be used for applying non-excitatory electric fields, including, DC fields, AC fields, unipolar and bipolar fields and combinations of such fields. Further, PCT/IL97/00012 also describes the possibility of using light radiation and RF
radiation to i o affect calcium transfer in cardiac muscle cells and thereby affect their force of contraction.
These apparatus may be adapted, in accordance with preferred embodiments of the present invention to supply non-excitatory electric fields to smooth muscles.
When adapting the apparatus described herein to a particular physiology, it is expected that the amplitudes, delays and frequencies of the non-excitatory may need to be adapted. In a ~ s preferred embodiment of the invention, the apparatus is programmable by RF
radiation. Thus, it can be implanted and different sets of pulse parameters may be tested to determine an optimal set. Additionally, the parameters may need to be adjusted after a time, due to adaptation of the controlled muscle, changes in impedance of the electrodes or to change the function of the controller.
2o As will be appreciated, some patients will require only a short course of treatment, while other patients will require a longer course, in some cases, a permanent treatment will be required. In a preferred embodiment of the invention, apparatus, as described herein is adapted to be implanted in the body, Alternatively, such apparatus is adapted to be inserted in the body, for a shorter period of time, such as under a month. This adaptation may provide for using z5 different materials for the electrodes and for a different tradeoff between battery life and degree of control. Alternatively, such apparatus is adapted to be external to the body, either carried by the patient or free-standing. Preferably, at least the electrodes are implanted in the body or inserted in a body lumen.
It should also be noted that the activity of smooth muscles is also modified by their ao tension. In a preferred embodiment of the invention, a controller for smooth muscle includes sensors which measure the tension in the muscle and modifies the applied field responsive to the measured tension. Preferably, the tension is measured on the outside of the lumen of the smooth muscle. Alternatively or additionally, the tension is measured inside the lumen formed by. the smooth muscle. Alternatively or additionally, the tension is measured inside the smooth muscle.
In a preferred embodiment of the invention, the orientation and polarity of the electric field relative to the muscle fibers are also varied to determine an optimal orientation and/or s polarity which effect the desired control on the muscle. It should be noted that the two perpendicular muscle layers have different characteristics, such as resting tension, and, probably, a different response to the non-excitatory field. In a preferred embodiment of the invention, various orientations of the electric field to the muscle fibers, such as 0°, 5°, 10°, 30°
and 45°, are tested without moving the electrodes. This is preferably achieved using a net-type ~ o electrode, where each junction of the net may be individually electrified.
Thus substantially any effective field direction and polarity may be tested without moving the electrodes. Such a net electrode can also be used as a sensor net to more precisely determine the propagation direction of an activation front, as this propagation direction will generally be perpendicular to iso-chronal lines which mark equal activation times. In addition, changes in the activation profile, such as the effect of the controlling fields and/or arrhythmias can be detected from changes in the electrical signals sensed at the plurality of junctions of the net. In addition, mechanical activity may be localized by impedance measurement between individual ones of the junctions, either neighboring junctions, in which case characteristics of the muscle are measured or junctions which are on opposite sides of the smooth muscle, in which case zo occupancy of the GI tract may be determined.
It should be noted that the frequency of contraction of smooth muscle is usually much lower than cardiac muscle, enabling the use of simpler electronics and slower-responding power sources, for controlling smooth muscle. Furthermore, the propagation time along smooth muscle is usually much slower than for cardiac muscle. As a result, several seconds z5 may pass between the activation time at one location and the activation time at a second location. Thus, to ensure a proper delay between local activation and local application of a non-excitatory field, local determination of activation time is especially preferred for smooth muscle control. Such local determination is preferably performed by local sensing, however, in other preferred embodiment of the invention, the local activation time is calculated using an 3o estimated propagation velocity.
Fig. 4 illustrates a method of advancing a colonoscope 90 using local control of a portion 92 of GI tract 22. As minimally invasive procedures gain acceptance, periodic examination of the large intestine, using a colonoscope and of the small intestine, using an endoscope are becoming more common. In colon examination, the colonoscope is inserted into the anus and advanced along the colon. Periodically, the advance is stopped and the colon, surrounding the tip of the colonoscope, is inflated using air, so as to aid the advance of the s colonoscope and to aid the examination of the colon wall. Drugs which relax the colon are usually administered to the patient prior to the examination.
In accordance with a preferred embodiment of the invention, a colonoscope 90 has a plurality of electrodes 94 at least at its tip. In a preferred embodiment of the invention, these electrodes are used to apply a relaxing electric field to the colon and thus, reduce the air i o pressure required to inflate it. In addition, such relaxing reduces the force required to advance the colonoscope, thereby reducing the danger of perforation. In a preferred embodiment of the invention, the electrodes are extendible from the tip of colonoscope 90 so that they can engage colon portion 92 even when it is inflated. Preferably, the electrodes can be temporarily hooked onto colon portion 92.
~ s In accordance with another preferred embodiment of the invention, electrodes 94 are electrified to as to cause colon portion 92 itself to advance or to aid in the advance, of colonoscope 90. This advance may be achieved in one of two ways, either by blocking the forward wave and allowing the returning wave to advance colonoscope 90 or by selectively exciting muscles fibers in layers 72 and 74 (Fig. 3) so as to advance the colonoscope. One zo regimen of selective excitation includes: controlling layer 74 to more firmly grasp colonoscope 90 at its tip and exciting layer 72 to advance colonoscope 92. The order of excitation and the point from which the colon is excited, will, to a great measure, determine the direction of transport of colonoscope 92. Preferably, additional electrodes along colonoscope 90 (not shown) are used either to perform the same advancing action or to relax layer 74 along the zs length of colonoscope 92, to aid its advance. Selective excitation of a particular orientation of muscle fibers may be achieved by first inhibiting the other orientation of muscle fibers and then applying an excitatory stimulus. Retracting the colonoscope may be assisted by pacing colon potion 92 at the tip of colonoscope 90, so as to use the natural rhythm of colon portion 92 to retract colonoscope 90.
ao As can be appreciated, what has been described for a colonoscope applies equally to an endoscope, especially for retracting it. In a preferred embodiment of the invention, colonoscope 90 includes electrodes which apply a fencing field which blocks any local excitations from propagating to the rest of GI tract 22.
In accordance with another preferred embodiment of the invention, an endoscope which is used for entry into the bile duct, includes electrodes at its tip to apply a relaxing electric field, so as to enlarge the sphincter from the bile duct into the intestines. Preferably, such enlargement, when applied by a device which does not obstruct the bile duct, is used in s conjunction with treatments for destroying gall bladder stones, to aid the exit of broken fragments of stone into the intestines. Alternatively, such a device is used to excite and/or increase the contractility of the bile duct to aid in the transport of such stones and/or to aid in its normal functioning. A non-obstructing device may be implanted externally to the gall bladder duct, such as inside small intestine 27 and only the leads for the electrodes need be in ~ o the duct. Alternatively, also the leads are implanted external to the duct.
Fig. 5 is a schematic illustration of a capsule 102 for treatment of a hemorrhoid 100 in accordance with a preferred embodiment of the present invention. It has recently been determined that a major cause of hemorrhoids and a major factor in the non-healing of hemorrhoids and anal fissures is increased tension in the lower colon. The increased tension reduces the flow of blood, delaying healing and, at the same time, causing pain. It should be noted that tension in the lower part of the colon blocks blood from the rectal area, i.e., at some distance thereof. Topically applied Nitroglycerin (both at the hemorrhoids and inside the colon) has been suggested for reducing the tension in the lower colon.
However, this drug has several side effects, such as dizziness. In accordance with a preferred embodiment of the 2o invention, capsule 102 is inserted into the lower colon, where it applies relaxing electric fields, which either completely inhibit local contraction or at least, reduce it.
Capsule 102 preferably includes a plurality of electrodes 104, a power supply 106 for electrifying the electrodes and, preferably, an attachment 110 for easy removal of capsule 102. Preferably, capsule 102 senses, using a pressure transducer {not shown) abnormal pressures in the colon and applies a relaxing 2s electrical field only at those times or after such abnormal pressure has continued for a significant period of time. Alternatively or additionally, a tension sensor and/or an electrical activity sensor are used to sense the local activity of the colon.
In a preferred embodiment of the invention, suitable for female patients, capsule 102 is adapted to be inserted into a vagina and apply an electric field which affects the lower colon.
3o Preferably. electrodes 104 are arranged so that the field is applied asymmetrically and mostly in the direction of the colon, since it is generally undesirable to effect a relaxing field on the muscles of the bladder or on the rectal sphincter. Thus, electrodes 104 are preferably arranged only on one side of capsule 102. Capsule 102 preferably includes a marking so that the patient will insert it in the proper orientation. Alternatively to using a capsule, a controller 108 may be implanted outside the colon.
Fig. 6 is a schematic diagram of a uterus 120, illustrating applying local inhibitory electric fields to small portions of thereof. Undesirable electrical activity in the uterus may a induce premature labor in women. It is hypothesized that such undesirable electrical activity may, in many cases be cause by small regions of tissue, for example, near fibroids or myomas, where the stretching of the uterus may be maximal, or at inflamed locations.
Unlike the heart, it may not be desirable to ablate portions of the uterus, as this may reduce the fertility and/or may irreversibly damage the uterus. In a preferred embodiment of the invention, electrical ~ o excitation from a fibroid 122 is blocked from propagating by fencing the fibroid or by desensitizing fibroid 122 and tissue surrounding it. Fig. 6 shows a controller 124 which administers such non-excitatory electrical fields using a plurality of electrodes 126. Preferably controller 124 is external to uterus 120, but it is preferably implanted inside the body.
However, in other embodiments of the invention, only electrodes 126 of controller 124 are inserted in the body, for example, using a laproscopic procedure. Electrodes which need to be inserted into the back of the uterus may be inserted through the intestines.
Areas of the uterus which might cause such premature electrical activity may include, inflamed tissue, scar tissue, fibroids and malformed portions of the uterus.
These types of tissue may be detected either by visual inspection {using a hysteroscope) or, preferably, using 2o an electrical mapping probe, as known in the art of electrophysiology. Such mapping may also be performed during pregnancy, in which case the electrodes may be implanted from inside the uterus, during, or shortly after the mapping procedure. The controller will then preferably be external to the body, or possibly, in the vagina.
It has been suggested that there is a small region of the uterus, shown in Fig. 6 as a zs region 128, which generates a pacing signal for the entire uterus, at least during labor. In a preferred embodiment of the invention, labor is delayed by selectively inhibiting this area or by fencing it in, using non-excitatory electrical fields.
One aspect of the present invention relates to providing a more exact control over the process of labor than is possible using drugs. Several situations, where the response time of 3o drugs is not sufficient, the side effects too great or proper dosage is difficult to establish, include:
(a) stopping premature labor;
(b) stopping a labor where a cesarean section is indicated;
(c) situations where fine control of the force of contraction of the uterus is required;
(d) assisting a labor which is not advancing properly; and (e) stopping labor from ever starting, where it is contra-indicated.
3 (f) dictating a preferred contraction profile during labor.
Fig. 7 illustrates a implantable mufti-site stimulator/inhibitor 130, attached to uterus 120, in accordance with a referred embodiment of the invention. Controller 130 includes a plurality of electrodes 132, preferably arranged to cover substantially all of uterus 120. These electrodes may be attached to the outside of uterus 120, for example during a laproscopic i o procedure. Alternatively electrodes 132 are attached to the inside of uterus 120, such as by an hysteroscopic procedure. Alternatively, these electrodes may be external to the body, such as on the skin, and possible, inserted in the intestines adjacent the uterus. In a preferred embodiment of the invention, electrodes 132 are implanted prior to the pregnancy, such as during a previous cesarean section and/or using a laproscopic procedure.
Alternatively or ~ s additionally, electrodes to control smooth muscle are implanted in the blood vessels which adjacent the smooth muscle, such as the vessels which supply the smooth muscle. Preferably, the electrification of individual ones of electrodes 132 is timed to local electrical activity.
Electrodes 132 can also be used to provide a stimulating signal, which will both induce and sustain labor.
zo In accordance with another preferred embodiment of the invention, mufti-site pacing, is used to dictate a preferred activation (contraction) to the uterus.
Preferably, mufti-site pacing is complemented by local control of force of contraction (usually increase).
Alternatively or additionally, fences are applied to the uterus, to channels the activation signals in a desired manner. It should be noted that fencing may be applied by itself, in combination with a single 2s pacing location of in combination with multiple activation locations, in various preferred embodiments of the invention.
In accordance with a preferred embodiment of the invention, labor is advanced and/or assisted by increasing the force of contraction. The increase in the force of contraction causes a positive feedback effect which further increases the force of contraction. An increase in the ao force of contraction is also useful for assisting artificial abortions. In other situations, the force of contraction may need to be reduced or labor may have to be stopped completely, such as in cases of fetal distress or where there is danger of a rupture of the uterus, in which cases a cesarean section is to be performed. In cases of malformed or heavily scarred uteruses and in patients having a previous history of premature labor, controller 130 is preferably used to stop labor from ever occurring. Preferably, electrodes 132 are electrified to produce an inhibiting electrical field. Preferably, they are electrified only when controller 130 detects local electrical activity. Alternatively or additionally electrodes 132 are electrified responsive to the frequency s of contraction of uterus 120.
In accordance with another preferred embodiment of the invention, a birth canal 134 and/or a cervix of uterus 120 is relaxed using a locally applied electric field, to aid in exiting of a baby therethrough. Alternatively, the force of contraction of the birth canal is increased prior to labor, to avoid a miscarriage. Alternatively or additionally, the muscles of the birth canal are ~ o also stimulated using excitatory signals to cause their contraction and avoid a miscarriage.
It should be appreciated that uterus 120 undergoes very significant changes in size over the course of a pregnancy. Thus, the leads of electrodes 132 are preferably made very flexible and elastic. In one preferred embodiment of the present invention, the leads are formed of a coiled wire, so that if the lead is stretched, the coil tightens, rather than break the wire.
~ s Preferably, the coil is wound about a flexible core. Preferably, the leads of electrodes 132 include weakened points, such that if strain of above a predetermined value is applied to the lead it will break at one of the preselected points, rather than damage tissue structures adjacent the lead.
In a preferred embodiment of the invention, each of electrodes 132 comprises an 2o encapsulated power supply and controller 130 coordinates the individual electrodes using wireless communication. Thus, electrodes 132 do not need to be interconnected by wires.
Alternatively, electrodes 132 are coordinate their electrification using techniques well known in the art of distributed computing and without a central controller.
Alternatively to synchronizing their activity, each of electrodes 132 operates responsive to local activity.
2s Fig. 8 illustrates a balloon-type insert 140 for uterus 120, for controlling cramps. Insert 140 comprises a plurality of electrodes 142, disposed on the outside of the device, which electrodes are electrified by a power source 144. Insert 140 is preferably inflatable to assure better contact with the inner wall of uterus 120. In a preferred mode of operation, various ones of electrodes 142 function as electrical activity sensors. Once such electrical activity is sensed, ao an inhibiting field is applied at those locations to prevent the future occurrence of electrical activation and/or to prevent its propagation. Alternatively, such a device continuously applies an inhibitory electrical field. In a preferred embodiment of the invention, the inhibitory electrical field is applied between electrodes 142 and an external electrode which is placed on the abdomen and/or on the back. Although point electrodes are shown in the figure, it should be appreciated that other forms of electrodes, such as elongated electrodes may also be used.
Preferably, the device is removed from the body when cramps are not expected.
Fig. 9 shows a controller 150 which modifies the output of a gland, such as a pancreas a 152. In some glands, such as pancreas 152, execration of hormones into a blood vessel 154 is meditated by electrical excitation of the hormone producing cells (beta islet cells in the pancreas). The electrical excitation, as in many smooth muscles, is initiated by chemical signals. In accordance with a preferred embodiment of the invention, the hormone execrating cells are desensitized so that they do not respond to these chemical signals, or, if some of the ~ o cells do respond, these cells cannot generate a propagating activation signal, since the surrounding cells are electrically deactivated. Thus, the amount of execrated hormone is reduced. This method is especially useful in diseases, such as tumors, where a gland over produces its hormone.
Controller 150 preferably includes an electrode 158 and, preferably, a second electrode 156 so as to create an electric field which inhibits or reduces the electrical activity of the hormone producing cells. The casing of controller I 50 may be used as the second electrode, in this and in other of the above described preferred embodiments. As can be appreciated, the levels of hormone in the blood and the electrical activity of the hormone producing cells is rather difficult to detect using current technology. Thus, in a preferred embodiment of the 2o invention, a substantially constant inhibitory electrical field is applied.
Preferably, the polarity of the field is changed periodically, so as to prevent ionic-meditated damage and the ionization of electrodes 156 and 158. Alternatively, controller 150 may measure local electrical activity, hormone levels or it may measure a bodily indicator, such as glucose level, which is correlated with the hormone level and apply a voltage to electrodes 156 and 158, as indicated.
25 Another aspect of the present invention relates to controlling blood pressure and/or other circulatory parameters such as the load on a heart. Preferably, the control is exerted in conjunction with the use of a cardiac controller, such as described in the above referenced PCT
applications. Fig. 10 illustrates a blood pressure and/or heart load controller 160, attached to major blood vessels, in accordance with a preferred embodiment of the invention. A heart 162 ao receives blood from an abdominal vena cava 168 and pumps it to an aorta 164 and from there to an abdominal aorta 166. In the event of a spasm in aorta 164, it greatly constricts, increasing the afterload on the heart. In many cases this types of spasm will cause dizziness. In patients having constricted coronary arteries, the increased cardiac demand may also cause a painful episode of angina pectoris.
In accordance with a preferred embodiment of the invention, the afterload of heart 162 is momentarily reduced by relaxing large arteries. Alternatively or additionally, the preload of heart 162 is momentarily reduced by relaxing large veins. Reducing either the preload and/or the afterload, reduces the work demanded from heart 162 and will, in many cases, stop the pain of angina pectoris. Alternatively or additionally, the walls of the large blood vessels are relaxed in order to lower the blood pressure, during an acute episode of high blood pressure.
Alternatively, the blood vessels may be constricted, such as during an acute episode of low i o blood pressure. Reducing the load on heart 162 is especially beneficial if practiced while extending the diastole of the left ventricle of heart 162, such as by extending the refractory periods of muscle cells therein, for example, as described in the above mentioned PCT
applications.
The choice of the particular blood vessel to relax depends, inter alia, on the type of ~ s load which is desirable to reduce, on whether the hypertension is pulmonary or systemic and, in case of a spasm, if the vessel having a spasm has implanted electrodes.
In a preferred embodiment of the invention, the vessel in spasm is detected using by measuring changes in the impedance between the electrodes surrounding the blood vessel.
Alternatively, rather than determining which vessel is in spasm, all wired blood vessels are 2o relaxed.
In a prefewed embodiment of the invention, controller 160 includes a pair of electrodes 170 and 172 for controlling abdominal vena cava 168. Alternatively or additionally, controller 160 includes a pair of electrodes 174 and 176 for controlling the abdominal aorta.
Alternatively or additionally, controller 160 includes a pair of electrode 178 and 180 for 2s controlling the aorta, preferably, at or about the aortic arch. In a preferred embodiment of the invention, the electrodes are net-type electrodes, since the muscle fibers in blood vessels are mostly oriented perpendicular to the direction of flow of blood and a field perpendicular to the blood flow direction is desirable. Alternatively, the electrodes are elongated electrodes, arranged parallel to the blood flow, to apply a field perpendicular to the blood flow, between 3o pairs of electrodes. Preferably, controller 160 is externally controllable, so that a patient can activate it when he feels pain and/or dizziness. Alternatively or additionally, controller 160 includes a blood pressure sensor (not shown), for automated closed loop blood pressure control. Alternatively or additionally, controller i60 includes an ECG sensor or a blood flow sensor, so that the application of the fields to the vascular system may be synchronized to the cardiac rhytlun. Preferably, controller 160 includes a fail-safe cutoff which prevents the patient from reducing or increasing the blood pressure beyond acceptable limits.
Figs. 11-16 describe experiments which show that the force of contraction of a smooth s muscle can be increased or decreased by application of non-excitatory electric fields directly to the muscle.
Male, New Zealand White rabbits (1-2Kg body weight) were dissected and various portions of their GI tract were removed and used for the following experiments. The animals were anesthetized using pentobarbitone (Ceva, France), 60 mg/Kg body weight, by IV. The ~ o abdominal wall was opened to expose the abdominal viscera. Required portions of the GI tract were removed and placed in a cold (4 °C) oxygenated (95/5 02/C02) Krebs-Heseleit solution, containing (in mM): KCI 4.5, NaCI 118, NaHC03 24, MgS04 1.19. KH2P04 1.18, Glucose 11 and CaCl2 2.52). The removed portions were then further dissected in a dissection chamber (Hugo Sachs Electronik (HSE), Germany) to produce a single strip of GI muscle which was ~s then placed in an organ bath. The organ bath is a type 813 (I-18E) by HSE
and it includes a temperature controller type 319 and a force transducer type F30 with a 660 type amplifier. The elapsed time for the removal procedure is about 3-5 minutes.
Fig. 11 is a schematic illustration of an experimental setup used to determine the effects of a non-excitatory field on smooth muscle cells. A GI muscle portion 200 is fixed in 2o an organ bath chamber, one end is fixed to the chamber using a plastic clip, while the other end is hooked to a pressure transducer 202. The length of the GI muscle is adjusted to allow maximal isometric force. The organ bath is temperature controlled and the GI
muscle is continuously perfused (7-12 ml/min) with the above described oxygenated solution, maintained at about 36.1 °C. The muscle was allowed to remain in the organ bath for a 30 2s minutes equilibrium period prior to experimentation.
The organ bath includes two Ag-AgCI electrodes 206 which were used to apply a pacing pulse, where required by the experimental protocol. These electrodes were chlorodized before each experiment. The pacing stimuli was provided by a constant current source. The pacing waveform was a square wave pulse. A non-excitatory electric field was applied using 3o carbon electrodes 208 (shaped from carbon rods provided by Goodfellow, UK) which were placed about 2-3 millimeters apart. The electrodes were electrified by a constant current source 210. The two constant current sources were home made current sources whose current level was modified by computer control. The output of these current sources was continuously monitored to verify that a constant current was produced. The entire experiment was controlled by a computer 212 and the data was acquired using dedicated data acquisition circuits, such as a PCI-MIO-16XE50 or an AT-MIO-16E-2 (National Instrument, USA). The organ bath was s placed on an anti-vibration table (TMC, USA). Both the pacing current and the non-excitatory current were constant current pulses. The amplitude of the pacing is different between the following experiments, in the main pat, to counteract polarization of the electrodes. The delay of the non-excitatory field (NT current) is from the start of the pacing signal.
Figs. 12-17 show experimental results using a section of GI tract from the Jejunum.
~ o The fields were applied and the transducer measured force were approximately along the direction of the GI tract. As described above, variations in the orientation can change the effect of the non-excitatory pulse. The polarity of the field was sometimes selected to cause a force increasing effect and sometimes to produce a force decreasing effect.
Fig. 12 is a graph of experimental results showing an increase in the force of ~ s contraction of a smooth muscle, as a result of the application of a non-excitatory electric field in accordance with a preferred embodiment of the invention. The non-excitatory field is shown as a full bar marked "NT."
In this experiment, the pacing was 0.15 Hz, 30ms duration and 3mA current. The non-excitatory field was a 200 ms current pulse at IOmA applied at a delay of SOms after the 2o pacing. As seen in Fig. 12, an increase of about 300% in the force of contraction was achieved.
Figs. 13-16 are graph of experimental results showing a significant decrease in the force of contraction of a smooth muscle, as a result of the application of a non-excitatory electric field in accordance with a preferred embodiment of the invention.
In Fig. 13, a 70% reduction in force of contraction was achieved. The pacing was the 2e same as in Fig. 12, while the non-excitatory pulse was applied for 100ms, at a 100ms delay after the pacing and at lOmA. It should be noted that the effect of the non-excitatory field lasted for a while after the removal thereof. In addition, the non-excitatory field also reduced the base tone of the muscle, i.e., it relaxed it.
In Fig. 14, a substantial reduction in force of contraction was achieved. The pacing ao was faster than in Figs. 12 and 13: 0.25 Hz, 30ms duration and IOmA
amplitude. The non-excitatory pulse was applied for SOms, at a SOms delay after the pacing and at a lOmA
amplitude. In this experiment too, a reduction in muscle tone is observed.
In Fig. 15, a substantial reduction in force of contraction was achieved. The pacing was different from that of Fig. 14: 0.25 Hz, 30ms duration and 3mA amplitude.
The non-excitatory pulse was applied for 60ms, at a 200ms delay after the pacing and at l OmA. In this experiment too, a reduction in muscle tone is observed.
In Fig. 16, a substantial reduction in force of contraction was achieved. The pacing was similar to that of Figs. 12 and 13: 0.15 Hz, 30ms duration and 3mA
amplitude. The non-excitatory pulse was applied for 100ms, at a SOms delay after the pacing and at l OmA. In this experiment too, a reduction in muscle tone is observed.
In Fig. 17, a substantial reduction in force of contraction was achieved using a i o substantially constant non-excitatory field. The pacing was 0.25 Hz, 2ms duration and SmA
amplitude. The non-excitatory pulse was applied for 3990ms, at a Sms delay after the pacing and at an amplitude of lSmA. A nearly complete blockage of contraction is observed of In this experiment too, a reduction in muscle tone is observed.
Fig. 18 is a graph of experimental results showing an increase in the force of i 5 contraction of a smooth muscle of a urine bladder, as a result of the application of a non excitatory electric field, in accordance with a preferred embodiment of the invention. The bladder segment was prepared as described above. It was paced at 0.2 Hz, 30ms duration and 6mA amplitude. The non-excitatory field was a 60ms duration pulse applied at a 30ms delay after pacing and having an amplitude of IOmA. It should be noted that the resting tension of Zo the bladder segment also increased as a result of applying the non-excitatory field.
Fig. 19 is a graph of experimental results showing an increase in the force of contraction of a smooth muscle of a rabbit uterus, as a result of the application of a non-excitatory electric field, in accordance with a preferred embodiment of the invention. The uterus segment was prepared as described above. The muscle segment was not artificially zs paced, it was self paced. The non-excitatory field was a pulse of 20ms duration, IOmA
amplitude and applied at 0.2 Hz. It should be noted that not only was the force of contraction signif candy reduced, after about 30 seconds of application of the non-excitatory field, the contraction of the tissue was apparently completely inhibited. The effects of the field also lasted for a short time after the removal thereof.
so It will be appreciated by a person skilled in the art, that although the present invention has been described with reference to the preferred embodiments, the scope of the invention is not limited by what has thus far been described. In particular adaptation of the above described durations, amplitudes and delays of non-excitatory signals to particular patients is considered to be within the ability of a man of the art and also within the scope of the present invention.
Thus, the scope of the present invention is limited only by the claims which follow.
Preferably, the apparatus includes an electrical activity sensor which detects electrical activity at the portion and wherein said controller electrifies said electrodes responsive to signals from said sensor. Preferably, the controller electrifies each of said electrodes is responsive to its local electrical activity. Additionally or alternatively, the electrical activity i o sensor senses electrical activity through ones of said plurality of electrodes.
Alternatively or additionally, the apparatus includes an impedance sensor, which senses at least one impedance between selected ones of said plurality of electrodes.
Alternatively or additionally, the apparatus includes a force transducer which detects mechanical activity at the portion and wherein said controller electrifies said electrodes responsive to signals from said sensor. Preferably, said controller applies an inhibitory electric field to the muscle, when said mechanical activity is above a certain threshold. Alternatively or additionally, the electrification at each of said electrodes is responsive to its local mechanical activity.
Alternatively or additionally, the non-excitatory field inhibits mechanical activity at the zo portion. Alternatively or additionally, the non-excitatory field reduces the force of contraction at the portion. Alternatively or additionally, the non-excitatory field increases the force of contraction at the portion. In a preferred embodiment of the invention, the controller electrifies at least one of said electrodes with an excitatory electric field.
In a preferred embodiment of the invention, the plurality of electrodes are arranged in a 2s two-dimensional matrix.
Alternatively or additionally, the controller selectively electrifies ones of said plurality of electrodes to selectively generate one of two perpendicular electric fields.
In a preferred embodiment of the invention, the controller is adapted to be implanted inside a stomach and attached to the stomach wall.
ao Alternatively or additionally, the apparatus is adapted to be implanted inside a uterus and attached to the uterus wall.
Alternatively or additionally, the apparatus is adapted to be implanted inside the body and outside a portion of the GI tract.
IO
Alternatively or additionally, the apparatus is adapted to be implanted inside the body and outside a uterus.
In a preferred embodiment of the invention, where the controller is adapted for a uterus, the controller determines a frequency of contractions in the uterus and wherein said controller electrifies said electrodes responsive to said determined frequency.
Preferably, the electrodes comprise elastic leads.
In a preferred embodiment of the invention, the electrodes are attached ~to a plurality of remote regions of said uterus.
In a preferred embodiment of the invention, the controller senses and inhibits ~ o mechanical activity in substantially the entire uterus. Alternatively or additionally, the controller increases the force of contraction in substantially the entire uterus.
In a preferred embodiment of the invention, the controller is in a capsule adapted to be inserted into a rectum or into a vagina.
Alternatively or additionally, the electrodes are adapted to be implanted inside the body while said controller is adapted to be situated outside the body. Preferably, the electrodes are adapted to be disconnected from said smooth muscle from outside the body.
There is also provided in accordance with a preferred embodiment of the invention, an anastomosis button comprising:
a sleeve portion for joining two portions of a GI tract;
2o at least two electrodes adapted to be in electrical contact with the GI
tract, at either side of the button; and a controller which electrifies the electrodes to reduce the force of contraction in the GI
tract near the button.
Preferably, the controller transmits a pacing signal from the GI tract on one side of the 25 button to the GI tract on the other side of the button.
Alternatively or additionally, reducing the force comprises inhibiting electrical activity of the GI tract at the button.
There is also provided in accordance with a preferred embodiment of the invention, apparatus for inhibiting a returning wave in an intestine, comprises:
so at least one electrode for applying an inhibiting electric field to a portion of the intestine;
a sensor which senses the propagation of waves in the intestine; and a controller which electrifies said electrode responsive to a sensed propagating wave.
Preferably, the sensor detects the returning wave.
There is also provided in accordance with a preferred embodiment of the invention, apparatus for advancing a bolus comprising:
s at least one first electrode, for applying an electrical Held to a first portion of the GI
tract adjacent said bolus;
at least one second electrode, for applying an electric field to a second portion of the GI
tract downstream from said bolus; and a controller which electrifies the at least one first electrode with a non-excitatory field ~ o which increases the force of contraction at the first portion and which electrifies the at least one second electrode with a non-excitatory electric field which relaxes the muscle at the second portion.
Preferably, the apparatus comprises an impedance sensor for detecting the existence of a bolus at the first portion of the GI tract.
There is also provided in accordance with a preferred embodiment of the invention, a method of aiding the examination of a GI tract, comprising:
providing an elongated probe, having a tip, inside a portion of a GI tract;
and applying a non-excitatory electric field to the portion of the GI tract adjacent the tip of the probe, which electric field is operative to relax the portion of the GI
tract.
Zo Preferably, the method includes inflating the portion of the GI tract after applying said field.
Preferably. the portion of the GI tract is a portion adjacent a bile duct.
There is also provided in accordance with a preferred embodiment of the invention, a method of advancing an elongated probe having a tip and inserted in a portion of the GI tract, 25 comprising:
applying a first electric field at the tip, which field constricts the portion of GI tract to grasp the probe; and applying a second electric field to a second portion of the GI tract adjacent a portion of the probe distal from the tip, which electric field causes the elongation of the second portion of 3o the GI tract.
Preferably, the method includes applying a third electrical field to a third portion of the GI tract, adjacent portions of the probe distal from the tip, which electrical field relaxes the third portion of the GI tract so that it does not constrict around the probe.
_ Alternatively or additionally, the method includes applying an inhibitory electric field to block the propagation of activation signals between the first portion and other portions of the GI tract.
There is also provided in accordance with a preferred embodiment of the invention, a s method of advancing an elongated probe, comprising:
providing an elongated probe, having a tip, inside a portion of a GI tract;
and applying an excitatory electric field to the portion of the GI tract, which excitatory electric field causes the bowel to transport the probe in a desired direction.
Preferably, the excitatory field is selectively applied either at the tip or at a different ~ o location along the probe, distal from the tip, depending on the desired direction of transport.
Alternatively or additionally, the method includes applying an inhibitory electric field, to the portion, to block the propagation of activation signals between the portion and the rest of the GI tract.
In a prefen-ed embodiment of the invention, the probe is an endoscope.
Alternatively, i s the probe is a colonoscope.
There is also provided in accordance with a preferred embodiment of the invention, an elongated probe adapted for advancing in a GI tract, comprising:
an elongated body having a tip;
a plurality of electrodes disposed at least at the tip; and 2o a controller which selectively electrifies the electrodes to produce non-excitatory electric fields which affect the contraction of smooth muscle.
Preferably, the probe includes a second plurality of electrodes distributed along at least a portion of the body of the probe.
Alternatively or additionally, the controller electrifies said first plurality of electrodes 25 to cause said portion of GI tract to selectively advance or retreat said probe.
Alternatively or additionally, the controller electrifies ones of said first and said second pluralities of electrodes to inhibit the propagation of activation signals from the portion of the GI tract adjacent the tip of the probe to other portions of the GI tract.
There is also provided in accordance with a preferred embodiment of the invention, a ao method of controlling a uterus, comprising:
determining a portion of the uterus suspected of generating undesirable activation signals; and applying a local inhibitory electrical field, to the uterus muscle, around the suspected portion.
There is also provided in accordance with a preferred embodiment of the invention, a method of controlling a uterus, comprising:
determining a portion of the uterus suspected of generating undesirable activation signals; and applying a local desensitizing electrical field to the suspected portion.
There is also provided in accordance with a preferred embodiment of the invention, a method of controlling labor, comprising:
determining a local activation at a plurality of locations of a uterus; and applying a non-excitatory electric field, to each of the plurality of locations, at a time delay from said local activation time.
Preferably. the non-excitatory field increases the force of contraction at ones of said plurality of locations.
Alternatively or additionally, said non-excitatory field reduces the force of contraction at ones of said plurality of locations.
Alternatively or additionally, the non-excitatory field inhibits the conduction of propagating action potentials across the uterus.
In a preferred embodiment of the invention, the method includes implanting a plurality zo of electrodes at the plurality of locations. Preferably, the electrodes comprise encapsulated power sources. Alternatively or additionally, the implanting is performed during a cesarean section.
There is also provided in accordance with a preferred embodiment of the invention, a method of aiding birth, comprising applying a non-excitatory electrical field to a birth canal, zs which non-excitatory f eld relaxes the birth canal.
There is also provided in accordance with a preferred embodiment of the invention, a method of preventing premature birth, comprising applying a non-excitatory electrical field to a birth canal, which non-excitatory field increases the force of contraction in the birth canal.
There is also provided in accordance with a preferred embodiment of the invention, a 3o method of Treating cramps of the uterus, comprising:
detecting electrical or mechanical activity in at least one location of the uterus; and applying a non-excitatory electrical field at the at least one location.
There is also provided in accordance with a preferred embodiment of the invention, a method of treating cramps, comprising:
providing at least one electrode inside the uterus, which one electrode is in contact with at least a portion of the uterus, at at least one location thereof; and s applying a non-excitatory electrical field to the portion.
In a preferred embodiment of the invention, the non-excitatory field inhibits the propagation of activation signals at the at least one location. Alternatively or additionally, non-excitatory field reduces the force of contraction at the at least one location.
There is also provided in accordance with a preferred embodiment of the invention, ~ o apparatus for controlling a smooth muscle, comprising a plurality of individual capsules, each capsule including at least one electrode and a power source which electrifies the electrode, which electrode applies a local non-excitatory field. Preferably, each of said capsules includes a sensor which measures local activity of the smooth muscle.
Alternatively or additionally, the capsules are operative to synchronize the electrification of their electrodes without the meditation of an external controller.
There is also provided in accordance with a preferred embodiment of the invention, apparatus for treating cramps, comprising:
a flexible body having an outside portion and adapted to snugly engage the inside of a uterus;
zo a plurality of electrodes disposed on the outside of said body; and a controller which electrifies said electrodes to generate a non-excitatory electrical field.
Preferably, the flexible body is inflatable. Alternatively or additionally, the apparatus includes a second electrode adapted to be placed outside the uterus.
zs There is also provided in accordance with a preferred embodiment of the invention, a method of controlling a circulatory system, including a heart, comprising:
providing electrodes adjacent a vein; and electrifying the electrodes to constrict the vein, such that the preload on the heart is - increased.
3o There is also provided in accordance with a preferred embodiment of the invention, a method of controlling a circulatory system, including a heart, comprising:
providing electrodes adjacent a vein; and electrifying the electrodes to expand the vein, such that the preload on the heart is reduced.
There is also provided in accordance with a preferred embodiment of the invention, a method of controlling a circulatory system, including a heart, comprising:
providing electrodes adjacent an artery; and electrifying the electrodes to constrict the artery, such that the afterload on the heart is increased.
There is also provided in accordance with a preferred embodiment of the invention, a method of controlling a circulatory system, including a heart, comprising:
~o providing electrodes adjacent an artery; and electrifying the electrodes to expand the artery, such that the afterload on the heart is reduced.
There is also provided in accordance with a preferred embodiment of the invention, a method of controlling vascular spasm, in a circulatory system having a heart, comprising:
determining a vessel in spasm, which results in an abnormally constricted lumen; and applying a non-excitatory electric field to the vessel, which field causes the lumen to expand.
It should be appreciated that two or more of the above methods of controlling the circulatory system may also be practiced together.
zo In a preferred embodiment of the invention, the method includes applying a non-excitatory electric field to at least a portion of the heart.
There is also provided in accordance with a preferred embodiment of the invention, apparatus for controlling a circulatory system having a heart, comprising:
a plurality of electrodes disposed about at least one major blood vessel;
zs a blood pressure sensor which measures blood pressure; and a controller which electrifies the plurality of electrodes responsive to the measured blood pressure.
Preferably. the apparatus includes an external control which activates said controller.
Alternatively or additionally, the apparatus includes an ECG sensor which detects the ao cardiac rhythm. Alternatively or additionally, the controller relaxes said blood vessel to reduce the blood pressure. Alternatively or additionally, the controller contracts said blood vessel to increase the blood pressure.
There is also provided in accordance with a preferred embodiment of the invention, a method of controlling the output of a gland, comprising:
providing at least one electrode near the gland; and applying a non-excitatory electric field to the gland.
Preferably, the non-excitatory electric field inhibits the activity of hormone producing cells in the gland. Alternatively or additionally, the non-excitatory electric field is a substantially DC field. Preferably, the method includes periodically changing the polarity of the field. Preferably, one polarity is applied for a significantly larger portion of the time.
In a preferred embodiment of the invention, the gland is a pancreas.
Preferably, the ~ o method includes monitoring a level of glucose in the blood, wherein applying said electric field comprises applying said field responsive to said monitored level.
There is also provided in accordance with a preferred embodiment of the invention, apparatus for controlling the output of a gland, comprising:
a sensor for measuring a level of a chemical in a blood stream;
at least one electrode adjacent said gland; and a controller which electrifies said electrode with a non-excitatory electric field, responsive to the measured level.
Preferably, the chemical is glucose. Alternatively or additionally, the apparatus is completely implantable.
2o There is also provided in accordance with a preferred embodiment of the invention, a method of controlling the activation profile of a smooth muscle organ, comprising:
determining a desired activation profile for the organ; and applying at least one non-excitatory field to a portion of the organ to modify its activation profile.
is Preferably, the activation profile comprises a mechanical activation profile.
In a preferred embodiment of the invention, the method includes:
measuring a tension in the smooth muscle; and modifying the application of the non-excitatory field responsive to the measured tension.
ao Alternatively or additionally, the method includes:
measuring a pressure in the smooth muscle; and modifying the application of the non-excitatory field responsive to the measured pressure.
Alternatively or additionally, the method includes applying at least one excitatory electric field to the smooth muscle.
Alternatively or additionally, the method includes applying a non-excitatory field comprises applying an inhibitory electric field to the muscle.
s Alternatively or additionally, applying a non-excitatory field comprises applying an electric field which reduces the force of contraction in the muscle.
Alternatively or additionally, applying a non-excitatory field comprises applying an electric field which increases the force of contraction in the muscle.
Preferably, the organ is a stomach. Alternatively or additionally, the organ is a small ~ o intestine. Alternatively or additionally, the organ is a large intestine.
Alternatively or additionally, the organ is a uterus.
There is also provided in accordance with a preferred embodiment of the invention, apparatus for dictating a mechanical activation profile to a smooth muscle organ, comprising:
at least three electrodes, adapted to be distributed over the organ;
i s at least one sensor which senses local mechanical activity of the organ;
and a controller which electrifies selected ones of said electrodes, responsive to the sensed local mechanical activity, to dictate a particular activation profile to the organ.
Preferably, the organ is a uterus and wherein the activation profile is a pattern of contraction during labor.
2o Although many embodiments of the present invention are described herein mainly as methods, it should be appreciated that the scope of the invention includes apparatus adapted to perform these methods. In particular, the scope of the invention includes programmable electric field generators which are programmed to supply an electric field in accordance with a preferred embodiment of the invention. In a preferred embodiment of the invention, 25 programmable variables include, waveforms, amplitudes, frequencies, durations, delays, synchronization and response to locally measured parameters of muscle activity. It should be appreciated that the behavior of a muscle in one portion thereof can be modified by applying an electric field to a second portion thereof, for example, by inhibiting the propagation of an activation signal to the one portion or by changing the layout of forces acting on the one 3o portion.
BRIEF DESCRIPTION OF THE DRAWINGS
. The present invention will be more clearly understood from the following detailed description of the preferred embodiments of the invention, together with the accompanying figures, in which:
Fig. 1 is a schematic illustration of a gastrointestinal (GI) tract;
Fig. 2 is a schematic illustration of an unfolded GI tract, illustrating various preferred embodiments of the present invention;
Fig. 3 is a partial cut-through schematic illustration of a laid-open portion of the GI
tract, showing the orientation of smooth muscle fibers of the GI tract;
Fig. 4 illustrates a method of advancing a colonoscope using local control of the GI
~o tract;
Fig. 5 is a schematic illustration of a capsule for treatment of hemorrhoids in accordance with a preferred embodiment of the present invention;
Fig. 6 is a schematic diagram of a uterus, illustrating applying local inhibitory electric fields to small portions of the uterus, in accordance with a preferred embodiment of the present ~ s invention;
Fig. 7 illustrates an implantable multi-site stimulator/inhibitor, attached to a uterus, in accordance with a preferred embodiment of the invention;
Fig. 8 illustrates a balloon-type insert for a uterus, for controlling cramps;
Fig. 9 illustrates a controller which modifies the output of a gland, such as the 2o pancreas;
Fig. 10 illustrates a blood pressure and/or heart load controller, attached to major blood vessels, in accordance with a preferred embodiment of the invention;
Fig. 11 is a schematic illustration of an experimental setup used to determine effects of a non-excitatory field on smooth muscle cells;
25 Fig. 12 is a graph of experimental results showing an increase in the force of contraction of a smooth muscle, as a result of the application of a non-excitatory electric field, in accordance with a preferred embodiment of the invention;
Figs. 13-17 are graphs of experimental results each showing a significant decrease in the force of contraction of a smooth muscle, as a result of the application of a non-excitatory 3o electric field in accordance with a preferred embodiment of the invention;
Fig. 18 is a graph of experimental results showing an increase in the force of contraction of a smooth muscle of the urine bladder, as a result of the application of a non-excitatory electric field, in accordance with a preferred embodiment of the invention; and Fig. 19 is a graph of experimental results showing a decrease in the force of contraction of a smooth muscle of an unpaced uterus, as a result of the application of a non-excitatory electric field, in accordance with a preferred embodiment of the invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Fig. 1 is a schematic illustration of a gastrointestinal (GI) tract 22 of a patient 20. In accordance with a preferred embodiment of the i-nvention, local control of the force of contraction and/or the sensitivity of portions of the GI tract to excitation is achieved by applying local, non-excitatory electric fields directly to the portion to be controlled. Although such non-excitatory electric fields do not create a propagating action potential in the controlled ~ o portion, the fields does modify the response of the portion to an artificial or naturally occurring activation signal, when it arrives. In particular, the inventors have found that it is possible to increase or to decrease the force of contraction of a portion of GI tract. In addition, it is possible to desensitize a muscle segment so that it has a reduced reaction or so it does not react at all to normal amplitudes of activation signals. This desensitization, while reversible, may be ~ s made to last a certain period of time after the removal of the controlling electric field.
Two particular waveforms of non-excitatory electric fields have been found to be beneficial. A first type is a substantially constant field (whose polarity may be occasionally switched to reduce ionic polarization effects). This field may be applied without any synchronization to the controlled muscle. However, the inventors have found it useful to stop 2o the inhibiting field shortly before the activation signal is to arrive at the controlled muscle, so as to reduce the amplitude of activation signal required to excite the controlled muscle. A
second type of non-excitatory field is a pulse which is applied in synchrony with the arrival of an activation signal. The pulse is applied either before, during the arrival of the signal or at a delay after its arrival (a long enough delay after activation is equivalent to applying the pulse 25 before activation). The inventors believe that a non-excitatory electric field applied after the activation signal tends to increase the force of contraction of the controlled muscle, by increasing a plateau duration of the muscle contraction. It is hypothesized that a non-excitatory field applied at a greater delay after the arrival of the activation signal extends the refractory period (possibly by hyperpolarizing the muscle cells so that the activation signal does not 3o cause a depolarization). As a result, at least some of the muscle cells do not respond to the activation signal and the force of contraction of the muscle is reduced. Thus, the stronger the non-excitatory signal, the more cells will be hyperpolarized and the lower will be the force of contraction. In an extreme case, none of the muscle cells will respond to the activation signal and the propagation thereof will be inhibited. It is also possible that the non-excitatory field directly reduces affects the force of contraction achieved by a single muscle fiber.
It should be noted that various embodiments of the present invention, as described herein, can be used in conjunction with drug therapies, with a synergistic interaction andlor to s allow a reduced dose of drug to produce a desired effect and/or to allow increased dosages of drugs to be used, while limiting their adverse side effects using electrical control. In addition, such electrical control may be practiced together with electrical pacing of the GI tract, including mufti-site pacing. In accordance with a preferred embodiment of the present invention, substantially any activation profile of the GI tract may be achieved by selectively ~ o pacing portions of the GI tract and creating desensitized regions between the paced portions, so that an activation signal does not propagate from one paced portion to the next. In addition, such electrical control may also be practiced in combination with electrical stimulation of a vagus nerve.
The term "electric field" has been used to described the non-excitatory field used to control a muscle. The terms "field" and "current pulse" are used interchangeably herein, since, in the body, both are generated when a voltage potential is created between two electrodes. In a preferred embodiment of the invention, the field is applied by maintaining a constant current between at least two electrodes. Alternatively, a voltage potential may be controlled instead of controlling the current.
2o Muscle tissue generally adapts to frequent and/or intense activation by increasing its mass. In a preferred embodiment of the invention, the pacing location is chosen to increase the strength of the muscle at the location. Preferably, the area around the location is desensitized so that the activation signal does not propagate to the rest of the GI tract.
Alternatively or additionally, local muscle mass is increased by modifying the force of contraction at the 25 location. Generally, a maximum force of contraction is desired, since it will generally cause the greatest increase in muscle mass.
Fig. 2 is a schematic drawing of GI tract 22, unfolded for illustrative purposes, for illustrating various preferred embodiments of the present invention. GI tract 22 includes a stomach 24, a duodenum 26, a small intestine 27 and a large intestine 29.
3o In accordance with a first preferred embodiment of the invention, a portion of the GI
tract is desensitized and/or electrically isolated from activation signals.
Isolation from electrical signals may be achieved by desensitizing tissue which surrounds the portion.
Ulcers cause inflammation of the GI tract tissue, which inflamed tissue may generate spurious activation signals. Alternatively, the inflamed tissue may exhibit a very low threshold of excitability. Both these abnormalities may cause arrhythmias in stomach 24.
In a preferred embodiment of the invention, an ulcer 28 is prevented from generating abnormal electrical activity in stomach 24 by desensitizing the tissue surrounding the ulcer.
Depending on the exact configuration, ulcer 28 itself may be desensitized. Alternatively or additionally, a non-excitatory field will be applied to regions surrounding ulcer 28 to fence it in by non-action potential propagating tissue.
The term fencing, as used herein ,refers to electrically isolating one segment of muscle ~ o from other segments, by inhibiting electrical activity in the tissue surrounding the one segment. Thus, an activation signal can neither enter nor leave the one segment. Alternatively to completely enclosing a segment, fences can be used to channel an activation signal along a desired path by creating fences on either side of the desired path. It should be noted that in channeling, it my be sufficient to significantly reduce the conduction velocity in the tissue where the fence is applied, since this will also modify the propagation vector of the activation front.
In a preferred embodiment of the invention, the tissue desensitization is accomplished by a controller 32, comprising an electrode 30, in contact with the tissue surrounding ulcer 28.
Although in this embodiment, controller 32 is shown to be external to stomach 24 and either zo inside or outside the body, in an alternative preferred embodiment of the invention, controller 32 is implanted inside the stomach, preferably placed by the aid of an endoscope and/or an electrical activity mapping probe, and preferably fixed to the wall of stomach 24, such as by using clips.
In accordance with another preferred embodiment of the invention, the pacemaker 25 portion of stomach 24, which is usually in the upper portion of stomach 24, is electrically isolated from other portions of the stomach. In Fig. 2 this is accomplished by applying a fence 25 in a band around stomach 24. Alternatively or additionally, the rest of stomach 24 may be desensitized. Alternatively or additionally, the pacemaker region itself may be desensitized to reduce its excitation rate. Desensitizing stomach 24 is useful for treating nausea, pregnancy 3o related nausea, reflex vomiting and other stomach conditions characterized by undesirable activation of the stomach.
A particular example of a condition is in the treatment of obesity, treatable by stomach desensitization. where delaying emptying of stomach 24 leads to a "full"
feeling and reduces the consumption of food by the patient. Desensitization of the stomach is preferably applied together with pacing of the stomach to achieve the desired activation.
Alternatively or additionally, intestines 27 are also controlled in a like manner, especially by blocking electrical activation signals from stomach 24 from arriving at intestine 27, such as by applying a fence at s duodenum 26 and/or at the antrum. In such examples, controller 32 is preferably controllable from outside the body, such as by using magnetic reed switches or using RF
telemetry. Thus, controller 32 may activated and deactivated when the patient needs it.
Alternatively or additionally, controller 32 includes sensors which sense various states of GI
tract 22, including, the location of food in a portion thereof and local electrical activity. In such an i o embodiment, controller 32 can modify the activation profile of GI tract 22, responsive to the existence and position of food matter therein.
In accordance with another preferred embodiment of the invention, a portion of GI tract 22 is desensitized and/or fenced in to allow it to heal. Fig. 2 shows a sutured region 38, and a controller 40 which applies a pair of fences 42 and 44, so that region 38 will be electrically isolated and so that local muscle activity will not damage the suture. Region 38 might also comprise an area from which an ulcer has been recently removed. In a preferred embodiment of the invention, such a controller is incorporated in an anastomosis button, which is used to connect two segments of the intestine. Preferably, such an anastomosis button senses electrical activity at one side thereof and applied an excitatory signal at an opposite side thereof to assure Zo a natural contraction of the intestines. Alternatively to completely inhibiting electrical activity at region 38 it may be desirable to intermittently allow local electrical and/or mechanical activity. Alternatively or additionally, the local force of contraction may be substantially reduced so as to reduce local stretching of the sutures. In a preferred embodiment of the invention, electrodes are implanted at the treated region during a laproscopic procedure (or an 25 open-abdomen procedure). An inhibitory electrical field is applied until it is deemed unnecessary by medical opinion.
1n a preferred embodiment of the invention, the electrodes are connected to an external muscle controller. Once the field is not necessary, the electrodes may be retracted, for example, using pull-out electrodes, as known in the art, for example, by twisting the electrodes ao or by releasing a suture which attaches the electrode to the muscle.
In a preferred embodiment of the invention, emptying of a stoma is inhibited by desensitizing the last few inches of the stoma, until such time as emptying thereof is desired. A
controller for a stoma preferably includes electrodes implanted along the last few inches of the WO 99!03533 PCT/IL97/00243 stoma for applying inhibitory or excitatory pulses. A stoma controller preferably also includes an external control button which allows the patient to choose between inhibiting the stoma, to stop exiting of solid wastes and stopping the inhibiting and/or stimulating the stoma, to allow travel of solid wastes along the stoma.
In a preferred embodiment of the invention, an electrical controller is used in lieu of a pharmaceutical to relax the bowels. One example which such a used is desirable is in spastic constipation, where a vicious cycle of tension-pain-constipation can be broken by relaxing the tension in the large intestines. A relaxing electrical field may be applied tanscutaneously, by implanted electrodes or may be applied using an inserted probe.
i o In another preferred embodiment of the invention, pains caused by ischemia of the intestines are reduced by reducing the contractility of the muscle at the diseased area, thereby reducing oxygen consumption and/or allowing better perfusion. Preferably, such a controller includes a pressure sensor and the controller is adjusted to reduce the force of contraction after a preset local force of contraction is reached.
In another preferred embodiment of the invention, acute diarrhea is treated by relaxing small intestine 27 and/or large intestine 29, so that they do not expel liquids. Such treatment may be advantageously applied using a probe with electrodes mounted thereon.
The electrodes are preferably spring electrodes which extend (radially) from the probe to assure good contact with the intestinal wall. This treatment is also useful for patients have a chronic irritated zo bowel, such as patients using strong medication and AIDS patients. In patients with a chronic problem, electrodes are preferably implanted on the outside of portions of the GI tract.
Another aspect of the present invention relates to increasing the contractility of at least a portion of GI tract 22, typically, to compensate for a medical conditions where the contractility of at least a portion of GI tract 22 is reduced to below normal levels. Such 2s conditions are typical in older patients. Subnormal contraction forces are also found in patients in whom a portion of the bowel is denervated, in particular, in patients having Aclazia (acquired or chronic) and in other disorders such as diffuse systemic sclerosis, diabetic enteropathy and primary visceral myopathies. In such conditions, the non-excitatory electric field is preferably applied using wire electrodes which are either attached to the inside of GI
ao tract 22, implanted in the muscle of GI tract 22 itself and/or using electrodes which are implanted on the outside surface of GI tract 22. Preferably, such electrodes are implanted by advancing a surgical probe along the outside of GI tract 22 and attaching electrodes at locations along the outside of the tract. Alternatively, a plurality of encapsulated controllers may be implanted at a plurality of points along GI tract 22. Each encapsulated controller includes a power source, electrodes and a controller which can be activated by external command to apply a non-excitatory field. Alternatively, each such encapsulated controller comprises an induction coil which converts RF radiation, which is transmitted to the coil from s an external source, to a non-excitatory electric field.
Another aspect of the present invention relates to simultaneously applying several different types of control so as to achieve more precise control of the activation profile of GI
tract 22. In one preferred embodiment of the invention, the motility of small intestine 27 and/or large intestine 29 is increased by inhibiting a returning wave. In a normally activated i o intestine, there is a forward wave which advances food matter in the intestine and also a returning wave, which causes the food to retreat along the intestine and assists in churning the food. In this preferred embodiment of the invention, the forward wave is not inhibited and the returning wave is inhibited so as to allow greater motility. Preferably, the returning wave is inhibited at its origin, the end of the intestine, by applying a fence at the location. Fig. 2 shows a controller 46 which applied a fence 48 at the end of small intestine 27.
Preferably, controller 46 uses a sensor 52 and/or a sensor 50 to detect the forward wave and/or the returning wave, either by their electrical activity or by their mechanical action. In a preferred embodiment of the invention, fence 48 is synchronized to the forward wave and applied only enough time to block the returning wave. Controller 46 is preferably inserted using an endoscope, preferably, zo from inside the small intestine.
In accordance with another preferred embodiment of the invention, electrical control is used to advance a stuck bolus 56. To advance bolus 56, electrical control is applied to an area 60, forward of bolus 56, to relax it. An area 58, behind and around bolus 56 is preferably controlled to increase its contractility. A controller 54 may be permanently implanted at Zs location 58, if, due to damage to nerve and/or muscle, boluses are expected to be stuck at this location. In a preferred embodiment of the invention, a significant portion of GI tract 22 is wired. A plurality of sensors are placed along the portion to detect a bolus in the portion.
Thereafter, the above described method for advancing the bolus is applied at the detected location. The plurality of sensors may be impedance sensors, which preferably use the same ao electrodes as the field applying electrodes.
Fig. 3 is a partial cut-through schematic illustration of a laid-open portion 72 of GI
tract 22, showing the orientation of smooth muscle fibers of the GI tract. GI
tract 22 is typically composed of three muscle layers, a thin, electrically conducting layer (not shown), a inner layer 72 of fibers aligned generally along the length of GI tract 22 and an outer layer 74 of fibers aligned generally perpendicular to the fibers in layer 72. Layer 72 controls local changes in length of GI tract 22, while layer 74 controls local changes in diameter of GI tract 22.
s In a preferred embodiment of the invention, a non-excitatory electrical field is selectively applied either to layer 72 or to layer 74, to either increase or decrease the local force of contraction. This selectivity may be achieved by aligning the direction of the electric field either in parallel to fibers in layer 72 or in parallel to fibers in layer 74. It should be noted that this type of selectivity is not possible when using an excitatory electric field, since such a ~ o field excites both layers 72 and 74.
In a preferred embodiment of the invention, a net electrode 76, having a plurality of individual electrodes 78, is used to affect this selectivity. If the net is placed so that its main axes are parallel to the fiber directions, an electrical field, having a direction parallel to one of the layers may be generated by choosing selected ones of electrodes 78. Ones of electrodes 78 ~ s can also be selected to apply a field which is diagonal to fibers in both layers. Alternatively or additionally, electrodes 78 are alternatively electrified, so that electric fields in both directions are alternatively applied. In particular, an inhibitory field may be applied in one direction while a contractility increasing field may be applied in the perpendicular direction. As can be appreciated, electrodes 78 may also be used to supply a pacing signal. In a preferred zo embodiment of the invention, electrodes 78 are also used to sense local electrical activity so as to better time the non-excitatory field.
Another type of electrode which is preferred for use in controlling smooth muscle, is an elongated electrode which is useful for applying an inhibiting electrical field, to create a fence.
The propagation of an activation signal is most advantageously controlled (increased or z5 decreased) by applying an electric field which is parallel to the fibers in the innermost layer of muscle, since that muscle layer conducts the activation signal. The propagation of the activation signal may be increased by applying a contractility enhancing electric field to the inner layer. Another method of selectively applying an electric field to only one layer is to insert the electrodes into the muscle, between the layers, so that substantially only one layer is ao inside the field.
Various apparatus for and methodologies for applying a non-excitatory electric field to cardiac muscle are described in six PCT applications, filed by applicant New Technologies (SA-YSY) Ltd. et al., in the Israel receiving office: PCT application PCT/IL97/00012, "Electrical Muscle Controller", filed January 8, 1997, and five PCT
applications filed on 3uly 9, 1997: PCT/IL97/00231, "Apparatus and Methods for Controlling the Contractility of Muscles", PCT/IL97/00232, "Drug-Device Combination for Controlling the Contractility of Muscles", PCT/IL97/00233, "Fencing of Cardiac Muscle", PCT/IL97/00235 "Cardiac Output s Controller" and PCT/IL97/00236, "Cardiac Output Enhanced Pacemaker", the disclosures of which are incorporated herein by reference. In particular, these PCT
applications describe various waveforms which may be used for applying non-excitatory electric fields, including, DC fields, AC fields, unipolar and bipolar fields and combinations of such fields. Further, PCT/IL97/00012 also describes the possibility of using light radiation and RF
radiation to i o affect calcium transfer in cardiac muscle cells and thereby affect their force of contraction.
These apparatus may be adapted, in accordance with preferred embodiments of the present invention to supply non-excitatory electric fields to smooth muscles.
When adapting the apparatus described herein to a particular physiology, it is expected that the amplitudes, delays and frequencies of the non-excitatory may need to be adapted. In a ~ s preferred embodiment of the invention, the apparatus is programmable by RF
radiation. Thus, it can be implanted and different sets of pulse parameters may be tested to determine an optimal set. Additionally, the parameters may need to be adjusted after a time, due to adaptation of the controlled muscle, changes in impedance of the electrodes or to change the function of the controller.
2o As will be appreciated, some patients will require only a short course of treatment, while other patients will require a longer course, in some cases, a permanent treatment will be required. In a preferred embodiment of the invention, apparatus, as described herein is adapted to be implanted in the body, Alternatively, such apparatus is adapted to be inserted in the body, for a shorter period of time, such as under a month. This adaptation may provide for using z5 different materials for the electrodes and for a different tradeoff between battery life and degree of control. Alternatively, such apparatus is adapted to be external to the body, either carried by the patient or free-standing. Preferably, at least the electrodes are implanted in the body or inserted in a body lumen.
It should also be noted that the activity of smooth muscles is also modified by their ao tension. In a preferred embodiment of the invention, a controller for smooth muscle includes sensors which measure the tension in the muscle and modifies the applied field responsive to the measured tension. Preferably, the tension is measured on the outside of the lumen of the smooth muscle. Alternatively or additionally, the tension is measured inside the lumen formed by. the smooth muscle. Alternatively or additionally, the tension is measured inside the smooth muscle.
In a preferred embodiment of the invention, the orientation and polarity of the electric field relative to the muscle fibers are also varied to determine an optimal orientation and/or s polarity which effect the desired control on the muscle. It should be noted that the two perpendicular muscle layers have different characteristics, such as resting tension, and, probably, a different response to the non-excitatory field. In a preferred embodiment of the invention, various orientations of the electric field to the muscle fibers, such as 0°, 5°, 10°, 30°
and 45°, are tested without moving the electrodes. This is preferably achieved using a net-type ~ o electrode, where each junction of the net may be individually electrified.
Thus substantially any effective field direction and polarity may be tested without moving the electrodes. Such a net electrode can also be used as a sensor net to more precisely determine the propagation direction of an activation front, as this propagation direction will generally be perpendicular to iso-chronal lines which mark equal activation times. In addition, changes in the activation profile, such as the effect of the controlling fields and/or arrhythmias can be detected from changes in the electrical signals sensed at the plurality of junctions of the net. In addition, mechanical activity may be localized by impedance measurement between individual ones of the junctions, either neighboring junctions, in which case characteristics of the muscle are measured or junctions which are on opposite sides of the smooth muscle, in which case zo occupancy of the GI tract may be determined.
It should be noted that the frequency of contraction of smooth muscle is usually much lower than cardiac muscle, enabling the use of simpler electronics and slower-responding power sources, for controlling smooth muscle. Furthermore, the propagation time along smooth muscle is usually much slower than for cardiac muscle. As a result, several seconds z5 may pass between the activation time at one location and the activation time at a second location. Thus, to ensure a proper delay between local activation and local application of a non-excitatory field, local determination of activation time is especially preferred for smooth muscle control. Such local determination is preferably performed by local sensing, however, in other preferred embodiment of the invention, the local activation time is calculated using an 3o estimated propagation velocity.
Fig. 4 illustrates a method of advancing a colonoscope 90 using local control of a portion 92 of GI tract 22. As minimally invasive procedures gain acceptance, periodic examination of the large intestine, using a colonoscope and of the small intestine, using an endoscope are becoming more common. In colon examination, the colonoscope is inserted into the anus and advanced along the colon. Periodically, the advance is stopped and the colon, surrounding the tip of the colonoscope, is inflated using air, so as to aid the advance of the s colonoscope and to aid the examination of the colon wall. Drugs which relax the colon are usually administered to the patient prior to the examination.
In accordance with a preferred embodiment of the invention, a colonoscope 90 has a plurality of electrodes 94 at least at its tip. In a preferred embodiment of the invention, these electrodes are used to apply a relaxing electric field to the colon and thus, reduce the air i o pressure required to inflate it. In addition, such relaxing reduces the force required to advance the colonoscope, thereby reducing the danger of perforation. In a preferred embodiment of the invention, the electrodes are extendible from the tip of colonoscope 90 so that they can engage colon portion 92 even when it is inflated. Preferably, the electrodes can be temporarily hooked onto colon portion 92.
~ s In accordance with another preferred embodiment of the invention, electrodes 94 are electrified to as to cause colon portion 92 itself to advance or to aid in the advance, of colonoscope 90. This advance may be achieved in one of two ways, either by blocking the forward wave and allowing the returning wave to advance colonoscope 90 or by selectively exciting muscles fibers in layers 72 and 74 (Fig. 3) so as to advance the colonoscope. One zo regimen of selective excitation includes: controlling layer 74 to more firmly grasp colonoscope 90 at its tip and exciting layer 72 to advance colonoscope 92. The order of excitation and the point from which the colon is excited, will, to a great measure, determine the direction of transport of colonoscope 92. Preferably, additional electrodes along colonoscope 90 (not shown) are used either to perform the same advancing action or to relax layer 74 along the zs length of colonoscope 92, to aid its advance. Selective excitation of a particular orientation of muscle fibers may be achieved by first inhibiting the other orientation of muscle fibers and then applying an excitatory stimulus. Retracting the colonoscope may be assisted by pacing colon potion 92 at the tip of colonoscope 90, so as to use the natural rhythm of colon portion 92 to retract colonoscope 90.
ao As can be appreciated, what has been described for a colonoscope applies equally to an endoscope, especially for retracting it. In a preferred embodiment of the invention, colonoscope 90 includes electrodes which apply a fencing field which blocks any local excitations from propagating to the rest of GI tract 22.
In accordance with another preferred embodiment of the invention, an endoscope which is used for entry into the bile duct, includes electrodes at its tip to apply a relaxing electric field, so as to enlarge the sphincter from the bile duct into the intestines. Preferably, such enlargement, when applied by a device which does not obstruct the bile duct, is used in s conjunction with treatments for destroying gall bladder stones, to aid the exit of broken fragments of stone into the intestines. Alternatively, such a device is used to excite and/or increase the contractility of the bile duct to aid in the transport of such stones and/or to aid in its normal functioning. A non-obstructing device may be implanted externally to the gall bladder duct, such as inside small intestine 27 and only the leads for the electrodes need be in ~ o the duct. Alternatively, also the leads are implanted external to the duct.
Fig. 5 is a schematic illustration of a capsule 102 for treatment of a hemorrhoid 100 in accordance with a preferred embodiment of the present invention. It has recently been determined that a major cause of hemorrhoids and a major factor in the non-healing of hemorrhoids and anal fissures is increased tension in the lower colon. The increased tension reduces the flow of blood, delaying healing and, at the same time, causing pain. It should be noted that tension in the lower part of the colon blocks blood from the rectal area, i.e., at some distance thereof. Topically applied Nitroglycerin (both at the hemorrhoids and inside the colon) has been suggested for reducing the tension in the lower colon.
However, this drug has several side effects, such as dizziness. In accordance with a preferred embodiment of the 2o invention, capsule 102 is inserted into the lower colon, where it applies relaxing electric fields, which either completely inhibit local contraction or at least, reduce it.
Capsule 102 preferably includes a plurality of electrodes 104, a power supply 106 for electrifying the electrodes and, preferably, an attachment 110 for easy removal of capsule 102. Preferably, capsule 102 senses, using a pressure transducer {not shown) abnormal pressures in the colon and applies a relaxing 2s electrical field only at those times or after such abnormal pressure has continued for a significant period of time. Alternatively or additionally, a tension sensor and/or an electrical activity sensor are used to sense the local activity of the colon.
In a preferred embodiment of the invention, suitable for female patients, capsule 102 is adapted to be inserted into a vagina and apply an electric field which affects the lower colon.
3o Preferably. electrodes 104 are arranged so that the field is applied asymmetrically and mostly in the direction of the colon, since it is generally undesirable to effect a relaxing field on the muscles of the bladder or on the rectal sphincter. Thus, electrodes 104 are preferably arranged only on one side of capsule 102. Capsule 102 preferably includes a marking so that the patient will insert it in the proper orientation. Alternatively to using a capsule, a controller 108 may be implanted outside the colon.
Fig. 6 is a schematic diagram of a uterus 120, illustrating applying local inhibitory electric fields to small portions of thereof. Undesirable electrical activity in the uterus may a induce premature labor in women. It is hypothesized that such undesirable electrical activity may, in many cases be cause by small regions of tissue, for example, near fibroids or myomas, where the stretching of the uterus may be maximal, or at inflamed locations.
Unlike the heart, it may not be desirable to ablate portions of the uterus, as this may reduce the fertility and/or may irreversibly damage the uterus. In a preferred embodiment of the invention, electrical ~ o excitation from a fibroid 122 is blocked from propagating by fencing the fibroid or by desensitizing fibroid 122 and tissue surrounding it. Fig. 6 shows a controller 124 which administers such non-excitatory electrical fields using a plurality of electrodes 126. Preferably controller 124 is external to uterus 120, but it is preferably implanted inside the body.
However, in other embodiments of the invention, only electrodes 126 of controller 124 are inserted in the body, for example, using a laproscopic procedure. Electrodes which need to be inserted into the back of the uterus may be inserted through the intestines.
Areas of the uterus which might cause such premature electrical activity may include, inflamed tissue, scar tissue, fibroids and malformed portions of the uterus.
These types of tissue may be detected either by visual inspection {using a hysteroscope) or, preferably, using 2o an electrical mapping probe, as known in the art of electrophysiology. Such mapping may also be performed during pregnancy, in which case the electrodes may be implanted from inside the uterus, during, or shortly after the mapping procedure. The controller will then preferably be external to the body, or possibly, in the vagina.
It has been suggested that there is a small region of the uterus, shown in Fig. 6 as a zs region 128, which generates a pacing signal for the entire uterus, at least during labor. In a preferred embodiment of the invention, labor is delayed by selectively inhibiting this area or by fencing it in, using non-excitatory electrical fields.
One aspect of the present invention relates to providing a more exact control over the process of labor than is possible using drugs. Several situations, where the response time of 3o drugs is not sufficient, the side effects too great or proper dosage is difficult to establish, include:
(a) stopping premature labor;
(b) stopping a labor where a cesarean section is indicated;
(c) situations where fine control of the force of contraction of the uterus is required;
(d) assisting a labor which is not advancing properly; and (e) stopping labor from ever starting, where it is contra-indicated.
3 (f) dictating a preferred contraction profile during labor.
Fig. 7 illustrates a implantable mufti-site stimulator/inhibitor 130, attached to uterus 120, in accordance with a referred embodiment of the invention. Controller 130 includes a plurality of electrodes 132, preferably arranged to cover substantially all of uterus 120. These electrodes may be attached to the outside of uterus 120, for example during a laproscopic i o procedure. Alternatively electrodes 132 are attached to the inside of uterus 120, such as by an hysteroscopic procedure. Alternatively, these electrodes may be external to the body, such as on the skin, and possible, inserted in the intestines adjacent the uterus. In a preferred embodiment of the invention, electrodes 132 are implanted prior to the pregnancy, such as during a previous cesarean section and/or using a laproscopic procedure.
Alternatively or ~ s additionally, electrodes to control smooth muscle are implanted in the blood vessels which adjacent the smooth muscle, such as the vessels which supply the smooth muscle. Preferably, the electrification of individual ones of electrodes 132 is timed to local electrical activity.
Electrodes 132 can also be used to provide a stimulating signal, which will both induce and sustain labor.
zo In accordance with another preferred embodiment of the invention, mufti-site pacing, is used to dictate a preferred activation (contraction) to the uterus.
Preferably, mufti-site pacing is complemented by local control of force of contraction (usually increase).
Alternatively or additionally, fences are applied to the uterus, to channels the activation signals in a desired manner. It should be noted that fencing may be applied by itself, in combination with a single 2s pacing location of in combination with multiple activation locations, in various preferred embodiments of the invention.
In accordance with a preferred embodiment of the invention, labor is advanced and/or assisted by increasing the force of contraction. The increase in the force of contraction causes a positive feedback effect which further increases the force of contraction. An increase in the ao force of contraction is also useful for assisting artificial abortions. In other situations, the force of contraction may need to be reduced or labor may have to be stopped completely, such as in cases of fetal distress or where there is danger of a rupture of the uterus, in which cases a cesarean section is to be performed. In cases of malformed or heavily scarred uteruses and in patients having a previous history of premature labor, controller 130 is preferably used to stop labor from ever occurring. Preferably, electrodes 132 are electrified to produce an inhibiting electrical field. Preferably, they are electrified only when controller 130 detects local electrical activity. Alternatively or additionally electrodes 132 are electrified responsive to the frequency s of contraction of uterus 120.
In accordance with another preferred embodiment of the invention, a birth canal 134 and/or a cervix of uterus 120 is relaxed using a locally applied electric field, to aid in exiting of a baby therethrough. Alternatively, the force of contraction of the birth canal is increased prior to labor, to avoid a miscarriage. Alternatively or additionally, the muscles of the birth canal are ~ o also stimulated using excitatory signals to cause their contraction and avoid a miscarriage.
It should be appreciated that uterus 120 undergoes very significant changes in size over the course of a pregnancy. Thus, the leads of electrodes 132 are preferably made very flexible and elastic. In one preferred embodiment of the present invention, the leads are formed of a coiled wire, so that if the lead is stretched, the coil tightens, rather than break the wire.
~ s Preferably, the coil is wound about a flexible core. Preferably, the leads of electrodes 132 include weakened points, such that if strain of above a predetermined value is applied to the lead it will break at one of the preselected points, rather than damage tissue structures adjacent the lead.
In a preferred embodiment of the invention, each of electrodes 132 comprises an 2o encapsulated power supply and controller 130 coordinates the individual electrodes using wireless communication. Thus, electrodes 132 do not need to be interconnected by wires.
Alternatively, electrodes 132 are coordinate their electrification using techniques well known in the art of distributed computing and without a central controller.
Alternatively to synchronizing their activity, each of electrodes 132 operates responsive to local activity.
2s Fig. 8 illustrates a balloon-type insert 140 for uterus 120, for controlling cramps. Insert 140 comprises a plurality of electrodes 142, disposed on the outside of the device, which electrodes are electrified by a power source 144. Insert 140 is preferably inflatable to assure better contact with the inner wall of uterus 120. In a preferred mode of operation, various ones of electrodes 142 function as electrical activity sensors. Once such electrical activity is sensed, ao an inhibiting field is applied at those locations to prevent the future occurrence of electrical activation and/or to prevent its propagation. Alternatively, such a device continuously applies an inhibitory electrical field. In a preferred embodiment of the invention, the inhibitory electrical field is applied between electrodes 142 and an external electrode which is placed on the abdomen and/or on the back. Although point electrodes are shown in the figure, it should be appreciated that other forms of electrodes, such as elongated electrodes may also be used.
Preferably, the device is removed from the body when cramps are not expected.
Fig. 9 shows a controller 150 which modifies the output of a gland, such as a pancreas a 152. In some glands, such as pancreas 152, execration of hormones into a blood vessel 154 is meditated by electrical excitation of the hormone producing cells (beta islet cells in the pancreas). The electrical excitation, as in many smooth muscles, is initiated by chemical signals. In accordance with a preferred embodiment of the invention, the hormone execrating cells are desensitized so that they do not respond to these chemical signals, or, if some of the ~ o cells do respond, these cells cannot generate a propagating activation signal, since the surrounding cells are electrically deactivated. Thus, the amount of execrated hormone is reduced. This method is especially useful in diseases, such as tumors, where a gland over produces its hormone.
Controller 150 preferably includes an electrode 158 and, preferably, a second electrode 156 so as to create an electric field which inhibits or reduces the electrical activity of the hormone producing cells. The casing of controller I 50 may be used as the second electrode, in this and in other of the above described preferred embodiments. As can be appreciated, the levels of hormone in the blood and the electrical activity of the hormone producing cells is rather difficult to detect using current technology. Thus, in a preferred embodiment of the 2o invention, a substantially constant inhibitory electrical field is applied.
Preferably, the polarity of the field is changed periodically, so as to prevent ionic-meditated damage and the ionization of electrodes 156 and 158. Alternatively, controller 150 may measure local electrical activity, hormone levels or it may measure a bodily indicator, such as glucose level, which is correlated with the hormone level and apply a voltage to electrodes 156 and 158, as indicated.
25 Another aspect of the present invention relates to controlling blood pressure and/or other circulatory parameters such as the load on a heart. Preferably, the control is exerted in conjunction with the use of a cardiac controller, such as described in the above referenced PCT
applications. Fig. 10 illustrates a blood pressure and/or heart load controller 160, attached to major blood vessels, in accordance with a preferred embodiment of the invention. A heart 162 ao receives blood from an abdominal vena cava 168 and pumps it to an aorta 164 and from there to an abdominal aorta 166. In the event of a spasm in aorta 164, it greatly constricts, increasing the afterload on the heart. In many cases this types of spasm will cause dizziness. In patients having constricted coronary arteries, the increased cardiac demand may also cause a painful episode of angina pectoris.
In accordance with a preferred embodiment of the invention, the afterload of heart 162 is momentarily reduced by relaxing large arteries. Alternatively or additionally, the preload of heart 162 is momentarily reduced by relaxing large veins. Reducing either the preload and/or the afterload, reduces the work demanded from heart 162 and will, in many cases, stop the pain of angina pectoris. Alternatively or additionally, the walls of the large blood vessels are relaxed in order to lower the blood pressure, during an acute episode of high blood pressure.
Alternatively, the blood vessels may be constricted, such as during an acute episode of low i o blood pressure. Reducing the load on heart 162 is especially beneficial if practiced while extending the diastole of the left ventricle of heart 162, such as by extending the refractory periods of muscle cells therein, for example, as described in the above mentioned PCT
applications.
The choice of the particular blood vessel to relax depends, inter alia, on the type of ~ s load which is desirable to reduce, on whether the hypertension is pulmonary or systemic and, in case of a spasm, if the vessel having a spasm has implanted electrodes.
In a preferred embodiment of the invention, the vessel in spasm is detected using by measuring changes in the impedance between the electrodes surrounding the blood vessel.
Alternatively, rather than determining which vessel is in spasm, all wired blood vessels are 2o relaxed.
In a prefewed embodiment of the invention, controller 160 includes a pair of electrodes 170 and 172 for controlling abdominal vena cava 168. Alternatively or additionally, controller 160 includes a pair of electrodes 174 and 176 for controlling the abdominal aorta.
Alternatively or additionally, controller 160 includes a pair of electrode 178 and 180 for 2s controlling the aorta, preferably, at or about the aortic arch. In a preferred embodiment of the invention, the electrodes are net-type electrodes, since the muscle fibers in blood vessels are mostly oriented perpendicular to the direction of flow of blood and a field perpendicular to the blood flow direction is desirable. Alternatively, the electrodes are elongated electrodes, arranged parallel to the blood flow, to apply a field perpendicular to the blood flow, between 3o pairs of electrodes. Preferably, controller 160 is externally controllable, so that a patient can activate it when he feels pain and/or dizziness. Alternatively or additionally, controller 160 includes a blood pressure sensor (not shown), for automated closed loop blood pressure control. Alternatively or additionally, controller i60 includes an ECG sensor or a blood flow sensor, so that the application of the fields to the vascular system may be synchronized to the cardiac rhytlun. Preferably, controller 160 includes a fail-safe cutoff which prevents the patient from reducing or increasing the blood pressure beyond acceptable limits.
Figs. 11-16 describe experiments which show that the force of contraction of a smooth s muscle can be increased or decreased by application of non-excitatory electric fields directly to the muscle.
Male, New Zealand White rabbits (1-2Kg body weight) were dissected and various portions of their GI tract were removed and used for the following experiments. The animals were anesthetized using pentobarbitone (Ceva, France), 60 mg/Kg body weight, by IV. The ~ o abdominal wall was opened to expose the abdominal viscera. Required portions of the GI tract were removed and placed in a cold (4 °C) oxygenated (95/5 02/C02) Krebs-Heseleit solution, containing (in mM): KCI 4.5, NaCI 118, NaHC03 24, MgS04 1.19. KH2P04 1.18, Glucose 11 and CaCl2 2.52). The removed portions were then further dissected in a dissection chamber (Hugo Sachs Electronik (HSE), Germany) to produce a single strip of GI muscle which was ~s then placed in an organ bath. The organ bath is a type 813 (I-18E) by HSE
and it includes a temperature controller type 319 and a force transducer type F30 with a 660 type amplifier. The elapsed time for the removal procedure is about 3-5 minutes.
Fig. 11 is a schematic illustration of an experimental setup used to determine the effects of a non-excitatory field on smooth muscle cells. A GI muscle portion 200 is fixed in 2o an organ bath chamber, one end is fixed to the chamber using a plastic clip, while the other end is hooked to a pressure transducer 202. The length of the GI muscle is adjusted to allow maximal isometric force. The organ bath is temperature controlled and the GI
muscle is continuously perfused (7-12 ml/min) with the above described oxygenated solution, maintained at about 36.1 °C. The muscle was allowed to remain in the organ bath for a 30 2s minutes equilibrium period prior to experimentation.
The organ bath includes two Ag-AgCI electrodes 206 which were used to apply a pacing pulse, where required by the experimental protocol. These electrodes were chlorodized before each experiment. The pacing stimuli was provided by a constant current source. The pacing waveform was a square wave pulse. A non-excitatory electric field was applied using 3o carbon electrodes 208 (shaped from carbon rods provided by Goodfellow, UK) which were placed about 2-3 millimeters apart. The electrodes were electrified by a constant current source 210. The two constant current sources were home made current sources whose current level was modified by computer control. The output of these current sources was continuously monitored to verify that a constant current was produced. The entire experiment was controlled by a computer 212 and the data was acquired using dedicated data acquisition circuits, such as a PCI-MIO-16XE50 or an AT-MIO-16E-2 (National Instrument, USA). The organ bath was s placed on an anti-vibration table (TMC, USA). Both the pacing current and the non-excitatory current were constant current pulses. The amplitude of the pacing is different between the following experiments, in the main pat, to counteract polarization of the electrodes. The delay of the non-excitatory field (NT current) is from the start of the pacing signal.
Figs. 12-17 show experimental results using a section of GI tract from the Jejunum.
~ o The fields were applied and the transducer measured force were approximately along the direction of the GI tract. As described above, variations in the orientation can change the effect of the non-excitatory pulse. The polarity of the field was sometimes selected to cause a force increasing effect and sometimes to produce a force decreasing effect.
Fig. 12 is a graph of experimental results showing an increase in the force of ~ s contraction of a smooth muscle, as a result of the application of a non-excitatory electric field in accordance with a preferred embodiment of the invention. The non-excitatory field is shown as a full bar marked "NT."
In this experiment, the pacing was 0.15 Hz, 30ms duration and 3mA current. The non-excitatory field was a 200 ms current pulse at IOmA applied at a delay of SOms after the 2o pacing. As seen in Fig. 12, an increase of about 300% in the force of contraction was achieved.
Figs. 13-16 are graph of experimental results showing a significant decrease in the force of contraction of a smooth muscle, as a result of the application of a non-excitatory electric field in accordance with a preferred embodiment of the invention.
In Fig. 13, a 70% reduction in force of contraction was achieved. The pacing was the 2e same as in Fig. 12, while the non-excitatory pulse was applied for 100ms, at a 100ms delay after the pacing and at lOmA. It should be noted that the effect of the non-excitatory field lasted for a while after the removal thereof. In addition, the non-excitatory field also reduced the base tone of the muscle, i.e., it relaxed it.
In Fig. 14, a substantial reduction in force of contraction was achieved. The pacing ao was faster than in Figs. 12 and 13: 0.25 Hz, 30ms duration and IOmA
amplitude. The non-excitatory pulse was applied for SOms, at a SOms delay after the pacing and at a lOmA
amplitude. In this experiment too, a reduction in muscle tone is observed.
In Fig. 15, a substantial reduction in force of contraction was achieved. The pacing was different from that of Fig. 14: 0.25 Hz, 30ms duration and 3mA amplitude.
The non-excitatory pulse was applied for 60ms, at a 200ms delay after the pacing and at l OmA. In this experiment too, a reduction in muscle tone is observed.
In Fig. 16, a substantial reduction in force of contraction was achieved. The pacing was similar to that of Figs. 12 and 13: 0.15 Hz, 30ms duration and 3mA
amplitude. The non-excitatory pulse was applied for 100ms, at a SOms delay after the pacing and at l OmA. In this experiment too, a reduction in muscle tone is observed.
In Fig. 17, a substantial reduction in force of contraction was achieved using a i o substantially constant non-excitatory field. The pacing was 0.25 Hz, 2ms duration and SmA
amplitude. The non-excitatory pulse was applied for 3990ms, at a Sms delay after the pacing and at an amplitude of lSmA. A nearly complete blockage of contraction is observed of In this experiment too, a reduction in muscle tone is observed.
Fig. 18 is a graph of experimental results showing an increase in the force of i 5 contraction of a smooth muscle of a urine bladder, as a result of the application of a non excitatory electric field, in accordance with a preferred embodiment of the invention. The bladder segment was prepared as described above. It was paced at 0.2 Hz, 30ms duration and 6mA amplitude. The non-excitatory field was a 60ms duration pulse applied at a 30ms delay after pacing and having an amplitude of IOmA. It should be noted that the resting tension of Zo the bladder segment also increased as a result of applying the non-excitatory field.
Fig. 19 is a graph of experimental results showing an increase in the force of contraction of a smooth muscle of a rabbit uterus, as a result of the application of a non-excitatory electric field, in accordance with a preferred embodiment of the invention. The uterus segment was prepared as described above. The muscle segment was not artificially zs paced, it was self paced. The non-excitatory field was a pulse of 20ms duration, IOmA
amplitude and applied at 0.2 Hz. It should be noted that not only was the force of contraction signif candy reduced, after about 30 seconds of application of the non-excitatory field, the contraction of the tissue was apparently completely inhibited. The effects of the field also lasted for a short time after the removal thereof.
so It will be appreciated by a person skilled in the art, that although the present invention has been described with reference to the preferred embodiments, the scope of the invention is not limited by what has thus far been described. In particular adaptation of the above described durations, amplitudes and delays of non-excitatory signals to particular patients is considered to be within the ability of a man of the art and also within the scope of the present invention.
Thus, the scope of the present invention is limited only by the claims which follow.
Claims (129)
1. A method of promoting the healing of a lesion in a smooth muscle, comprising:
selecting a smooth muscle portion having a lesion; and applying a non-excitatory electric field to the portion, which field reduces the mechanical activity at the portion.
selecting a smooth muscle portion having a lesion; and applying a non-excitatory electric field to the portion, which field reduces the mechanical activity at the portion.
2. A method according to claim 1, wherein applying an electric field comprises desensitizing the smooth muscle portion.
3. A method according to claim 1, wherein applying an electric field comprises blocking the electrical activity of smooth muscle surrounding the lesion.
4. A method according to claim 1, wherein the lesion is an ischemic portion of the muscle.
5. A method according to claim 1, wherein the lesion is a sutured portion of the muscle.
6. A method according to claim 1, wherein reducing the mechanical activity comprises inhibiting mechanical activity at the location.
7. A method according to any of claims 1-6, wherein the smooth muscle portion is part of a gastrointestinal (GI) tract.
8. A method of treating diarrhea, comprising:
selecting a portion of irritated intestine; and applying an electric field to the portion, which field reduces the mechanical activity at the portion.
selecting a portion of irritated intestine; and applying an electric field to the portion, which field reduces the mechanical activity at the portion.
9. A method of treating obesity, comprising:
selecting at least a portion of a stomach; and applying an electric field to the portion, which field delays or prevents the emptying of the stomach.
selecting at least a portion of a stomach; and applying an electric field to the portion, which field delays or prevents the emptying of the stomach.
10. A method of treating nausea, comprising, selecting at least a portion of a stomach; and applying an electric field to the portion, which field reduces the mechanical activity of the stomach.
11. A method of controlling emptying of a stoma, comprising:
applying an electric field to an exit portion of the stoma, which field reduces the motility of the end portion; and removing said field when emptying of the stoma is desired.
applying an electric field to an exit portion of the stoma, which field reduces the motility of the end portion; and removing said field when emptying of the stoma is desired.
12. A method according top claim 11, and further comprising applying a second electric field to the exit portion, which second field increases the motility of the stoma, when emptying of the stoma is desired.
13. A method of treating a hemorrhoid, comprising:
providing a patient having a colon; and applying an electric field to a portion of the colon, which field relaxes at least a portion of the colon, near an exit therefrom.
providing a patient having a colon; and applying an electric field to a portion of the colon, which field relaxes at least a portion of the colon, near an exit therefrom.
14. A method according to claim 13, wherein said hemorrhoid is not situated at said portion of the colon.
15. A method according to claim 13, comprising:
measuring a tension in the portion of the colon, wherein applying an electric field comprises applying an electric field when the measured tension is above a predetermined amount.
measuring a tension in the portion of the colon, wherein applying an electric field comprises applying an electric field when the measured tension is above a predetermined amount.
16. A method according to any of claims 1-6 or 8-15, wherein applying an electric field comprises applying the electric field at a delay after a local activation time.
17. A method of increasing the motility of a GI tract, comprising:
selecting a portion of the GI tract; and applying a non-excitatory electric field to the portion, which field increases the force of contraction at the portion.
selecting a portion of the GI tract; and applying a non-excitatory electric field to the portion, which field increases the force of contraction at the portion.
18. A method according to claim 17, comprising applying a second electric field to a second portion of the GI tract, downstream from said portion, which second electric field decreases the force of contraction at the second portion.
19. A method of increasing the motility of a GI tract, comprising:
determining a timing of a returning wave in the GI tract; and applying an electric field to at least a portion of the GI tract, which electric field reduces the response of the GI tract to the returning wave.
determining a timing of a returning wave in the GI tract; and applying an electric field to at least a portion of the GI tract, which electric field reduces the response of the GI tract to the returning wave.
20. A method according to claim 19, wherein determining a timing comprises detecting a forward wave and wherein applying an electric field comprises applying an electric field only at times where it does not substantially interfere with the forward wave.
21. A method according to claim 19, wherein determining a timing comprises detecting a returning wave and wherein applying an electric field comprises applying an electric field only at times where it substantially interfere with the returning wave.
22. A method according to any of claims 19-21, wherein applying an electric field comprises applying an electric field which inhibits the propagation of an activation signal, which activation signal synchronizes the returning wave.
23. A method according to any of claims 19-21, wherein applying an electric field comprises applying an electric field which reduces the force of contraction in at least a portion of the GI tract.
24. A method of selectively exciting only a layer of muscle in a smooth muscle having a plurality of muscle layers, each with a different fiber orientation, comprising:
applying an inhibitory electrical field, parallel to the a fiber orientation of a first layer of muscle, to the muscle; and applying an excitatory electric field to the muscle, which electrical field excites a second layer of the muscle.
applying an inhibitory electrical field, parallel to the a fiber orientation of a first layer of muscle, to the muscle; and applying an excitatory electric field to the muscle, which electrical field excites a second layer of the muscle.
25. A method of selectively increasing the force of contraction of only a layer of muscle in a smooth muscle having a plurality of muscle layers, each with a different fiber orientation, comprising:
applying an inhibitory electrical field, parallel to the a fiber orientation of a first layer of muscle, to the muscle; and applying a second electric field to the muscle, which second electric field is oriented parallel to the fiber orientation of a second layer of muscle and which second field increases the force of contraction in the second layer of muscle.
applying an inhibitory electrical field, parallel to the a fiber orientation of a first layer of muscle, to the muscle; and applying a second electric field to the muscle, which second electric field is oriented parallel to the fiber orientation of a second layer of muscle and which second field increases the force of contraction in the second layer of muscle.
26. A method of multi-point pacing for a smooth muscle, comprising:
applying excitatory electric fields at a plurality of locations on said muscle; and applying at least one inhibitory electric field at a second plurality of locations, situated among said plurality of locations, wherein said inhibitory electric field prevents the propagation of an activation signal between said first plurality of paced locations.
applying excitatory electric fields at a plurality of locations on said muscle; and applying at least one inhibitory electric field at a second plurality of locations, situated among said plurality of locations, wherein said inhibitory electric field prevents the propagation of an activation signal between said first plurality of paced locations.
27. Apparatus for controlling at least the local activity of a portion of an in vivo smooth muscle, comprising:
a plurality of electrodes, adapted to be in contact with a portion of smooth muscle to be controlled; and a controller which electrifies said electrodes with an electrical field which does not generate a propagating action potential in the smooth muscle, which electrical field modifies the reaction of the smooth muscle to an activation signal.
a plurality of electrodes, adapted to be in contact with a portion of smooth muscle to be controlled; and a controller which electrifies said electrodes with an electrical field which does not generate a propagating action potential in the smooth muscle, which electrical field modifies the reaction of the smooth muscle to an activation signal.
28. Apparatus according to claim 27, comprising an electrical activity sensor which detects electrical activity at the portion and wherein said controller electrifies said electrodes responsive to signals from said sensor.
29. Apparatus according to claim 28, wherein the electrification at each of said electrodes is responsive to its local electrical activity.
30. Apparatus according to claim 28, wherein said electrical activity sensor senses electrical activity through ones of said plurality of electrodes.
31. Apparatus according to claim 27, comprising an impedance sensor, which senses at least one impedance between selected ones of said plurality of electrodes.
32. Apparatus according to claim 27, comprising a force transducer which detects mechanical activity at the portion and wherein said controller electrifies said electrodes responsive to signals from said sensor.
33. Apparatus according to claim 32, wherein said controller applies an inhibitory electric field to the muscle, when said mechanical activity is above a certain threshold.
34. Apparatus according to claim 32, wherein the electrification at each of said electrodes is responsive to its local mechanical activity.
35. Apparatus according to claim 27, wherein said non-excitatory field inhibits mechanical activity at the portion.
36. Apparatus according to claim 27, wherein said non-excitatory field reduces the force of contraction at the portion.
37. Apparatus according to claim 27, wherein said non-excitatory field increases the force of contraction at the portion.
38. Apparatus according to claim 27, wherein said controller electrifies at least one of said electrodes with an excitatory electric field.
39. Apparatus according to claim 27, wherein said plurality of electrodes are arranged in a two-dimensional matrix.
40. Apparatus according to claim 27, wherein said controller selectively electrifies ones of said plurality of electrodes to selectively generate one of two perpendicular electric fields.
41. Apparatus according to any of claims 27-40, wherein said controller is adapted to be implanted inside a stomach and attached to the stomach wall.
42. Apparatus according to any of claims 27-40, wherein said controller is adapted to be implanted inside a uterus and attached to the uterus wall.
43. Apparatus according to any of claims 27-40, wherein said controller is adapted to be implanted inside the body and outside a portion of the GI tract.
44. Apparatus according to any of claims 27-40, wherein said controller is adapted to be implanted inside the body and outside a uterus.
45. Apparatus according to claim 44, wherein said controller determines a frequency of contractions in the uterus and wherein said controller electrifies said electrodes responsive to said determined frequency.
46. Apparatus according to claim 44, wherein said electrodes comprise elastic leads.
47. Apparatus according to claim 44, wherein said electrodes are attached to a plurality of remote regions of said uterus.
48. Apparatus according to claim 47, wherein said controller senses and inhibits mechanical activity in substantially the entire uterus.
49. Apparatus according to claim 47, wherein said controller increases the force of contraction in substantially the entire uterus.
50. Apparatus according to nay of claims 27-40, wherein said controller is in a capsule adapted to be inserted into a rectum.
51. Apparatus according to any of claims 27-40, wherein said electrodes are adapted to be implanted inside the body while said controller is adapted to be situated outside the body.
52. Apparatus according to claim 51, wherein said electrodes are adapted to be disconnected from said smooth muscle from outside the body.
53. An anastomosis button comprising:
a sleeve portion for joining two portions of a GI tract;
at least two electrodes adapted to be in electrical contact with the GI tract, at either side of the button; and a controller which electrifies the electrodes to reduce the force of contraction in the GI
tract near the button.
a sleeve portion for joining two portions of a GI tract;
at least two electrodes adapted to be in electrical contact with the GI tract, at either side of the button; and a controller which electrifies the electrodes to reduce the force of contraction in the GI
tract near the button.
54. Apparatus according to claim 53, wherein said controller transmits a pacing signal from the GI tract on one side of the button to the GI tract on the other side of the button.
55. Apparatus according to claim 53, wherein reducing the force comprises inhibiting electrical activity of the GI tract at the button.
56. Apparatus for inhibiting a returning wave in an intestine, comprises:
at least one electrode for applying an inhibiting electric field to a portion of the intestine;
a sensor which senses the propagation of waves in the intestine; and a controller which electrifies said electrode responsive to a sensed propagating wave.
at least one electrode for applying an inhibiting electric field to a portion of the intestine;
a sensor which senses the propagation of waves in the intestine; and a controller which electrifies said electrode responsive to a sensed propagating wave.
57. Apparatus according to claim 56, wherein said sensor detects the returning wave.
58. Apparatus for advancing a bolus comprising:
at least one first electrode, for applying an electrical field to a first portion of the GI
tract adjacent said bolus;
at least one second electrode, for applying an electric field to a second portion of the GI
tract downstream from said bolus; and a controller which electrifies the at least one first electrode with a non-excitatory field which increases the force of contraction at the first portion and which electrifies the at least one second electrode with a non-excitatory electric field which relaxes the muscle at the second portion.
at least one first electrode, for applying an electrical field to a first portion of the GI
tract adjacent said bolus;
at least one second electrode, for applying an electric field to a second portion of the GI
tract downstream from said bolus; and a controller which electrifies the at least one first electrode with a non-excitatory field which increases the force of contraction at the first portion and which electrifies the at least one second electrode with a non-excitatory electric field which relaxes the muscle at the second portion.
59. Apparatus according to claim 58, comprising an impedance sensor for detecting the existence of a bolus at the first portion of the GI tract.
60. A method of aiding the examination of a GI tract, comprising:
providing an elongated probe, having a tip, inside a portion of a GI tract;
and applying a non-excitatory electric field to the portion of the GI tract adjacent the tip of the probe, which electric field is operative to relax the portion of the GI
tract.
providing an elongated probe, having a tip, inside a portion of a GI tract;
and applying a non-excitatory electric field to the portion of the GI tract adjacent the tip of the probe, which electric field is operative to relax the portion of the GI
tract.
61. A method according to claim 60, comprising inflating the portion of the GI
tract after applying said field.
tract after applying said field.
62. A method according to claim 60, wherein the portion of the GI tract is a portion adjacent a bile duct.
63. A method of advancing an elongated probe having a tip and inserted in a portion of the GI tract, comprising:
applying a first electric field at the tip, which field constricts the portion of GI tract to grasp the probe; and applying a second electric field to a second portion of the GI tract adjacent a portion of the probe distal from the tip, which electric field causes the elongation of the second portion of the GI tract.
applying a first electric field at the tip, which field constricts the portion of GI tract to grasp the probe; and applying a second electric field to a second portion of the GI tract adjacent a portion of the probe distal from the tip, which electric field causes the elongation of the second portion of the GI tract.
64. A method according to claim 63, comprising applying a third electrical field to a third portion of the GI tract, adjacent portions of the probe distal from the tip, which electrical field relaxes the third portion of the GI tract so that it does not constrict around the probe.
65. A method according to claim 63 or claim 64, comprising applying an inhibitory electric field to block the propagation of activation signals between the first portion and other portions of the GI tract.
66. A method of advancing an elongated probe, comprising:
providing an elongated probe, having a tip, inside a portion of a GI tract;
and applying an excitatory electric field to the portion of the GI tract, which excitatory electric field causes the bowel to transport the probe in a desired direction.
providing an elongated probe, having a tip, inside a portion of a GI tract;
and applying an excitatory electric field to the portion of the GI tract, which excitatory electric field causes the bowel to transport the probe in a desired direction.
67. A method according to claim 66, wherein the excitatory field is selectively applied either at the tip or at a different location along the probe, distal from the tip, depending on the desired direction of transport.
68. A method according to claim 66 or claim 67, comprising applying an inhibitory electric field, to the portion, to block the propagation of activation signals between the portion and the rest of the GI tract.
69. A method according to any of claims 63-64 and 66-67, wherein the probe is an endoscope.
70. A method according to any of claims 63-64 and 66-67, wherein the probe is a colonoscope.
71. An elongated probe adapted for advancing in a GI tract, comprising:
an elongated body having a tip;
a plurality of electrodes disposed at least at the tip; and a controller which selectively electrifies the electrodes to produce non-excitatory electric fields which affect the contraction of smooth muscle.
an elongated body having a tip;
a plurality of electrodes disposed at least at the tip; and a controller which selectively electrifies the electrodes to produce non-excitatory electric fields which affect the contraction of smooth muscle.
72. A probe according to claim 71, comprising a second plurality of electrodes distributed along at least a portion of the body of the probe.
73. A probe according to claim 71 or claim 72, wherein said controller electrifies said first plurality of electrodes to cause said portion of GI tract to selectively advance or retreat said probe.
74. A probe according to claim 71 or claim 72, wherein said controller electrifies ones of said first and said second pluralities of electrodes to inhibit the propagation of activation signals from the portion of the GI tract adjacent the tip of the probe to other portions of the GI
tract.
tract.
75. A method of controlling a uterus, comprising:
determining a portion of the uterus suspected of generating undesirable activation signals; and applying a local inhibitory electrical field, to the uterus muscle, around the suspected portion.
determining a portion of the uterus suspected of generating undesirable activation signals; and applying a local inhibitory electrical field, to the uterus muscle, around the suspected portion.
76. A method of controlling a uterus, comprising:
determining a portion of the uterus suspected of generating undesirable activation signals; and applying a local desensitizing electrical field to the suspected portion.
determining a portion of the uterus suspected of generating undesirable activation signals; and applying a local desensitizing electrical field to the suspected portion.
77. A method of controlling labor, comprising:
determining a local activation at a plurality of locations of a uterus; and applying a non-excitatory electric field, to each of the plurality of locations, at a time delay from said local activation time.
determining a local activation at a plurality of locations of a uterus; and applying a non-excitatory electric field, to each of the plurality of locations, at a time delay from said local activation time.
78. A method according to claim 77, wherein said non-excitatory field increases the force of contraction at said plurality of locations.
79. A method according to claim 77, wherein said non-excitatory field reduces the force of contraction at said plurality of locations.
80. A method according to claim 77, wherein said non-excitatory field inhibits the conduction of propagating action potentials across the uterus.
81. A method according to any of claims 77-80, comprising implanting a plurality of electrodes at the plurality of locations.
82. A method according to any of claims 77-80, comprising implanting a plurality of encapsulated electrical sources at the plurality of locations.
83. A method according to claim 81, wherein said implanting is performed during a cesarean section.
84. A method of aiding birth, comprising applying a non-excitatory electrical field to a birth canal, which non-excitatory field relaxes the birth canal.
85. A method of preventing premature birth, comprising applying a non-excitatory electrical field to a birth canal, which non-excitatory field increases the force of contraction in the birth canal.
86. A method of treating cramps of the uterus, comprising:
detecting electrical or mechanical activity in at least one location of the uterus; and applying a non-excitatory electrical field at the at least one location.
detecting electrical or mechanical activity in at least one location of the uterus; and applying a non-excitatory electrical field at the at least one location.
87. A method of treating cramps, comprising:
providing at least one electrode inside the uterus, which one electrode is in contact with at least a portion of the uterus, at at least one location thereof; and applying a non-excitatory electrical field to the portion.
providing at least one electrode inside the uterus, which one electrode is in contact with at least a portion of the uterus, at at least one location thereof; and applying a non-excitatory electrical field to the portion.
88. A method according to claim 86 or claim 87, wherein the non-excitatory field inhibits the propagation of activation signals at the at least one location.
89. A method according to claim 86 or claim 87, wherein the non-excitatory field reduces the force of contraction at the at least one location.
90. Apparatus for controlling a smooth muscle, comprising a plurality of individual capsules, each capsule including at least one electrode and a power source which electrifies the electrode, which electrode applies a local non-excitatory field.
91. Apparatus according to claim 90, wherein each of said capsules includes a sensor which measures local activity of the smooth muscle.
92. Apparatus according to claim 90 or claim 91, wherein said capsules are operative to synchronize the electrification of their electrodes without the meditation of an external controller.
93. Apparatus for treating cramps, comprising:
a flexible body having an outside portion and adapted to snugly engage the inside of a uterus;
a plurality of electrodes disposed on the outside of said body; and a controller which electrifies said electrodes to generate a non-excitatory electrical field.
a flexible body having an outside portion and adapted to snugly engage the inside of a uterus;
a plurality of electrodes disposed on the outside of said body; and a controller which electrifies said electrodes to generate a non-excitatory electrical field.
94. Apparatus according to claim 93, wherein said flexible body is inflatable.
95. Apparatus according to claim 93 or claim 94, comprising a second electrode adapted to be placed outside the uterus.
96. A method of controlling a circulatory system, including a heart, comprising:
providing electrodes adjacent a vein; and electrifying the electrodes to constrict the vein, such that the preload on the heart is increased.
providing electrodes adjacent a vein; and electrifying the electrodes to constrict the vein, such that the preload on the heart is increased.
97. A method of controlling a circulatory system, including a heart, comprising:
providing electrodes adjacent a vein; and electrifying the electrodes to expand the vein, such that the preload on the heart is reduced.
providing electrodes adjacent a vein; and electrifying the electrodes to expand the vein, such that the preload on the heart is reduced.
98. A method of controlling a circulatory system, including a heart, comprising:
providing electrodes adjacent an artery; and electrifying the electrodes to constrict the artery, such that the afterload on the heart is increased.
providing electrodes adjacent an artery; and electrifying the electrodes to constrict the artery, such that the afterload on the heart is increased.
99. A method of controlling a circulatory system, including a heart, comprising:
providing electrodes adjacent an artery; and electrifying the electrodes to expand the artery, such that the afterload on the heart is reduced.
providing electrodes adjacent an artery; and electrifying the electrodes to expand the artery, such that the afterload on the heart is reduced.
100. A method of controlling vascular spasm, in a circulatory system having a heart, comprising:
determining a vessel in spasm, which results in an abnormally constricted lumen; and applying a non-excitatory electric field to the vessel, which field causes the lumen to expand.
determining a vessel in spasm, which results in an abnormally constricted lumen; and applying a non-excitatory electric field to the vessel, which field causes the lumen to expand.
101. A method according to any of claims 96-100, and further comprising applying a non-excitatory electric field to at least a portion of the heart.
102. Apparatus for controlling a circulatory system having a heart, comprising:
a plurality of electrodes disposed about at least one major blood vessel;
a blood pressure sensor which measures blood pressure; and a controller which electrifies the plurality of electrodes responsive to the measured blood pressure.
a plurality of electrodes disposed about at least one major blood vessel;
a blood pressure sensor which measures blood pressure; and a controller which electrifies the plurality of electrodes responsive to the measured blood pressure.
103. Apparatus according to claim 102, comprising an external control which activates said controller.
104. Apparatus according to claim 102 or claim 103, comprising an ECG sensor which detects the cardiac rhythm.
105. Apparatus according to claim 102 or claim 103, wherein said controller relaxes said blood vessel to reduce the blood pressure.
106. Apparatus according to claim 102 or claim 103, wherein said controller contracts said blood vessel to increase the blood pressure.
107. A method of controlling the output of a gland, comprising:
providing at least one electrode near the gland; and applying a non-excitatory electric field to the gland.
providing at least one electrode near the gland; and applying a non-excitatory electric field to the gland.
108. A method according to claim 107, wherein the non-excitatory electric field inhibits the activity of hormone producing cells in the gland.
109. A method according to claim 107, wherein the non-excitatory electric field is a substantially DC field.
110. A method according to claim 109, comprising periodically changing the polarity of the field.
111. A method according to any of claims 107-110, wherein the gland is a pancreas.
112. A method according to claim 111, comprising monitoring a level of glucose in the blood, wherein applying said electric field comprises applying said field responsive to said monitored level.
113. Apparatus for controlling the output of a gland, comprising:
a sensor for measuring a level of a chemical in a blood stream;
at least one electrode adjacent said gland; and a controller which electrifies said electrode with a non-excitatory electric field, responsive to the measured level.
a sensor for measuring a level of a chemical in a blood stream;
at least one electrode adjacent said gland; and a controller which electrifies said electrode with a non-excitatory electric field, responsive to the measured level.
114. Apparatus according to claim 113, wherein said chemical is glucose.
115. Apparatus according to claim 113, wherein said apparatus is completely implantable.
116. A method of controlling the activation profile of a smooth muscle organ, comprising:
determining a desired activation profile for the organ; and applying at least one non-excitatory field to a portion of the organ to modify its activation profile.
determining a desired activation profile for the organ; and applying at least one non-excitatory field to a portion of the organ to modify its activation profile.
117. A method according to claim 116, wherein said activation profile comprises a mechanical activation profile.
118. A method according to claim 117, comprising:
measuring a tension in the smooth muscle; and modifying the application of the non-excitatory field responsive to the measured tension.
measuring a tension in the smooth muscle; and modifying the application of the non-excitatory field responsive to the measured tension.
119. A method according to claim 117, comprising:
measuring a pressure in the smooth muscle; and modifying the application of the non-excitatory field responsive to the measured pressure.
measuring a pressure in the smooth muscle; and modifying the application of the non-excitatory field responsive to the measured pressure.
120. A method according to claim 117, further comprising, applying at least one excitatory electric field to the smooth muscle.
121. A method according to claim 117, wherein applying a non-excitatory field comprises applying an inhibitory electric field to the muscle.
122. A method according to claim 117, wherein applying a non-excitatory field comprises applying an electric field which reduces the force of contraction in the muscle.
123. A method according to claim 117, wherein applying a non-excitatory field comprises applying an electric field which increases the force of contraction in the muscle.
124. A method according to any of claims 116-123, wherein the organ is a stomach.
125. A method according to any of claims 116-123, wherein the organ is a small intestine.
126. A method according to any of claims 116-123, wherein the organ is a large intestine.
127. A method according to any of claims 116-123, wherein the organ is a uterus.
128. Apparatus for dictating a mechanical activation profile to a smooth muscle organ, comprising:
at least three electrodes, adapted to be distributed over the organ;
at least one sensor which senses local mechanical activity of the organ; and a controller which electrifies selected ones of said electrodes, responsive to the sensed local mechanical activity, to dictate a particular activation profile to the organ.
at least three electrodes, adapted to be distributed over the organ;
at least one sensor which senses local mechanical activity of the organ; and a controller which electrifies selected ones of said electrodes, responsive to the sensed local mechanical activity, to dictate a particular activation profile to the organ.
129. Apparatus according to claim 128, wherein the organ is a uterus and wherein the activation profile is a pattern of contraction during labor.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IL1997/000243 WO1999003533A1 (en) | 1997-07-16 | 1997-07-16 | Smooth muscle controller |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2296632A1 true CA2296632A1 (en) | 1999-01-28 |
Family
ID=11062008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002296632A Abandoned CA2296632A1 (en) | 1997-07-16 | 1997-07-16 | Smooth muscle controller |
Country Status (12)
Country | Link |
---|---|
US (9) | US6571127B1 (en) |
EP (2) | EP0996482B1 (en) |
JP (1) | JP4102545B2 (en) |
KR (1) | KR20010021797A (en) |
AT (2) | ATE426430T1 (en) |
AU (1) | AU3458197A (en) |
CA (1) | CA2296632A1 (en) |
DE (2) | DE69737367T2 (en) |
ES (1) | ES2283020T3 (en) |
IL (1) | IL133902A0 (en) |
WO (1) | WO1999003533A1 (en) |
ZA (1) | ZA976341B (en) |
Families Citing this family (377)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8825152B2 (en) | 1996-01-08 | 2014-09-02 | Impulse Dynamics, N.V. | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue |
US7167748B2 (en) | 1996-01-08 | 2007-01-23 | Impulse Dynamics Nv | Electrical muscle controller |
JP4175662B2 (en) | 1996-01-08 | 2008-11-05 | インパルス ダイナミクス エヌ.ヴイ. | Electric muscle control device |
US8321013B2 (en) * | 1996-01-08 | 2012-11-27 | Impulse Dynamics, N.V. | Electrical muscle controller and pacing with hemodynamic enhancement |
US9289618B1 (en) | 1996-01-08 | 2016-03-22 | Impulse Dynamics Nv | Electrical muscle controller |
US9713723B2 (en) | 1996-01-11 | 2017-07-25 | Impulse Dynamics Nv | Signal delivery through the right ventricular septum |
US8447399B2 (en) * | 1996-08-19 | 2013-05-21 | Mr3 Medical, Llc | System and method for managing detrimental cardiac remodeling |
US7840264B1 (en) | 1996-08-19 | 2010-11-23 | Mr3 Medical, Llc | System and method for breaking reentry circuits by cooling cardiac tissue |
US7440800B2 (en) * | 1996-08-19 | 2008-10-21 | Mr3 Medical, Llc | System and method for managing detrimental cardiac remodeling |
US7908003B1 (en) | 1996-08-19 | 2011-03-15 | Mr3 Medical Llc | System and method for treating ischemia by improving cardiac efficiency |
US7006871B1 (en) | 1997-07-16 | 2006-02-28 | Metacure N.V. | Blood glucose level control |
ATE426430T1 (en) | 1997-07-16 | 2009-04-15 | Metacure N V | DEVICE FOR CONTROLLING A SMOOTH MUSCLE |
WO1999007354A2 (en) | 1997-08-08 | 1999-02-18 | Duke University | Compositions, apparatus and methods for facilitating surgical procedures |
US6463323B1 (en) | 1998-11-12 | 2002-10-08 | Em Vascular, Inc. | Electrically mediated angiogenesis |
US6152882A (en) * | 1999-01-26 | 2000-11-28 | Impulse Dynamics N.V. | Apparatus and method for chronic measurement of monophasic action potentials |
US8700161B2 (en) | 1999-03-05 | 2014-04-15 | Metacure Limited | Blood glucose level control |
US9101765B2 (en) | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
US8346363B2 (en) * | 1999-03-05 | 2013-01-01 | Metacure Limited | Blood glucose level control |
US8666495B2 (en) | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US8019421B2 (en) * | 1999-03-05 | 2011-09-13 | Metacure Limited | Blood glucose level control |
EP1825880B1 (en) | 1999-03-05 | 2016-05-11 | Metacure Limited | Blood glucose level control |
EP1159030B1 (en) | 1999-03-05 | 2007-06-13 | Impulse Dynamics N.V. | Blood glucose level control |
WO2001091854A1 (en) * | 2000-05-31 | 2001-12-06 | Impulse Dynamics Nv | Electropancreatography |
US6263242B1 (en) | 1999-03-25 | 2001-07-17 | Impulse Dynamics N.V. | Apparatus and method for timing the delivery of non-excitatory ETC signals to a heart |
US6370430B1 (en) | 1999-03-25 | 2002-04-09 | Impulse Dynamics N.V. | Apparatus and method for controlling the delivery of non-excitatory cardiac contractility modulating signals to a heart |
US6355425B1 (en) * | 1999-03-26 | 2002-03-12 | Billups-Rothenberg, Inc. | Mutations associated with iron disorders |
US6292704B1 (en) | 1999-05-25 | 2001-09-18 | Impulse Dynamics N. V. | High capacitance myocardial electrodes |
US7171263B2 (en) | 1999-06-04 | 2007-01-30 | Impulse Dynamics Nv | Drug delivery device |
US7190997B1 (en) | 1999-06-04 | 2007-03-13 | Impulse Dynamics Nv | Drug delivery device |
US7092753B2 (en) | 1999-06-04 | 2006-08-15 | Impulse Dynamics Nv | Drug delivery device |
US6233487B1 (en) | 1999-06-08 | 2001-05-15 | Impulse Dynamics N.V. | Apparatus and method for setting the parameters of an alert window used for timing the delivery of ETC signals to a heart under varying cardiac conditions |
US6223072B1 (en) | 1999-06-08 | 2001-04-24 | Impulse Dynamics N.V. | Apparatus and method for collecting data useful for determining the parameters of an alert window for timing delivery of ETC signals to a heart under varying cardiac conditions |
WO2001010375A2 (en) * | 1999-08-04 | 2001-02-15 | Impulse Dynamics Nv | Inhibition of action potentials |
AUPQ202699A0 (en) * | 1999-08-04 | 1999-08-26 | University Of Melbourne, The | Prosthetic device for incontinence |
US6482145B1 (en) | 2000-02-14 | 2002-11-19 | Obtech Medical Ag | Hydraulic anal incontinence treatment |
US6464628B1 (en) | 1999-08-12 | 2002-10-15 | Obtech Medical Ag | Mechanical anal incontinence |
US6471635B1 (en) | 2000-02-10 | 2002-10-29 | Obtech Medical Ag | Anal incontinence disease treatment with controlled wireless energy supply |
US6360126B1 (en) | 1999-08-20 | 2002-03-19 | Impulse Dynamics N.V. | Apparatus and method for controlling the delivery of contractility modulating non-excitatory signals to the heart |
US6556872B2 (en) | 1999-08-24 | 2003-04-29 | Ev Vascular, Inc. | Therapeutic device and method for treating diseases of cardiac muscle |
US6560489B2 (en) | 1999-08-24 | 2003-05-06 | Em Vascular, Inc. | Therapeutic device and method for treating diseases of cardiac muscle |
US7300449B2 (en) * | 1999-12-09 | 2007-11-27 | Mische Hans A | Methods and devices for the treatment of neurological and physiological disorders |
US20070203531A9 (en) * | 1999-12-03 | 2007-08-30 | Medtronic, Inc. | Heart rate variability control of gastric electrical stimulator |
US6600953B2 (en) | 2000-12-11 | 2003-07-29 | Impulse Dynamics N.V. | Acute and chronic electrical signal therapy for obesity |
WO2001047434A2 (en) | 2000-02-10 | 2001-07-05 | Potencia Medical Ag | Mechanical impotence treatment apparatus |
CN1698552B (en) | 2000-02-10 | 2010-05-12 | 厄罗洛吉卡股份公司 | Controlled urinary incontinence treatment |
DE60136910D1 (en) | 2000-02-11 | 2009-01-22 | Potentica Ag | DEVICE WITH ENERGY CONVERSION DEVICES FOR IMPOTENA TREATMENT |
CA2397284C (en) | 2000-02-14 | 2010-05-18 | Potencia Medical Ag | Male impotence prosthesis apparatus with wireless energy supply |
US7442165B2 (en) * | 2000-02-14 | 2008-10-28 | Obtech Medical Ag | Penile prosthesis |
US6810286B2 (en) | 2000-03-06 | 2004-10-26 | Medtronic, Inc | Stimulation for delivery of molecular therapy |
US8761903B2 (en) * | 2000-10-11 | 2014-06-24 | The Board Of Regents Of The University Of Texas | Gastrointestinal electrical stimulation |
US8467874B2 (en) * | 2000-04-11 | 2013-06-18 | The Board Of Regents Of The University Of Texas System | Gastrointestinal electrical stimulation |
EP1272250A4 (en) * | 2000-04-11 | 2003-07-09 | Univ Texas | Gastrointestinal electrical stimulation |
US6826428B1 (en) * | 2000-04-11 | 2004-11-30 | The Board Of Regents Of The University Of Texas System | Gastrointestinal electrical stimulation |
US6694192B2 (en) * | 2000-07-06 | 2004-02-17 | Impulse Dynamics N.V. | Uterus muscle controller |
EP1322380A4 (en) | 2000-09-26 | 2009-06-03 | Transneuronix Inc | Method and apparatus for treating obesity by electrical stimulation of the gastrointestinal tract using sensed activity |
US7499742B2 (en) * | 2001-09-26 | 2009-03-03 | Cvrx, Inc. | Electrode structures and methods for their use in cardiovascular reflex control |
US6845267B2 (en) * | 2000-09-28 | 2005-01-18 | Advanced Bionics Corporation | Systems and methods for modulation of circulatory perfusion by electrical and/or drug stimulation |
EP1357971B1 (en) * | 2001-01-05 | 2015-05-20 | Metacure Limited | Regulation of eating habits |
CA2440514A1 (en) * | 2001-03-05 | 2002-09-12 | Medtronic, Inc. | Stimulation for delivery of molecular therapy |
CN1270667C (en) | 2001-04-18 | 2006-08-23 | 超治疗股份有限公司 | Analysis of eating habits |
US6535764B2 (en) * | 2001-05-01 | 2003-03-18 | Intrapace, Inc. | Gastric treatment and diagnosis device and method |
US9668690B1 (en) | 2001-05-01 | 2017-06-06 | Intrapace, Inc. | Submucosal gastric implant device and method |
US7643887B2 (en) * | 2001-05-01 | 2010-01-05 | Intrapace, Inc. | Abdominally implanted stimulator and method |
US7756582B2 (en) | 2001-05-01 | 2010-07-13 | Intrapace, Inc. | Gastric stimulation anchor and method |
US20080065169A1 (en) * | 2001-05-01 | 2008-03-13 | Intrapace, Inc. | Endoscopic Instrument for Engaging a Device |
US20050143784A1 (en) | 2001-05-01 | 2005-06-30 | Imran Mir A. | Gastrointestinal anchor with optimal surface area |
US7747322B2 (en) * | 2001-05-01 | 2010-06-29 | Intrapace, Inc. | Digestive organ retention device |
US7689284B2 (en) * | 2001-05-01 | 2010-03-30 | Intrapace, Inc. | Pseudounipolar lead for stimulating a digestive organ |
US7702394B2 (en) | 2001-05-01 | 2010-04-20 | Intrapace, Inc. | Responsive gastric stimulator |
US7616996B2 (en) * | 2005-09-01 | 2009-11-10 | Intrapace, Inc. | Randomized stimulation of a gastrointestinal organ |
US7020531B1 (en) | 2001-05-01 | 2006-03-28 | Intrapace, Inc. | Gastric device and suction assisted method for implanting a device on a stomach wall |
US7979127B2 (en) * | 2001-05-01 | 2011-07-12 | Intrapace, Inc. | Digestive organ retention device |
US7308303B2 (en) * | 2001-11-01 | 2007-12-11 | Advanced Bionics Corporation | Thrombolysis and chronic anticoagulation therapy |
AU2002363756A1 (en) * | 2001-11-12 | 2003-05-26 | Andre Johan Nel | Determining progesterone cycles in livestock |
US20070060812A1 (en) * | 2001-11-29 | 2007-03-15 | Metacure N.V. | Sensing of pancreatic electrical activity |
US8175711B2 (en) * | 2002-04-08 | 2012-05-08 | Ardian, Inc. | Methods for treating a condition or disease associated with cardio-renal function |
US7653438B2 (en) | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US9308043B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US8131371B2 (en) | 2002-04-08 | 2012-03-06 | Ardian, Inc. | Methods and apparatus for monopolar renal neuromodulation |
US7162303B2 (en) | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US20140018880A1 (en) | 2002-04-08 | 2014-01-16 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US8145316B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US7853333B2 (en) | 2002-04-08 | 2010-12-14 | Ardian, Inc. | Methods and apparatus for multi-vessel renal neuromodulation |
US8774922B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods |
US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US7756583B2 (en) | 2002-04-08 | 2010-07-13 | Ardian, Inc. | Methods and apparatus for intravascularly-induced neuromodulation |
US9308044B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US8347891B2 (en) | 2002-04-08 | 2013-01-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
US6978174B2 (en) | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US20070129761A1 (en) | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
US8774913B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravasculary-induced neuromodulation |
US8145317B2 (en) * | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods for renal neuromodulation |
US7620451B2 (en) | 2005-12-29 | 2009-11-17 | Ardian, Inc. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
US20070135875A1 (en) | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
US7043295B2 (en) | 2002-04-26 | 2006-05-09 | Medtronic, Inc. | Methods and apparatus for delivering a drug influencing appetite for treatment of eating disorders |
WO2004011085A1 (en) * | 2002-07-26 | 2004-02-05 | Transneuronix, Inc. | Improved process for electrostimulation treatment of morbid obesity |
AU2003278172A1 (en) * | 2002-10-01 | 2004-04-23 | University Of Zurich | Urethro-anal electrostimulation method and device |
US7613515B2 (en) * | 2003-02-03 | 2009-11-03 | Enteromedics Inc. | High frequency vagal blockage therapy |
US7844338B2 (en) | 2003-02-03 | 2010-11-30 | Enteromedics Inc. | High frequency obesity treatment |
US20040172084A1 (en) | 2003-02-03 | 2004-09-02 | Knudson Mark B. | Method and apparatus for treatment of gastro-esophageal reflux disease (GERD) |
US7444183B2 (en) * | 2003-02-03 | 2008-10-28 | Enteromedics, Inc. | Intraluminal electrode apparatus and method |
US20040158235A1 (en) * | 2003-02-11 | 2004-08-12 | Robert Rudko | TMR system and handpiece with ECG electrodes |
WO2004080533A1 (en) | 2003-03-10 | 2004-09-23 | Impulse Dynamics Nv | Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue |
US11439815B2 (en) | 2003-03-10 | 2022-09-13 | Impulse Dynamics Nv | Protein activity modification |
EP1641522B1 (en) * | 2003-06-20 | 2012-12-19 | Metacure Limited | Gastrointestinal apparatus for detecting a change in posture |
US7725176B2 (en) * | 2003-07-10 | 2010-05-25 | Schuler Eleanor L | Method and system for regulation of endocrine and exocrine glands by means of neuro-electrical coded signals |
US9254388B2 (en) | 2003-07-10 | 2016-02-09 | Codes Of Life, Llc | Method and system for regulation of endocrine and exocrine glands by means of neuro-electrical coded signals |
US10322284B2 (en) * | 2003-07-18 | 2019-06-18 | The John Hopkins University | Method for treating nausea and vomiting by vagus nerve stimulation with selectable stimulation modes |
US20070060971A1 (en) * | 2003-07-21 | 2007-03-15 | Ofer Glasberg | Hepatic device for treatment or glucose detection |
EP1646423A4 (en) * | 2003-07-21 | 2010-09-15 | Metacure Nv | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US8792985B2 (en) | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US7840270B2 (en) | 2003-07-23 | 2010-11-23 | Synapse Biomedical, Inc. | System and method for conditioning a diaphragm of a patient |
WO2005018417A2 (en) * | 2003-08-13 | 2005-03-03 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compressive device for percutaneous treatment of obesity |
US20050070974A1 (en) * | 2003-09-29 | 2005-03-31 | Knudson Mark B. | Obesity and eating disorder stimulation treatment with neural block |
US7200443B2 (en) * | 2003-10-07 | 2007-04-03 | John Faul | Transcutaneous electrical nerve stimulator for appetite control |
US7054690B2 (en) | 2003-10-22 | 2006-05-30 | Intrapace, Inc. | Gastrointestinal stimulation device |
WO2005051486A1 (en) * | 2003-11-28 | 2005-06-09 | University Technologies International Inc. | Method and apparatus for gastrointestinal motility control |
US8086315B2 (en) | 2004-02-12 | 2011-12-27 | Asap Medical, Inc. | Cardiac stimulation apparatus and method for the control of hypertension |
US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
US11779768B2 (en) | 2004-03-10 | 2023-10-10 | Impulse Dynamics Nv | Protein activity modification |
US8548583B2 (en) | 2004-03-10 | 2013-10-01 | Impulse Dynamics Nv | Protein activity modification |
US7255675B2 (en) * | 2004-03-23 | 2007-08-14 | Michael Gertner | Devices and methods to treat a patient |
US7946976B2 (en) * | 2004-03-23 | 2011-05-24 | Michael Gertner | Methods and devices for the surgical creation of satiety and biofeedback pathways |
US20060142790A1 (en) * | 2004-03-23 | 2006-06-29 | Michael Gertner | Methods and devices to facilitate connections between body lumens |
WO2006049725A2 (en) * | 2004-03-23 | 2006-05-11 | Minimus Surgical Systems | Surgical systems and devices to enhance gastric restriction therapies |
US20070233170A1 (en) * | 2004-03-23 | 2007-10-04 | Michael Gertner | Extragastric Balloon |
US20060195139A1 (en) * | 2004-03-23 | 2006-08-31 | Michael Gertner | Extragastric devices and methods for gastroplasty |
US20050222637A1 (en) * | 2004-03-30 | 2005-10-06 | Transneuronix, Inc. | Tachygastrial electrical stimulation |
US7803195B2 (en) * | 2004-06-03 | 2010-09-28 | Mayo Foundation For Medical Education And Research | Obesity treatment and device |
DE202004009224U1 (en) * | 2004-06-14 | 2004-08-12 | Isra Vision Systems Ag | Sensor for measuring the surface of an object |
US7640046B2 (en) * | 2004-06-18 | 2009-12-29 | Cardiac Pacemakers, Inc. | Methods and apparatuses for localizing myocardial infarction during catheterization |
US7664551B2 (en) | 2004-07-07 | 2010-02-16 | Medtronic Transneuronix, Inc. | Treatment of the autonomic nervous system |
US20060020277A1 (en) * | 2004-07-20 | 2006-01-26 | Gostout Christopher J | Gastric reshaping devices and methods |
WO2006018851A2 (en) * | 2004-08-18 | 2006-02-23 | Metacure Ltd. | Monitoring, analysis, and regulation of eating habits |
US20060070334A1 (en) * | 2004-09-27 | 2006-04-06 | Blue Hen, Llc | Sidewall plank for constructing a trailer and associated trailer sidewall construction |
CA2583404A1 (en) | 2004-10-20 | 2006-04-27 | Boston Scientific Limited | Leadless cardiac stimulation systems |
US7650186B2 (en) * | 2004-10-20 | 2010-01-19 | Boston Scientific Scimed, Inc. | Leadless cardiac stimulation systems |
US7937143B2 (en) | 2004-11-02 | 2011-05-03 | Ardian, Inc. | Methods and apparatus for inducing controlled renal neuromodulation |
US7483746B2 (en) * | 2004-12-06 | 2009-01-27 | Boston Scientific Neuromodulation Corp. | Stimulation of the stomach in response to sensed parameters to treat obesity |
EP1827571B1 (en) | 2004-12-09 | 2016-09-07 | Impulse Dynamics NV | Protein activity modification |
US20060161217A1 (en) * | 2004-12-21 | 2006-07-20 | Jaax Kristen N | Methods and systems for treating obesity |
US9821158B2 (en) | 2005-02-17 | 2017-11-21 | Metacure Limited | Non-immediate effects of therapy |
WO2006087712A2 (en) | 2005-02-17 | 2006-08-24 | Metacure N.V. | Charger with data transfer capabilities |
US20060212086A1 (en) * | 2005-03-17 | 2006-09-21 | Mintchev Martin P | Gastrointestinal volume manipulation |
WO2006097934A2 (en) | 2005-03-18 | 2006-09-21 | Metacure Limited | Pancreas lead |
US8265758B2 (en) | 2005-03-24 | 2012-09-11 | Metacure Limited | Wireless leads for gastrointestinal tract applications |
WO2007080595A2 (en) * | 2006-01-12 | 2007-07-19 | Metacure N.V. | Electrode assemblies, tools, and methods for gastric wall implantation |
US20060247717A1 (en) * | 2005-04-28 | 2006-11-02 | Medtronic, Inc. | Electrical stimulation of the gastrointestinal tract to regulate motility |
AU2006323195A1 (en) * | 2005-05-10 | 2007-06-14 | Michael Gertner | Obesity treatment systems |
US8301256B2 (en) * | 2005-06-02 | 2012-10-30 | Metacure Limited | GI lead implantation |
US20070016262A1 (en) | 2005-07-13 | 2007-01-18 | Betastim, Ltd. | Gi and pancreatic device for treating obesity and diabetes |
WO2007013065A2 (en) | 2005-07-25 | 2007-02-01 | Rainbow Medical Ltd. | Electrical stimulation of blood vessels |
EP1931319A2 (en) | 2005-08-09 | 2008-06-18 | Tylerton International Inc. | Satiety |
US7672727B2 (en) * | 2005-08-17 | 2010-03-02 | Enteromedics Inc. | Neural electrode treatment |
US7822486B2 (en) * | 2005-08-17 | 2010-10-26 | Enteromedics Inc. | Custom sized neural electrodes |
US20070044669A1 (en) * | 2005-08-24 | 2007-03-01 | Geise Gregory D | Aluminum can compacting mechanism with improved actuation handle assembly |
US9050005B2 (en) | 2005-08-25 | 2015-06-09 | Synapse Biomedical, Inc. | Method and apparatus for transgastric neurostimulation |
US20070078494A1 (en) * | 2005-09-23 | 2007-04-05 | Mintchev Martin P | Method and apparatus for controlling motility of gastrointestinal organs for the treatment of obesity |
US20070073354A1 (en) * | 2005-09-26 | 2007-03-29 | Knudson Mark B | Neural blocking therapy |
US7509175B2 (en) | 2006-08-03 | 2009-03-24 | Intrapace, Inc. | Method and devices for stimulation of an organ with the use of a transectionally placed guide wire |
US20090018606A1 (en) * | 2005-10-12 | 2009-01-15 | Intrapace, Inc. | Methods and Devices for Stimulation of an Organ with the Use of a Transectionally Placed Guide Wire |
US8442841B2 (en) * | 2005-10-20 | 2013-05-14 | Matacure N.V. | Patient selection method for assisting weight loss |
US20070106338A1 (en) * | 2005-11-10 | 2007-05-10 | Electrocore, Inc. | Direct and Indirect Control of Muscle for the Treatment of Pathologies |
CA2631915A1 (en) * | 2005-12-02 | 2007-06-07 | Synapse Biomedical, Inc. | Transvisceral neurostimulation mapping device and method |
US8295932B2 (en) * | 2005-12-05 | 2012-10-23 | Metacure Limited | Ingestible capsule for appetite regulation |
EP1957147B1 (en) | 2005-12-09 | 2010-12-29 | Boston Scientific Scimed, Inc. | Cardiac stimulation system |
US8050774B2 (en) * | 2005-12-22 | 2011-11-01 | Boston Scientific Scimed, Inc. | Electrode apparatus, systems and methods |
AU2007204602A1 (en) * | 2006-01-16 | 2007-07-19 | Continence Control Systems International Pty Limited | A stimulator for the control of a bodily function |
US8676323B2 (en) | 2006-03-09 | 2014-03-18 | Synapse Biomedical, Inc. | Ventilatory assist system and methods to improve respiratory function |
US7937161B2 (en) * | 2006-03-31 | 2011-05-03 | Boston Scientific Scimed, Inc. | Cardiac stimulation electrodes, delivery devices, and implantation configurations |
US20090157138A1 (en) * | 2006-04-18 | 2009-06-18 | Electrocore, Inc. | Methods And Apparatus For Treating Ileus Condition Using Electrical Signals |
US20100057178A1 (en) * | 2006-04-18 | 2010-03-04 | Electrocore, Inc. | Methods and apparatus for spinal cord stimulation using expandable electrode |
US8585733B2 (en) * | 2006-04-19 | 2013-11-19 | Vibrynt, Inc | Devices, tools and methods for performing minimally invasive abdominal surgical procedures |
US20090281386A1 (en) * | 2006-04-19 | 2009-11-12 | Acosta Pablo G | Devices, system and methods for minimally invasive abdominal surgical procedures |
US20090275972A1 (en) * | 2006-04-19 | 2009-11-05 | Shuji Uemura | Minimally-invasive methods for implanting obesity treatment devices |
US8556925B2 (en) * | 2007-10-11 | 2013-10-15 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US20110172767A1 (en) * | 2006-04-19 | 2011-07-14 | Pankaj Rathi | Minimally invasive, direct delivery methods for implanting obesity treatment devices |
US8342183B2 (en) * | 2006-04-19 | 2013-01-01 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US8398668B2 (en) | 2006-04-19 | 2013-03-19 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US20090287227A1 (en) * | 2006-04-19 | 2009-11-19 | Newell Matthew B | Minimally invasive ,methods for implanting obesity treatment devices |
US7976554B2 (en) * | 2006-04-19 | 2011-07-12 | Vibrynt, Inc. | Devices, tools and methods for performing minimally invasive abdominal surgical procedures |
US20090281498A1 (en) * | 2006-04-19 | 2009-11-12 | Acosta Pablo G | Devices, system and methods for minimally invasive abdominal surgical procedures |
US8187297B2 (en) | 2006-04-19 | 2012-05-29 | Vibsynt, Inc. | Devices and methods for treatment of obesity |
US8070768B2 (en) | 2006-04-19 | 2011-12-06 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US8019435B2 (en) * | 2006-05-02 | 2011-09-13 | Boston Scientific Scimed, Inc. | Control of arterial smooth muscle tone |
WO2007136712A2 (en) * | 2006-05-17 | 2007-11-29 | Medtronic, Inc. | Electrical stimulation therapy to promote gastric distention for obesity management |
US9020597B2 (en) | 2008-11-12 | 2015-04-28 | Endostim, Inc. | Device and implantation system for electrical stimulation of biological systems |
US8718758B2 (en) * | 2006-06-19 | 2014-05-06 | Highland Instruments, Inc. | Interface apparatus for stimulation of biological tissue |
US9913976B2 (en) | 2006-06-19 | 2018-03-13 | Highland Instruments, Inc. | Systems and methods for stimulating and monitoring biological tissue |
AU2007261108A1 (en) | 2006-06-19 | 2007-12-27 | Highland Instruments, Inc. | Apparatus and method for stimulation of biological tissue |
US8892200B2 (en) | 2006-06-19 | 2014-11-18 | Highland Instruments, Inc. | Systems and methods for stimulating tissue using focused energy |
US7840281B2 (en) | 2006-07-21 | 2010-11-23 | Boston Scientific Scimed, Inc. | Delivery of cardiac stimulation devices |
US20090018613A1 (en) * | 2006-08-02 | 2009-01-15 | Genestim, Llc | Regulation of vascular endothelial growth factor (vegf) gene expression in tissue via the application of electric and/or electromagnetic fields |
US20080086180A1 (en) * | 2006-10-05 | 2008-04-10 | Omry Ben-Ezra | Techniques for gall bladder stimulation |
US20150224310A1 (en) | 2006-10-09 | 2015-08-13 | Endostim, Inc. | Device and Implantation System for Electrical Stimulation of Biological Systems |
US11577077B2 (en) | 2006-10-09 | 2023-02-14 | Endostim, Inc. | Systems and methods for electrical stimulation of biological systems |
US9724510B2 (en) | 2006-10-09 | 2017-08-08 | Endostim, Inc. | System and methods for electrical stimulation of biological systems |
US9345879B2 (en) | 2006-10-09 | 2016-05-24 | Endostim, Inc. | Device and implantation system for electrical stimulation of biological systems |
US7839952B2 (en) * | 2006-12-05 | 2010-11-23 | Provigent Ltd | Data rate coordination in protected variable-rate links |
WO2008070189A2 (en) | 2006-12-06 | 2008-06-12 | The Cleveland Clinic Foundation | Method and system for treating acute heart failure by neuromodulation |
WO2008085290A2 (en) * | 2006-12-28 | 2008-07-17 | Vibrynt, Inc. | Devices and methods for treatment of obesity |
US9079016B2 (en) | 2007-02-05 | 2015-07-14 | Synapse Biomedical, Inc. | Removable intramuscular electrode |
US9037244B2 (en) * | 2007-02-13 | 2015-05-19 | Virender K. Sharma | Method and apparatus for electrical stimulation of the pancreatico-biliary system |
US8442639B2 (en) * | 2007-02-13 | 2013-05-14 | Cardiac Pacemakers, Inc. | Systems and methods for electrical stimulation of blood vessels |
US8417329B2 (en) * | 2007-05-09 | 2013-04-09 | Metacure Ltd. | Analysis and regulation of food intake |
DE202007018528U1 (en) * | 2007-05-11 | 2008-12-18 | Chamalow S.A. | System for temporary heart stimulation by radio frequency for pacemaker replacement |
US9820671B2 (en) | 2007-05-17 | 2017-11-21 | Synapse Biomedical, Inc. | Devices and methods for assessing motor point electromyogram as a biomarker |
US7925351B2 (en) * | 2007-06-13 | 2011-04-12 | Betastim, Ltd. | Gastrointestinal device for treating obesity and diabetes |
US8032222B2 (en) | 2007-06-19 | 2011-10-04 | Loushin Michael K H | Device for electrically and mechanically stimulating a compartment in a body |
WO2009013749A2 (en) * | 2007-07-24 | 2009-01-29 | Betastim, Ltd. | Duodenal eating sensor |
US20090105781A1 (en) * | 2007-09-26 | 2009-04-23 | Genestim Nascent Enterprises Llc | Regulation of matrix metalloproteinase (mmp) gene expression in tumor cells via the application of electric and/or electromagnetic fields |
JP2011500135A (en) | 2007-10-11 | 2011-01-06 | ミルックス・ホールディング・エスエイ | Implantable device for external urination control |
EP3922212A1 (en) * | 2007-10-11 | 2021-12-15 | Implantica Patent Ltd | Apparatus for controlling flow of blood in a vessel |
EP2211771B1 (en) * | 2007-10-11 | 2021-01-13 | Implantica Patent Ltd. | Apparatus for the treatment of gallstones |
US8795153B2 (en) | 2007-10-11 | 2014-08-05 | Peter Forsell | Method for treating female sexual dysfunction |
US8696543B2 (en) * | 2007-10-11 | 2014-04-15 | Kirk Promotion Ltd. | Method for controlling flow of intestinal contents in a patient's intestines |
EP2211768B1 (en) * | 2007-10-11 | 2021-03-24 | Implantica Patent Ltd. | Apparatus for controlling flow in a bodily organ |
US8992409B2 (en) * | 2007-10-11 | 2015-03-31 | Peter Forsell | Method for controlling flow in a bodily organ |
WO2010042045A1 (en) | 2008-10-10 | 2010-04-15 | Milux Holding S.A. | A system, an apparatus, and a method for treating a sexual dysfunctional female patient |
US20090248033A1 (en) * | 2007-10-11 | 2009-10-01 | Milux Holding S.A. | Method for the treatment of gallstones |
HUE055695T2 (en) * | 2007-10-11 | 2021-12-28 | Implantica Patent Ltd | Apparatus for controlling flow in a bodily organ |
US20090112327A1 (en) * | 2007-10-26 | 2009-04-30 | Courtney Lane | Burr hole plug designs |
WO2009059033A1 (en) * | 2007-10-30 | 2009-05-07 | Synapse Biomedical, Inc. | Method of improving sleep disordered breathing |
US8428726B2 (en) | 2007-10-30 | 2013-04-23 | Synapse Biomedical, Inc. | Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system |
US7765006B2 (en) * | 2007-12-13 | 2010-07-27 | Leto Medical, Llc | Method and apparatus for providing continence to a gastrointestinal ostomy |
US8961448B2 (en) | 2008-01-28 | 2015-02-24 | Peter Forsell | Implantable drainage device |
EP2240138B1 (en) | 2008-01-29 | 2021-07-21 | Implantica Patent Ltd. | Apparatus for treating obesity |
US20100305392A1 (en) * | 2008-01-31 | 2010-12-02 | Enopace Biomedical Ltd. | Thoracic aorta and vagus nerve stimulation |
US8626299B2 (en) | 2008-01-31 | 2014-01-07 | Enopace Biomedical Ltd. | Thoracic aorta and vagus nerve stimulation |
US9005106B2 (en) | 2008-01-31 | 2015-04-14 | Enopace Biomedical Ltd | Intra-aortic electrical counterpulsation |
US8538535B2 (en) | 2010-08-05 | 2013-09-17 | Rainbow Medical Ltd. | Enhancing perfusion by contraction |
US8626290B2 (en) | 2008-01-31 | 2014-01-07 | Enopace Biomedical Ltd. | Acute myocardial infarction treatment by electrical stimulation of the thoracic aorta |
US8423130B2 (en) | 2008-05-09 | 2013-04-16 | Metacure Limited | Optimization of thresholds for eating detection |
KR20110067042A (en) * | 2008-09-19 | 2011-06-20 | 테리 윌리엄 버톤 무어 | A method and device for reducing muscle tension through electrical manipulation |
US9079028B2 (en) | 2008-10-09 | 2015-07-14 | Virender K. Sharma | Method and apparatus for stimulating the vascular system |
US10603489B2 (en) | 2008-10-09 | 2020-03-31 | Virender K. Sharma | Methods and apparatuses for stimulating blood vessels in order to control, treat, and/or prevent a hemorrhage |
EP2349170B1 (en) | 2008-10-10 | 2023-09-27 | Implantica Patent Ltd. | Apparatus for the treatment of female sexual dysfunction |
WO2010042032A1 (en) | 2008-10-10 | 2010-04-15 | Milux Holding S.A. | Fastening means for implantable medcial control assembly |
EP2349096B1 (en) | 2008-10-10 | 2021-01-27 | MedicalTree Patent Ltd. | An improved artificial valve |
SI2349383T1 (en) | 2008-10-10 | 2022-02-28 | Medicaltree Patent Ltd. | Heart help device and system |
US20110196484A1 (en) | 2008-10-10 | 2011-08-11 | Milux Holding Sa | Heart help method |
US8255057B2 (en) | 2009-01-29 | 2012-08-28 | Nevro Corporation | Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions |
US8311639B2 (en) | 2009-07-08 | 2012-11-13 | Nevro Corporation | Systems and methods for adjusting electrical therapy based on impedance changes |
US9327121B2 (en) | 2011-09-08 | 2016-05-03 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods |
US8652129B2 (en) | 2008-12-31 | 2014-02-18 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation |
WO2010101877A1 (en) * | 2009-03-03 | 2010-09-10 | Medtronic, Inc. | Electrical stimulation therapy to promote gastric distention for obesity management |
EP2414032A4 (en) * | 2009-04-03 | 2016-08-10 | Intrapace Inc | Feedback systems and methods for communicating diagnostic and/or treatment signals to enhance obesity treatments |
US8606371B2 (en) * | 2009-04-07 | 2013-12-10 | Dignity Health | Uterine electrical stimulation system and method |
EP2756864B1 (en) | 2009-04-22 | 2023-03-15 | Nevro Corporation | Spinal cord modulation systems for inducing paresthetic and anesthetic effects |
DE202010018338U1 (en) | 2009-04-22 | 2015-10-12 | Nevro Corporation | Spinal cord modulation system for the relief of chronic pain |
US20110066175A1 (en) * | 2009-05-07 | 2011-03-17 | Rainbow Medical Ltd. | Gastric anchor |
US20100286628A1 (en) * | 2009-05-07 | 2010-11-11 | Rainbow Medical Ltd | Gastric anchor |
US8414559B2 (en) * | 2009-05-07 | 2013-04-09 | Rainbow Medical Ltd. | Gastroretentive duodenal pill |
US10952836B2 (en) | 2009-07-17 | 2021-03-23 | Peter Forsell | Vaginal operation method for the treatment of urinary incontinence in women |
US9949812B2 (en) | 2009-07-17 | 2018-04-24 | Peter Forsell | Vaginal operation method for the treatment of anal incontinence in women |
US8498710B2 (en) | 2009-07-28 | 2013-07-30 | Nevro Corporation | Linked area parameter adjustment for spinal cord stimulation and associated systems and methods |
BR112012001910A2 (en) * | 2009-09-21 | 2019-09-24 | Medtronic Inc | waveforms for electrical stimulation therapy |
US8934975B2 (en) | 2010-02-01 | 2015-01-13 | Metacure Limited | Gastrointestinal electrical therapy |
DE212011100038U1 (en) | 2010-03-05 | 2012-07-17 | Endostim, Inc. | Device and implantation system for electrical stimulation of biological systems |
US11717681B2 (en) | 2010-03-05 | 2023-08-08 | Endostim, Inc. | Systems and methods for treating gastroesophageal reflux disease |
EP3949901A1 (en) * | 2010-04-12 | 2022-02-09 | Implantica Patent Ltd | System for treating a patient having an intestinal disorder |
EP2579809B1 (en) | 2010-06-08 | 2020-11-25 | Regents of the University of Minnesota | Vascular elastance |
US8825164B2 (en) | 2010-06-11 | 2014-09-02 | Enteromedics Inc. | Neural modulation devices and methods |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US20130165964A1 (en) * | 2010-09-21 | 2013-06-27 | Regents Of The University Of Minnesota | Active pressure control for vascular disease states |
WO2012045030A2 (en) | 2010-10-01 | 2012-04-05 | Intrapace, Inc. | Feedback systems and methods to enhance obstructive and other obesity treatments, optionally using multiple sensors |
US20140148726A1 (en) | 2010-10-21 | 2014-05-29 | Timothy Andrew WAGNER | Methods for detecting a condition |
JP6046041B2 (en) | 2010-10-25 | 2016-12-14 | メドトロニック アーディアン ルクセンブルク ソシエテ ア レスポンサビリテ リミテ | Devices, systems, and methods for neuromodulation therapy evaluation and feedback |
US8972028B2 (en) | 2010-10-27 | 2015-03-03 | Dignity Health | Uterine electrical stimulation system and method |
US9872983B2 (en) | 2010-10-27 | 2018-01-23 | Dignity Health | Uterine electrical stimulation system and method |
US9020604B2 (en) * | 2010-10-29 | 2015-04-28 | Sapiens Steering Brain Stimulation B.V. | Multi-electrode neurostimulation device |
CN103260547B (en) | 2010-11-22 | 2016-08-10 | 阿里阿Cv公司 | For reducing the system and method for fluctuation pressure |
WO2012075198A2 (en) | 2010-11-30 | 2012-06-07 | Nevro Corporation | Extended pain relief via high frequency spinal cord modulation, and associated systems and methods |
US8649863B2 (en) | 2010-12-20 | 2014-02-11 | Rainbow Medical Ltd. | Pacemaker with no production |
US8888732B2 (en) * | 2011-03-11 | 2014-11-18 | Apollo Endosurgery, Inc. | Intraluminal sleeve with active agents |
EP3308830A1 (en) | 2011-04-14 | 2018-04-18 | Endostim, Inc. | Systems and methods for treating gastroesophageal reflux disease |
US8738127B1 (en) | 2011-04-20 | 2014-05-27 | Metacure Limited | Method of treating a patient |
US9061153B1 (en) | 2011-04-20 | 2015-06-23 | Metacure Limited | Method of treating a patient |
WO2012149167A2 (en) | 2011-04-26 | 2012-11-01 | Christopher Gerard Kunis | Method and device for treatment of hypertension and other maladies |
JP6108410B2 (en) * | 2011-06-27 | 2017-04-05 | イーエモーション メディカル エルティーディー.E−Motion Medical Ltd. | Esophageal stimulation device and method |
US9999767B2 (en) | 2011-06-27 | 2018-06-19 | E-Motion Medical, Ltd. | Esophageal stimulation system |
US9492113B2 (en) | 2011-07-15 | 2016-11-15 | Boston Scientific Scimed, Inc. | Systems and methods for monitoring organ activity |
US8594783B2 (en) | 2011-08-24 | 2013-11-26 | Highland Instruments, Inc. | Systems and methods for stimulating cellular function in tissue |
WO2013033673A1 (en) | 2011-09-02 | 2013-03-07 | Endostim, Inc. | Endoscopic lead implantation method |
US9925367B2 (en) | 2011-09-02 | 2018-03-27 | Endostim, Inc. | Laparoscopic lead implantation method |
US8855783B2 (en) | 2011-09-09 | 2014-10-07 | Enopace Biomedical Ltd. | Detector-based arterial stimulation |
EP2872070B1 (en) | 2011-09-09 | 2018-02-07 | Enopace Biomedical Ltd. | Wireless endovascular stent-based electrodes |
WO2013052852A1 (en) | 2011-10-07 | 2013-04-11 | Boston Scientific Scimed, Inc. | Methods and systems for detection and thermal treatment of lower urinary tract conditions |
US20130090640A1 (en) * | 2011-10-07 | 2013-04-11 | University Of Surrey | Methods and systems for detection and thermal treatment of lower urinary tract conditions |
US9814884B2 (en) | 2011-11-04 | 2017-11-14 | Nevro Corp. | Systems and methods for detecting faults and/or adjusting electrical therapy based on impedance changes |
US8382775B1 (en) | 2012-01-08 | 2013-02-26 | Vibrynt, Inc. | Methods, instruments and devices for extragastric reduction of stomach volume |
US9314362B2 (en) | 2012-01-08 | 2016-04-19 | Vibrynt, Inc. | Methods, instruments and devices for extragastric reduction of stomach volume |
US9386991B2 (en) | 2012-02-02 | 2016-07-12 | Rainbow Medical Ltd. | Pressure-enhanced blood flow treatment |
US8706234B2 (en) | 2012-02-21 | 2014-04-22 | Virender K. Sharma | System and method for electrical stimulation of anorectal structures to treat anal dysfunction |
US9782583B2 (en) | 2012-02-21 | 2017-10-10 | Virender K. Sharma | System and method for electrical stimulation of anorectal structures to treat urinary dysfunction |
US10576278B2 (en) | 2012-02-21 | 2020-03-03 | Virender K. Sharma | System and method for electrical stimulation of anorectal structures to treat urinary dysfunction |
US9750568B2 (en) | 2012-03-08 | 2017-09-05 | Medtronic Ardian Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
CA2865242A1 (en) | 2012-03-08 | 2013-09-12 | Medtronic Ardian Luxembourg S.A.R.L. | Biomarker sampling in the context of neuromodulation devices and associated systems and methods |
US8676331B2 (en) | 2012-04-02 | 2014-03-18 | Nevro Corporation | Devices for controlling spinal cord modulation for inhibiting pain, and associated systems and methods, including controllers for automated parameter selection |
US20140051924A1 (en) * | 2012-08-16 | 2014-02-20 | Capso Vision, Inc | In Vivo Capsule Device with Electrodes |
US9456916B2 (en) | 2013-03-12 | 2016-10-04 | Medibotics Llc | Device for selectively reducing absorption of unhealthy food |
US9833614B1 (en) | 2012-06-22 | 2017-12-05 | Nevro Corp. | Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods |
CN104736197A (en) | 2012-08-23 | 2015-06-24 | 恩多斯提姆公司 | Device and implantation system for electrical stimulation of biological systems |
US8755888B2 (en) | 2012-10-17 | 2014-06-17 | Melcap Systems Ltd. | Gastrointestinal system |
US20140110296A1 (en) | 2012-10-19 | 2014-04-24 | Medtronic Ardian Luxembourg S.A.R.L. | Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods |
US9008769B2 (en) | 2012-12-21 | 2015-04-14 | Backbeat Medical, Inc. | Methods and systems for lowering blood pressure through reduction of ventricle filling |
US10384052B2 (en) | 2012-12-24 | 2019-08-20 | E-Motion Medical, Ltd | GI tract stimulation devices and methods |
US20140194949A1 (en) * | 2013-01-04 | 2014-07-10 | Brian D. Wichner | Multiplex Electrodes for Applying Transcutaneous Interferential Current |
US9731133B1 (en) | 2013-01-22 | 2017-08-15 | Nevro Corp. | Systems and methods for systematically testing a plurality of therapy programs in patient therapy devices |
US9295840B1 (en) | 2013-01-22 | 2016-03-29 | Nevro Corporation | Systems and methods for automatically programming patient therapy devices |
US9895538B1 (en) | 2013-01-22 | 2018-02-20 | Nevro Corp. | Systems and methods for deploying patient therapy devices |
US9498619B2 (en) | 2013-02-26 | 2016-11-22 | Endostim, Inc. | Implantable electrical stimulation leads |
US9067070B2 (en) | 2013-03-12 | 2015-06-30 | Medibotics Llc | Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type |
US9011365B2 (en) | 2013-03-12 | 2015-04-21 | Medibotics Llc | Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food |
US9895539B1 (en) | 2013-06-10 | 2018-02-20 | Nevro Corp. | Methods and systems for disease treatment using electrical stimulation |
AU2014315411A1 (en) | 2013-09-03 | 2016-03-10 | Endostim, Inc. | Methods and systems of electrode polarity switching in electrical stimulation therapy |
US10779965B2 (en) | 2013-11-06 | 2020-09-22 | Enopace Biomedical Ltd. | Posts with compliant junctions |
US10149978B1 (en) | 2013-11-07 | 2018-12-11 | Nevro Corp. | Spinal cord modulation for inhibiting pain via short pulse width waveforms, and associated systems and methods |
US9370662B2 (en) | 2013-12-19 | 2016-06-21 | Backbeat Medical, Inc. | Methods and systems for controlling blood pressure by controlling atrial pressure |
US10123896B2 (en) | 2014-03-06 | 2018-11-13 | Mayo Foundation For Medical Education And Research | Apparatus and methods of inducing weight loss using blood flow control |
US10194979B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US9980766B1 (en) | 2014-03-28 | 2018-05-29 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and systems for renal neuromodulation |
US10194980B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
EP3136959A4 (en) * | 2014-04-29 | 2017-12-13 | The Regents of the University of California | Bio-impedance measurement method using bi-phasic current stimulus excitation for implantable stimulator |
WO2015179634A2 (en) | 2014-05-22 | 2015-11-26 | CARDIONOMIC, Inc. | Catheter and catheter system for electrical neuromodulation |
US10940318B2 (en) * | 2014-06-17 | 2021-03-09 | Morton M. Mower | Method and apparatus for electrical current therapy of biological tissue |
US8876850B1 (en) | 2014-06-19 | 2014-11-04 | Aria Cv, Inc. | Systems and methods for treating pulmonary hypertension |
AU2015315658B2 (en) | 2014-09-08 | 2019-05-23 | CARDIONOMIC, Inc. | Catheter and electrode systems for electrical neuromodulation |
EP3194017A1 (en) | 2014-09-08 | 2017-07-26 | Cardionomic, Inc. | Methods for electrical neuromodulation of the heart |
USD759803S1 (en) | 2014-10-28 | 2016-06-21 | Highland Instruments, Inc. | Adjustable headpiece with anatomical markers |
US9597507B2 (en) | 2014-10-31 | 2017-03-21 | Medtronic, Inc. | Paired stimulation pulses based on sensed compound action potential |
EP3220999A2 (en) | 2014-11-17 | 2017-09-27 | Endostim, Inc. | Implantable electro-medical device programmable for improved operational life |
EP3242717B1 (en) | 2015-01-05 | 2019-06-12 | Cardionomic, Inc. | Cardiac modulation facilitation systems |
US10335302B2 (en) | 2015-02-24 | 2019-07-02 | Elira, Inc. | Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions |
US20220062621A1 (en) | 2015-02-24 | 2022-03-03 | Elira, Inc. | Electrical Stimulation-Based Weight Management System |
US10864367B2 (en) | 2015-02-24 | 2020-12-15 | Elira, Inc. | Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions |
US10765863B2 (en) | 2015-02-24 | 2020-09-08 | Elira, Inc. | Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy |
US10376145B2 (en) | 2015-02-24 | 2019-08-13 | Elira, Inc. | Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch |
CA2977584C (en) | 2015-02-24 | 2024-03-05 | Elira Therapeutics, Inc. | Systems and methods for enabling appetite modulation and/or improving dietary compliance using an electro-dermal patch |
US9956393B2 (en) | 2015-02-24 | 2018-05-01 | Elira, Inc. | Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch |
US9517344B1 (en) | 2015-03-13 | 2016-12-13 | Nevro Corporation | Systems and methods for selecting low-power, effective signal delivery parameters for an implanted pulse generator |
US10232169B2 (en) | 2015-07-23 | 2019-03-19 | Boston Scientific Neuromodulation Corporation | Burr hole plugs for electrical stimulation systems and methods of making and using |
US11154238B2 (en) | 2015-08-07 | 2021-10-26 | Electroceuticals, Llc | Systems, methods and apparatuses for providing bioelectronic neurocode-based therapies to mammals |
US10342982B2 (en) | 2015-09-11 | 2019-07-09 | Backbeat Medical, Inc. | Methods and systems for treating cardiac malfunction |
US11318310B1 (en) | 2015-10-26 | 2022-05-03 | Nevro Corp. | Neuromodulation for altering autonomic functions, and associated systems and methods |
JP6785301B2 (en) | 2015-11-04 | 2020-11-18 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Medical devices and related methods |
US10300277B1 (en) | 2015-12-14 | 2019-05-28 | Nevro Corp. | Variable amplitude signals for neurological therapy, and associated systems and methods |
CN109310865B (en) | 2016-01-25 | 2022-09-13 | 内弗洛公司 | Electrostimulation treatment of congestive heart failure, and associated systems and methods |
EP3426338A4 (en) | 2016-03-09 | 2019-10-30 | Cardionomic, Inc. | Cardiac contractility neurostimulation systems and methods |
US10799701B2 (en) | 2016-03-30 | 2020-10-13 | Nevro Corp. | Systems and methods for identifying and treating patients with high-frequency electrical signals |
US10485658B2 (en) | 2016-04-22 | 2019-11-26 | Backbeat Medical, Inc. | Methods and systems for controlling blood pressure |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US11446504B1 (en) | 2016-05-27 | 2022-09-20 | Nevro Corp. | High frequency electromagnetic stimulation for modulating cells, including spontaneously active and quiescent cells, and associated systems and methods |
US9700719B1 (en) * | 2016-06-21 | 2017-07-11 | Yamil Dominguez | Device using electrotherapy for the relief of hemorrhoid inflammation |
US11331105B2 (en) | 2016-10-19 | 2022-05-17 | Aria Cv, Inc. | Diffusion resistant implantable devices for reducing pulsatile pressure |
US11819683B2 (en) | 2016-11-17 | 2023-11-21 | Endostim, Inc. | Modular stimulation system for the treatment of gastrointestinal disorders |
CN109429487A (en) * | 2017-06-29 | 2019-03-05 | 亚米尔·多明格斯 | The equipment of the method that applies medical diathermy alleviation hemorrhoid inflammation |
EP3664703A4 (en) | 2017-09-13 | 2021-05-12 | Cardionomic, Inc. | Neurostimulation systems and methods for affecting cardiac contractility |
US10814833B1 (en) | 2017-10-23 | 2020-10-27 | James Goetzinger | Anti-theft license plate display and secure storage system |
CN111344042B (en) | 2017-11-13 | 2023-09-26 | 波士顿科学神经调制公司 | Systems and methods for manufacturing and using low profile control modules of an electrical stimulation system |
WO2019143574A1 (en) | 2018-01-16 | 2019-07-25 | Boston Scientific Neuromodulation Corporation | An electrical stimulation system with a case-neutral battery and a control module for such a system |
WO2019173281A1 (en) | 2018-03-09 | 2019-09-12 | Boston Scientific Neuromodulation Corporation | Burr hole plugs for electrical stimulation systems |
US11013913B2 (en) | 2018-03-16 | 2021-05-25 | Boston Scientific Neuromodulation Corporation | Kits and methods for securing a burr hole plugs for stimulation systems |
CA3107959A1 (en) | 2018-08-13 | 2020-02-20 | CARDIONOMIC, Inc. | Systems and methods for affecting cardiac contractility and/or relaxation |
AU2020207940A1 (en) | 2019-01-17 | 2021-08-12 | Nevro Corp. | Sensory threshold and/or adaptation for neurological therapy screening and/or parameter selection, and associated systems and methods |
US11590352B2 (en) | 2019-01-29 | 2023-02-28 | Nevro Corp. | Ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods |
US11471683B2 (en) | 2019-01-29 | 2022-10-18 | Synapse Biomedical, Inc. | Systems and methods for treating sleep apnea using neuromodulation |
CA3137307A1 (en) | 2019-05-06 | 2020-11-12 | CARDIONOMIC, Inc. | Systems and methods for denoising physiological signals during electrical neuromodulation |
WO2020247756A1 (en) * | 2019-06-05 | 2020-12-10 | Forcyte Biotechnologies, Inc. | Small molecules to relax uterine smooth muscle contractions |
WO2021046252A1 (en) | 2019-09-06 | 2021-03-11 | Aria Cv, Inc. | Diffusion and infusion resistant implantable devices for reducing pulsatile pressure |
US11400299B1 (en) | 2021-09-14 | 2022-08-02 | Rainbow Medical Ltd. | Flexible antenna for stimulator |
Family Cites Families (179)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US577961A (en) * | 1897-03-02 | lindsay | ||
US1515102A (en) | 1922-07-05 | 1924-11-11 | Gabler Johann | Device for introducing the woof by means of a gripping contrivance in looms |
GB304587A (en) * | 1928-01-21 | 1930-03-13 | Abraham Esau | Improvements in apparatus for treatment by diathermy |
US1918368A (en) | 1929-05-31 | 1933-07-18 | Condit Electrical Mfg Corp | Electric switch and means to delay the successive opening thereof |
US2593067A (en) | 1947-02-13 | 1952-04-15 | Raytheon Mfg Co | High-frequency apparatus |
US6141587A (en) * | 1996-08-19 | 2000-10-31 | Mower Family Chf Treatment Irrevocable Trust | Augmentation of muscle contractility by biphasic stimulation |
DE1679493B1 (en) | 1967-05-02 | 1970-06-04 | Berckheim Graf Von | Arrangement for the electrical air conditioning of rooms in buildings and vehicles |
US3658051A (en) * | 1967-11-13 | 1972-04-25 | Kenneth Sheldon Maclean | Method of treating living things using high intensity pulsed magnetic field |
US3522811A (en) * | 1969-02-13 | 1970-08-04 | Medtronic Inc | Implantable nerve stimulator and method of use |
SE346468B (en) * | 1969-02-24 | 1972-07-10 | Lkb Medical Ab | |
US3933147A (en) | 1970-04-02 | 1976-01-20 | Vall Wilbur E Du | Apparatus and method for treating disorders in the region of the pubococcygeous muscle |
SU386634A1 (en) | 1971-08-06 | 1973-06-21 | METHOD OF INTERRUPTION OF PREGNANCY | |
GB1394171A (en) | 1973-05-16 | 1975-05-14 | Whittaker Corp | Blood glucose level monitoring-alarm system and method therefor |
US3911930A (en) | 1974-03-01 | 1975-10-14 | Stimulation Tech | Method and structure of preventing and treating ileus, and reducing acute pain by electrical pulse stimulation |
SU553977A1 (en) | 1975-03-12 | 1977-04-15 | Свердловский научно-исследовательский институт охраны материнства и младенчества | Electric Stimulator |
CA1086831A (en) | 1975-11-07 | 1980-09-30 | Kurt H. Carlsson | Microwave oven with radiating transmission line in the form of a strip conductor |
US4342896A (en) | 1976-12-23 | 1982-08-03 | Raytheon Company | Radiating mode stirrer heating system |
SU709078A1 (en) | 1977-08-29 | 1980-01-15 | Всесоюзный Научно-Исследовательский Институт Акушерства И Гинекологии | Method of prophylaxis of postpartum hemorrhage |
JPS54134479A (en) | 1978-04-10 | 1979-10-18 | Sharp Corp | Wireless temperature measuring device |
JPS5539162A (en) | 1978-09-12 | 1980-03-18 | Sharp Kk | Cooking device heating source controller |
US4377733A (en) | 1978-08-31 | 1983-03-22 | Sharp Kabushiki Kaisha | Temperature-sensing probe structure for wireless temperature-sensing system |
US4431888A (en) | 1978-12-21 | 1984-02-14 | Amana Refrigeration, Inc. | Microwave oven with improved feed structure |
SU831131A1 (en) | 1979-04-19 | 1981-05-23 | Всесоюзный Научно-Исследовательскийинститут Акушерства И Гинекологии | Method of curing pregnancy preinterruption |
US4447693A (en) | 1979-09-06 | 1984-05-08 | Litton Systems, Inc. | Power controlled microwave oven |
US4354153A (en) | 1979-11-19 | 1982-10-12 | Litton Systems, Inc. | Microwave oven leakage detector and method of using same to test door seal leakage |
US4337776A (en) * | 1980-08-29 | 1982-07-06 | Telectronics Pty. Ltd. | Impedance measuring pacer |
JPS5772627A (en) | 1980-10-21 | 1982-05-07 | Tokyo Shibaura Electric Co | Apparatus for detecting abnormal cell |
WO1982001656A1 (en) | 1980-11-20 | 1982-05-27 | Roy E Mcdonnell | Electrical control of body discharges and headaches |
SU1039506A1 (en) | 1981-03-30 | 1983-09-07 | Киевский научно-исследовательский институт клинической и экспериментальной хирургии | Method of reabilitation of patients with postresection damping=syndrom |
US4406288A (en) | 1981-04-06 | 1983-09-27 | Hugh P. Cash | Bladder control device and method |
US4411268A (en) * | 1982-02-10 | 1983-10-25 | Medtronic, Inc. | Muscle stimulator |
SU1147408A1 (en) | 1982-07-01 | 1985-03-30 | Киевский научно-исследовательский институт клинической и экспериментальной хирургии | Method of treatment of postoperational hepatic insufficiency |
US4554922A (en) | 1982-09-30 | 1985-11-26 | Prystowsky Eric N | Method of inhibiting cardiac arrhythmias |
SU1149408A1 (en) | 1982-11-09 | 1985-04-07 | Гомельский политехнический институт | Angular displacement encoder |
CA1247960A (en) * | 1983-03-24 | 1989-01-03 | Hideki Aoki | Transcutaneously implantable element |
US4552150A (en) * | 1983-06-14 | 1985-11-12 | Fred Zacouto | Method and apparatus to assist cardiac muscle functioning |
US4554992A (en) | 1983-09-09 | 1985-11-26 | Fmc Corporation | Hydraulically operated four wheel sweeper |
US4596915A (en) | 1985-05-07 | 1986-06-24 | Amana Refrigeration, Inc. | Microwave oven having resonant antenna |
CA1328123C (en) * | 1986-10-08 | 1994-03-29 | Nigel John Randall | Intrauterine probe |
US4771156A (en) | 1986-10-20 | 1988-09-13 | Micro Dry Incorporated | Method and apparatus for heating and drying moist articles |
US4873986A (en) * | 1987-04-01 | 1989-10-17 | Utah Medical Products | Disposable apparatus for monitoring intrauterine pressure and fetal heart rate |
SU1827793A1 (en) | 1988-12-06 | 1995-05-10 | Институт радиотехники и электроники | Method and device for detecting and determining location of atherosclerotic stenosis of a blood vessel |
US5202095A (en) | 1988-12-27 | 1993-04-13 | Matsushita Electric Industrial Co., Ltd. | Microwave plasma processor |
US5144554A (en) | 1989-03-04 | 1992-09-01 | Xueshan Zhang | Apparatus for diagnosing and providing therapy for gastrointestinal diseases without causing patient discomfort and injury |
US5031617A (en) * | 1989-03-13 | 1991-07-16 | Klettner Harold L | Method of altering human blood glucose levels by the application of electric charge |
US5097833A (en) | 1989-09-19 | 1992-03-24 | Campos James M | Transcutaneous electrical nerve and/or muscle stimulator |
GB8922368D0 (en) | 1989-10-04 | 1989-11-22 | Steeper Hugh Ltd | Multifunction control of a prosthetic limb using syntactic analysis of the dynamic myoelectric signal patterns associated with the onset of muscle contraction |
US5236413B1 (en) * | 1990-05-07 | 1996-06-18 | Andrew J Feiring | Method and apparatus for inducing the permeation of medication into internal tissue |
US5320642A (en) | 1990-06-01 | 1994-06-14 | Board Of Regents For The University Of Ok | Method for alleviating and diagnosing symptoms of heart block |
US5083564A (en) * | 1990-06-01 | 1992-01-28 | Board Of Regents Of The University Of Oklahoma | Method for alleviating and diagnosing symptoms of heart block |
US5205284A (en) | 1990-06-12 | 1993-04-27 | Zoll Medical Corporation | Method and apparatus for transcutaneous electrical cardiac pacing with background stimulation |
US5087243A (en) * | 1990-06-18 | 1992-02-11 | Boaz Avitall | Myocardial iontophoresis |
US5083565A (en) * | 1990-08-03 | 1992-01-28 | Everest Medical Corporation | Electrosurgical instrument for ablating endocardial tissue |
US5133354A (en) | 1990-11-08 | 1992-07-28 | Medtronic, Inc. | Method and apparatus for improving muscle tone |
US5188104A (en) | 1991-02-01 | 1993-02-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
GB9111900D0 (en) | 1991-06-03 | 1991-07-24 | Efamol Holdings | Fatty acid compositions |
US5231988A (en) | 1991-08-09 | 1993-08-03 | Cyberonics, Inc. | Treatment of endocrine disorders by nerve stimulation |
US5961871A (en) | 1991-11-14 | 1999-10-05 | Lockheed Martin Energy Research Corporation | Variable frequency microwave heating apparatus |
FR2686684B1 (en) | 1992-01-23 | 1995-06-09 | Toshiba Ave Kk | HIGH FREQUENCY HEATING APPARATUS. |
US5562720A (en) * | 1992-05-01 | 1996-10-08 | Vesta Medical, Inc. | Bipolar/monopolar endometrial ablation device and method |
RU2014844C1 (en) | 1992-05-06 | 1994-06-30 | Московский областной научно-исследовательский клинический институт | Method for treating viral diarrhea |
US5501662A (en) * | 1992-05-22 | 1996-03-26 | Genetronics, Inc. | Implantable electroporation method and apparatus for drug and gene delivery |
IT1260485B (en) | 1992-05-29 | 1996-04-09 | PROCEDURE AND DEVICE FOR THE TREATMENT OF THE OBESITY OF A PATIENT | |
RU2055606C1 (en) | 1992-06-15 | 1996-03-10 | Научно-исследовательский институт полупроводниковых приборов | Electric stimulator for stomach-guts section |
US5292344A (en) | 1992-07-10 | 1994-03-08 | Douglas Donald D | Percutaneously placed electrical gastrointestinal pacemaker stimulatory system, sensing system, and pH monitoring system, with optional delivery port |
US5634899A (en) * | 1993-08-20 | 1997-06-03 | Cortrak Medical, Inc. | Simultaneous cardiac pacing and local drug delivery method |
JP2713072B2 (en) | 1992-12-21 | 1998-02-16 | 松下電器産業株式会社 | Induction heating cooker |
US5991649A (en) * | 1992-12-22 | 1999-11-23 | University Of Texas | Methods for activating the muscle cells or nerves of the uterus or cervix |
US5397344A (en) | 1992-12-22 | 1995-03-14 | Schering Aktiengesellschaft | Methods of and apparatus for measuring uterine electrical and mechanical activity |
US5447526A (en) | 1992-12-24 | 1995-09-05 | Karsdon; Jeffrey | Transcutaneous electric muscle/nerve controller/feedback unit |
GB9302335D0 (en) * | 1993-02-05 | 1993-03-24 | Macdonald Alexander J R | Electrotherapeutic apparatus |
US5702359A (en) * | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
JPH06310268A (en) | 1993-04-20 | 1994-11-04 | Zojirushi Corp | Cooking material heating method |
US5445609A (en) * | 1993-05-28 | 1995-08-29 | Alza Corporation | Electrotransport agent delivery device having a disposable component and a removable liner |
US5415629A (en) * | 1993-09-15 | 1995-05-16 | Henley; Julian L. | Programmable apparatus for the transdermal delivery of drugs and method |
RU2077273C1 (en) | 1994-02-08 | 1997-04-20 | Вениамин Иванович Шапошников | Method to apply intestinal and gastric fistulas |
JP2691510B2 (en) | 1994-06-02 | 1997-12-17 | 株式会社バイオセンサー研究所 | Enzyme measuring device |
US5681278A (en) * | 1994-06-23 | 1997-10-28 | Cormedics Corp. | Coronary vasculature treatment method |
US5616268A (en) | 1994-07-07 | 1997-04-01 | Microwave Medical Systems | Microwave blood thawing with feedback control |
JPH0864359A (en) | 1994-08-17 | 1996-03-08 | Sanyo Electric Co Ltd | High frequency heating device |
SE9403344L (en) | 1994-09-30 | 1996-03-31 | Synectics Medical Ab | Procedure and apparatus for mainly electrogastrography and electrourography |
JPH08153682A (en) * | 1994-11-29 | 1996-06-11 | Nec Corp | Plasma cvd device |
SE9500620D0 (en) | 1995-02-20 | 1995-02-20 | Pacesetter Ab | Cardiac stimulation device |
JP3787171B2 (en) | 1995-03-15 | 2006-06-21 | 株式会社氷温 | Non-freezing preservation method of foods etc. in temperature zone below freezing point |
US5540730A (en) | 1995-06-06 | 1996-07-30 | Cyberonics, Inc. | Treatment of motility disorders by nerve stimulation |
US6476766B1 (en) | 1997-11-07 | 2002-11-05 | Nathan Cohen | Fractal antenna ground counterpoise, ground planes, and loading elements and microstrip patch antennas with fractal structure |
US5700282A (en) * | 1995-10-13 | 1997-12-23 | Zabara; Jacob | Heart rhythm stabilization using a neurocybernetic prosthesis |
RU2078547C1 (en) | 1995-11-28 | 1997-05-10 | Центральный научно-исследовательский рентгено-радиологический институт МЗМП РФ | Method for treating polyposis of stomach and duodenum |
US5779661A (en) * | 1995-12-11 | 1998-07-14 | Physion, S.R.L. | Method of treating dysfunctional bladder syndromes by electromotive drug administration |
US6363279B1 (en) * | 1996-01-08 | 2002-03-26 | Impulse Dynamics N.V. | Electrical muscle controller |
ATE290905T1 (en) | 1996-01-08 | 2005-04-15 | Impulse Dynamics Nv | DEVICE FOR CONTROLLING HEART ACTIVITY USING NON-EXCITING PRE-STIMULATION |
RU2075980C1 (en) | 1996-01-18 | 1997-03-27 | Акционерное общество открытого типа "Завод "Компонент" | Electrostimulator of gastrointestinal tract |
US5727558A (en) * | 1996-02-14 | 1998-03-17 | Hakki; A-Hamid | Noninvasive blood pressure monitor and control device |
JP3669030B2 (en) | 1996-02-23 | 2005-07-06 | 松下電器産業株式会社 | High frequency heating device |
WO1997036916A1 (en) * | 1996-03-29 | 1997-10-09 | The University Of Medicine And Dentistry Of New Jersey | dUTPASE, ITS ISOFORMS, AND DIAGNOSTIC AND OTHER USES |
US5925070A (en) | 1996-04-04 | 1999-07-20 | Medtronic, Inc. | Techniques for adjusting the locus of excitation of electrically excitable tissue |
US5690691A (en) | 1996-05-08 | 1997-11-25 | The Center For Innovative Technology | Gastro-intestinal pacemaker having phased multi-point stimulation |
GB2316102B (en) | 1996-08-09 | 2001-03-07 | Mark Eliott Fisher | Truss |
US5871506A (en) | 1996-08-19 | 1999-02-16 | Mower; Morton M. | Augmentation of electrical conduction and contractility by biphasic cardiac pacing |
CA2264831C (en) | 1996-09-05 | 2003-08-12 | The Governors Of The University Of Alberta | Gastro-intestinal electrical pacemaker |
ZA976113B (en) * | 1996-09-16 | 1998-03-19 | New Technologies Sa Ysy Ltd | Drug-device combination for controlling the contractility of muscles. |
WO1998010828A1 (en) | 1996-09-16 | 1998-03-19 | Impulse Dynamics (Israel) Ltd. | Apparatus and method for controlling the contractility of muscles |
US5800464A (en) | 1996-10-03 | 1998-09-01 | Medtronic, Inc. | System for providing hyperpolarization of cardiac to enhance cardiac function |
US5814079A (en) | 1996-10-04 | 1998-09-29 | Medtronic, Inc. | Cardiac arrhythmia management by application of adnodal stimulation for hyperpolarization of myocardial cells |
US6026326A (en) * | 1997-01-13 | 2000-02-15 | Medtronic, Inc. | Apparatus and method for treating chronic constipation |
US5836994A (en) | 1997-04-30 | 1998-11-17 | Medtronic, Inc. | Method and apparatus for electrical stimulation of the gastrointestinal tract |
US5861014A (en) | 1997-04-30 | 1999-01-19 | Medtronic, Inc. | Method and apparatus for sensing a stimulating gastrointestinal tract on-demand |
US6381495B1 (en) | 1997-05-28 | 2002-04-30 | Transneuronix, Inc. | Medical device for use in laparoscopic surgery |
US5919216A (en) | 1997-06-16 | 1999-07-06 | Medtronic, Inc. | System and method for enhancement of glucose production by stimulation of pancreatic beta cells |
US6093167A (en) | 1997-06-16 | 2000-07-25 | Medtronic, Inc. | System for pancreatic stimulation and glucose measurement |
US7006871B1 (en) * | 1997-07-16 | 2006-02-28 | Metacure N.V. | Blood glucose level control |
ATE426430T1 (en) | 1997-07-16 | 2009-04-15 | Metacure N V | DEVICE FOR CONTROLLING A SMOOTH MUSCLE |
RU2260451C2 (en) | 1997-07-16 | 2005-09-20 | Импалс Дайнемикс Н.В. | Device for controlling smooth muscle operation |
SE9704076D0 (en) | 1997-11-06 | 1997-11-06 | Holdingbolaget Vid Goeteborgs | Method for permeabilization of cell structures and use thereof |
US6135987A (en) | 1997-12-22 | 2000-10-24 | Kimberly-Clark Worldwide, Inc. | Synthetic fiber |
US6949081B1 (en) * | 1998-08-26 | 2005-09-27 | Non-Invasive Technology, Inc. | Sensing and interactive drug delivery |
WO2000016741A1 (en) | 1998-09-21 | 2000-03-30 | Elan Corporation, Plc | Method and system for enhancing delivery of an agent |
US6463323B1 (en) | 1998-11-12 | 2002-10-08 | Em Vascular, Inc. | Electrically mediated angiogenesis |
EP1159030B1 (en) | 1999-03-05 | 2007-06-13 | Impulse Dynamics N.V. | Blood glucose level control |
WO2004112883A2 (en) * | 2003-06-20 | 2004-12-29 | Metacure N.V. | Hepatic device for treatment or glucose detection |
US8346363B2 (en) * | 1999-03-05 | 2013-01-01 | Metacure Limited | Blood glucose level control |
US9101765B2 (en) * | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
US20040249421A1 (en) | 2000-09-13 | 2004-12-09 | Impulse Dynamics Nv | Blood glucose level control |
US8700161B2 (en) * | 1999-03-05 | 2014-04-15 | Metacure Limited | Blood glucose level control |
US8019421B2 (en) * | 1999-03-05 | 2011-09-13 | Metacure Limited | Blood glucose level control |
US8666495B2 (en) * | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
WO2005087310A2 (en) | 2004-03-18 | 2005-09-22 | Metacure Nv | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
WO2001091854A1 (en) | 2000-05-31 | 2001-12-06 | Impulse Dynamics Nv | Electropancreatography |
US6023640A (en) * | 1999-03-29 | 2000-02-08 | Ross; Jesse | Method contributing to obviating male impotency |
US6684104B2 (en) * | 1999-04-14 | 2004-01-27 | Transneuronix, Inc. | Gastric stimulator apparatus and method for installing |
US7092753B2 (en) * | 1999-06-04 | 2006-08-15 | Impulse Dynamics Nv | Drug delivery device |
WO2000074773A1 (en) | 1999-06-04 | 2000-12-14 | Impulse Dynamics N.V. | Drug delivery device |
US7171263B2 (en) * | 1999-06-04 | 2007-01-30 | Impulse Dynamics Nv | Drug delivery device |
US7190997B1 (en) * | 1999-06-04 | 2007-03-13 | Impulse Dynamics Nv | Drug delivery device |
WO2001010375A2 (en) * | 1999-08-04 | 2001-02-15 | Impulse Dynamics Nv | Inhibition of action potentials |
JP2001086967A (en) | 1999-09-22 | 2001-04-03 | Airtech Japan Ltd | Method for freezing and freezer using variance of magnetic field or electric field |
US20020026141A1 (en) * | 1999-11-04 | 2002-02-28 | Medtronic, Inc. | System for pancreatic stimulation and glucose measurement |
US6594515B2 (en) * | 2000-01-10 | 2003-07-15 | Richard L. Watson | Noninvasive, intrauterine fetal ECG strip electrode |
WO2001052931A1 (en) | 2000-01-21 | 2001-07-26 | Impulse Dynamics Nv | Blood flow controller |
US6600953B2 (en) * | 2000-12-11 | 2003-07-29 | Impulse Dynamics N.V. | Acute and chronic electrical signal therapy for obesity |
US6810286B2 (en) | 2000-03-06 | 2004-10-26 | Medtronic, Inc | Stimulation for delivery of molecular therapy |
EP1326675B1 (en) | 2000-09-07 | 2011-04-13 | Mann Medical Research Organization | Apparatus for control of bowel function |
SE521313C2 (en) | 2000-09-15 | 2003-10-21 | Whirlpool Co | Microwave and procedure for such |
US6832114B1 (en) | 2000-11-21 | 2004-12-14 | Advanced Bionics Corporation | Systems and methods for modulation of pancreatic endocrine secretion and treatment of diabetes |
EP1357971B1 (en) * | 2001-01-05 | 2015-05-20 | Metacure Limited | Regulation of eating habits |
JP3825644B2 (en) | 2001-02-28 | 2006-09-27 | 三洋電機株式会社 | microwave |
CN1270667C (en) | 2001-04-18 | 2006-08-23 | 超治疗股份有限公司 | Analysis of eating habits |
JP2003139460A (en) | 2001-11-01 | 2003-05-14 | Abi:Kk | Variable magnetic field generator, refrigerating device and generation method for constant variable magnetic field |
US20070060812A1 (en) * | 2001-11-29 | 2007-03-15 | Metacure N.V. | Sensing of pancreatic electrical activity |
EP1603365A1 (en) | 2002-03-12 | 2005-12-07 | Matsushita Electric Industrial Co., Ltd. | High-frequency heating apparatus and control method thereof |
EP1515102A1 (en) | 2002-05-10 | 2005-03-16 | Glocal Co., Ltd. | Freezer, freezing method and frozen objects |
US7105787B2 (en) | 2002-10-29 | 2006-09-12 | Fiore Industries, Inc. | Reverberating adaptive microwave-stirred exposure system |
US20040158289A1 (en) * | 2002-11-30 | 2004-08-12 | Girouard Steven D. | Method and apparatus for cell and electrical therapy of living tissue |
WO2004080533A1 (en) | 2003-03-10 | 2004-09-23 | Impulse Dynamics Nv | Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue |
EP1641522B1 (en) * | 2003-06-20 | 2012-12-19 | Metacure Limited | Gastrointestinal apparatus for detecting a change in posture |
US20070060971A1 (en) * | 2003-07-21 | 2007-03-15 | Ofer Glasberg | Hepatic device for treatment or glucose detection |
US8792985B2 (en) * | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
EP1646423A4 (en) | 2003-07-21 | 2010-09-15 | Metacure Nv | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US8548583B2 (en) | 2004-03-10 | 2013-10-01 | Impulse Dynamics Nv | Protein activity modification |
US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
JP2005315487A (en) | 2004-04-28 | 2005-11-10 | Matsushita Electric Ind Co Ltd | Method and device for heating by microwave |
WO2006018851A2 (en) | 2004-08-18 | 2006-02-23 | Metacure Ltd. | Monitoring, analysis, and regulation of eating habits |
KR101048916B1 (en) * | 2004-09-08 | 2011-07-12 | 올림푸스 가부시키가이샤 | Capsule Type Medical Device |
EP1827571B1 (en) | 2004-12-09 | 2016-09-07 | Impulse Dynamics NV | Protein activity modification |
US7219856B2 (en) * | 2005-02-04 | 2007-05-22 | Lockheed Martin Corporation | UAV recovery system |
EP1868679B1 (en) | 2005-02-17 | 2017-05-03 | MetaCure Limited | Non-immediate effects of therapy |
WO2006087712A2 (en) | 2005-02-17 | 2006-08-24 | Metacure N.V. | Charger with data transfer capabilities |
DE102005012337B3 (en) * | 2005-03-17 | 2006-03-16 | Mannesmann Plastics Machinery Gmbh | Drive system for plasticization unit of injection molding machine, including moment distribution drive between motor and plasticizing screw to allow both rotary and axial movement of screw by single main drive |
WO2006097934A2 (en) * | 2005-03-18 | 2006-09-21 | Metacure Limited | Pancreas lead |
US8265758B2 (en) * | 2005-03-24 | 2012-09-11 | Metacure Limited | Wireless leads for gastrointestinal tract applications |
WO2007080595A2 (en) | 2006-01-12 | 2007-07-19 | Metacure N.V. | Electrode assemblies, tools, and methods for gastric wall implantation |
US8301256B2 (en) * | 2005-06-02 | 2012-10-30 | Metacure Limited | GI lead implantation |
US8442841B2 (en) * | 2005-10-20 | 2013-05-14 | Matacure N.V. | Patient selection method for assisting weight loss |
US8295932B2 (en) * | 2005-12-05 | 2012-10-23 | Metacure Limited | Ingestible capsule for appetite regulation |
WO2007096878A2 (en) | 2006-02-21 | 2007-08-30 | Rf Dynamics Ltd. | Electromagnetic heating |
CN101513118A (en) | 2006-07-10 | 2009-08-19 | 射频动力学有限公司 | Food preparation |
US7926358B2 (en) * | 2007-01-29 | 2011-04-19 | Metacure Limited | Method for testing fatigue of a lead |
US8417329B2 (en) | 2007-05-09 | 2013-04-09 | Metacure Ltd. | Analysis and regulation of food intake |
US8423130B2 (en) | 2008-05-09 | 2013-04-16 | Metacure Limited | Optimization of thresholds for eating detection |
-
1997
- 1997-07-16 AT AT06127216T patent/ATE426430T1/en not_active IP Right Cessation
- 1997-07-16 EP EP97930724A patent/EP0996482B1/en not_active Expired - Lifetime
- 1997-07-16 DE DE69737367T patent/DE69737367T2/en not_active Expired - Lifetime
- 1997-07-16 IL IL13390297A patent/IL133902A0/en unknown
- 1997-07-16 ES ES97930724T patent/ES2283020T3/en not_active Expired - Lifetime
- 1997-07-16 KR KR1020007000361A patent/KR20010021797A/en not_active Application Discontinuation
- 1997-07-16 CA CA002296632A patent/CA2296632A1/en not_active Abandoned
- 1997-07-16 EP EP06127216A patent/EP1779890B8/en not_active Expired - Lifetime
- 1997-07-16 JP JP2000502823A patent/JP4102545B2/en not_active Expired - Lifetime
- 1997-07-16 AT AT97930724T patent/ATE353689T1/en active
- 1997-07-16 WO PCT/IL1997/000243 patent/WO1999003533A1/en active IP Right Grant
- 1997-07-16 DE DE69739334T patent/DE69739334D1/en not_active Expired - Lifetime
- 1997-07-16 AU AU34581/97A patent/AU3458197A/en not_active Abandoned
- 1997-07-17 ZA ZA9706341A patent/ZA976341B/en unknown
-
2000
- 2000-01-11 US US09/481,253 patent/US6571127B1/en not_active Expired - Lifetime
-
2002
- 2002-10-29 US US10/282,959 patent/US7120497B2/en not_active Expired - Fee Related
- 2002-10-29 US US10/282,639 patent/US6947792B2/en not_active Expired - Lifetime
- 2002-10-29 US US10/282,968 patent/US7221978B2/en not_active Expired - Fee Related
-
2007
- 2007-04-17 US US11/736,183 patent/US8219201B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/932,963 patent/US7966071B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/932,812 patent/US7765008B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/932,881 patent/US8805507B2/en not_active Expired - Fee Related
-
2014
- 2014-07-16 US US14/332,700 patent/US9265930B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9265930B2 (en) | Methods and devices for modifying vascular parameters | |
US7006871B1 (en) | Blood glucose level control | |
US8744584B2 (en) | Electrical stimulation of the colon to treat chronic constipation | |
US6694192B2 (en) | Uterus muscle controller | |
US8346363B2 (en) | Blood glucose level control | |
EP1159030B1 (en) | Blood glucose level control | |
AU2012249906A1 (en) | Detecting food intake based on impedance | |
JP4351709B2 (en) | Smooth muscle control device | |
RU2260451C2 (en) | Device for controlling smooth muscle operation | |
Karsdon et al. | Electrical inhibition of preterm birth: inhibition of uterine contractility in the rabbit and pup births in the rat | |
EP1825880B1 (en) | Blood glucose level control | |
RU2000101000A (en) | SMOOTH CONTROL DEVICE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |